PATENT COOPERATION TREATY

20 SEP 2004

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF RECEIPT OF RECORD COPY

(PCT Rule 24.2(a))

To:

MEYERS, Hans-Wilhelm
Postfach 10 22 41
50462 Köln
Germany

AvK	Sg	W	Ua	Hi	HPJ	ME	TW	JH	KB

1 9. MAI 2003

CS K

Date of mailing (day/month/year) 28 April 2003 (28.04.03)	**IMPORTANT NOTIFICATION**
Applicant's or agent's file reference 030640woMebs	International application No. PCT/EP03/02857

The applicant is hereby **notified** that the International Bureau has received the record copy of the international application as detailed below.

Name(s) of the applicant(s) and State(s) for which they are applicants:

EVOTEC NEUROSCIENCES GMBH (for all designated States except US)
VON DER KAMMER, Heinz et al (for US)

International filing date	:	19 March 2003 (19.03.03)
Priority date(s) claimed	:	21 March 2002 (21.03.02)
		21 March 2002 (21.03.02)
Date of receipt of the record copy by the International Bureau	:	15 April 2003 (15.04.03)
List of designated Offices	:	

AP : GH,GM,KE,LS,MW,MZ,SD,SL,SZ,TZ,UG,ZM,ZW
EA : AM,AZ,BY,KG,KZ,MD,RU,TJ,TM
EP : AT,BE,BG,CH,CY,CZ,DE,DK,EE,ES,FI,FR,GB,GR,HU,IE,IT,LU,MC,NL,PT,RO,SE,SI,SK,TR
OA : BF,BJ,CF,CG,CI,CM,GA,GN,GQ,GW,ML,MR,NE,SN,TD,TG
National : AE,AG,AL,AM,AT,AU,AZ,BA,BB,BG,BR,BY,BZ,CA,CH,CN,CO,CR,CU,CZ,DE,DK,DM,DZ,
EC,EE,ES,FI,GB,GD,GE,GH,GM,HR,HU,ID,IL,IN,IS,JP,KE,KG,KP,KR,KZ,LC,LK,LR,LS,LT,LU,
LV,MA,MD,MG,MK,MN,MW,MX,MZ,NI,NO,NZ,OM,PH,PL,PT,RO,RU,SC,SD,SE,SG,SK,SL,TJ,TM,TN,
TR,TT,TZ,UA,UG,US,UZ,VC,VN,YU,ZA,ZM,ZW

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer: R. Grenier (Fax 338 8970)
Facsimile No. (41-22) 338.89.70	Telephone No. (41-22) 338 8277

Form PCT/IB/301 (April 2002)

005604901

PCT/EP03/02857

PATENT COOPERATION TREATY

PCT

**NOTIFICATION CONCERNING
SUBMISSION OR TRANSMITTAL
OF PRIORITY DOCUMENT**

(PCT Administrative Instructions, Section 411)

From the INTERNATIONAL BUREAU

To:

MEYERS, Hans-Wilhelm
Postfach 10 22 41
50462 Köln
Germany

AvK Sg W Oa Hi HP M TW JH KB

0 6. OKT. 2003

CS K

Date of mailing (day/month/year) 30 September 2003 (30.09.03)	**IMPORTANT NOTIFICATION**
Applicant's or agent's file reference 030640woMebs	**IMPORTANT NOTIFICATION**
International application No. PCT/EP03/02857	International filing date (day/month/year) 19 March 2003 (19.03.03)
International publication date (day/month/year) Not yet published	Priority date (day/month/year) 21 March 2002 (21.03.02)

Applicant

EVOTEC NEUROSCIENCES GMBH et al

1. The applicant is hereby notified of the date of receipt (except where the letters "NR" appear in the right-hand column) by the International Bureau of the priority document(s) relating to the earlier application(s) indicated below. Unless otherwise indicated by an asterisk appearing next to a date of receipt, or by the letters "NR", in the right-hand column, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).

2. This updates and replaces any previously issued notification concerning submission or transmittal of priority documents.

3. An asterisk(*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b). In such a case, **the attention of the applicant is directed** to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

4. The **letters "NR"** appearing in the right-hand column denote a priority document which was not received by the International Bureau or which the applicant did not request the receiving Office to prepare and transmit to the International Bureau, as provided by Rule 17.1(a) or (b), respectively. In such a case, **the attention of the applicant is directed** to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

Priority date	Priority application No.	Country or regional Office or PCT receiving Office	Date of receipt of priority document
21 Marc 2002 (21.03.02)	02006353.3	EP	16 Sept 2003 (16.09.03)
21 Marc 2002 (21.03.02)	60/365,815	US	12 June 2003 (12.06.03)

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Elisabeth KÖNIG (Fax 338 8970)
Facsimile No. (41-22) 338.89.70	Telephone No. (41-22) 338 8748

Form PCT/IB/304 (July 1998)

005882118

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTICE INFORMING THE APPLICANT OF THE
COMMUNICATION OF THE INTERNATIONAL
APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

To:

20 SEP 2004

MEYERS, Hans-Wilhelm
Postfach 10 22 41
50462 Köln
ALLEMAGNE

YK	Sg	W	Da	Hi	HPJ	ME	TW	JH	KB

1 3. OKT. 2003

CS K

| Date of mailing(*day/month/year*)
02 October 2003 (02.10.03) | |

| Applicant's or agent's file reference
030640woMebs | IMPORTANT NOTICE |

| International application No.
PCT/EP03/02857 | International filing date(*day/month/year*)
19 March 2003 (19.03.03) | Priority date(*day/month/year*)
21 March 2002 (21.03.02) |

| Applicant | EVOTEC NEUROSCIENCES GMBH |

1. Notice is hereby given that the International Bureau has **communicated**, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this notice:

   AU, AZ, BY, CH, CN, CO, DE, DZ, HU, JP, KG, KP, KR, MD, MK, MZ, RU, TM, US

   In accordance with Rule 47.1(c), third sentence, those Offices will accept the present notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:

   AE, AG, AL, AM, AP, AT, BA, BB, BG, BR, BZ, CA, CR, CU, CZ, DK, DM, EA, EC, EE, EP, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, IS, KE, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MG, MN, MW, MX, NI, NO, NZ, OA, OM, PH, PL, PT, RO, SC, SD, SE, SG, SK, SL, TJ, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

   The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-*bis*)).

3. Enclosed with this notice is a copy of the international application as published by the International Bureau on 02 October 2003 (02.10.03) under No. 03/080661

4. **TIME LIMITS for filing a demand for international preliminary examination and for entry into the national phase**

   The applicable time limit for entering the national phase will, **subject to what is said in the following paragraph, be 30 MONTHS** from the priority date, not only in respect of any elected Office if a demand for international preliminary examination is filed before the expiration of **19 months** from the priority date, but also in respect of any designated Office, in the absence of filing of such demand, where Article 22(1) as modified with effect from 1 April 2002 applies in respect of that designated Office. For further details, see *PCT Gazette* No. 44/2001 of 1 November 2001, pages 19926, 19932 and 19934, as well as the *PCT Newsletter*, October and November 2001 and February 2002 issues.

   In practice, **time limits other than the 30-month time limit** will continue to apply, for various periods of time, in respect of certain designated or elected Offices. For **regular updates on the applicable time limits** (20, 21, 30 or 31 months, or other time limit), Office by Office, refer to the *PCT Gazette*, the *PCT Newsletter* and the *PCT Applicant's Guide*, Volume II, National Chapters, all available from WIPO's Internet site, at http://www.wipo.int/pct/en/index.html.

   For filing a **demand for international preliminary examination**, see the *PCT Applicant's Guide*, Volume I/A, Chapter IX. Only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination (at present, all PCT Contracting States are bound by Chapter II).

   It is the applicant's **sole responsibility** to monitor all these time limits.

| The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland | Authorized officer
Judith Zahra |

| Facsimile No.(41-22) 740.14.35 | Telephone No.(41-22) 338.91.11 |

Form PCT/IB/308 (April 2002)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

20 SEP 2004

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 030640woMebs	**FOR FURTHER ACTION**	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. PCT/EP 03/02857	International filing date *(day/month/year)* 19/03/2003	(Earliest) Priority Date *(day/month/year)* 21/03/2002

Applicant
EVOTEC NEUROSCIENCES GMBH

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of ____3____ sheets.

[X] It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**

   a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

   [ ] the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

   b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

   [X] contained in the international application in written form.

   [X] filed together with the international application in computer readable form.

   [ ] furnished subsequently to this Authority in written form.

   [ ] furnished subsequently to this Authority in computer readble form.

   [ ] the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

   [ ] the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. [X] **Certain claims were found unsearchable** (See Box I).

3. [ ] **Unity of invention is lacking** (see Box II).

4. With regard to the **title,**

   [ ] the text is approved as submitted by the applicant.

   [X] the text has been established by this Authority to read as follows:

   DIAGNOSTIC AND THERAPEUTIC USE OF HUMAN MAGUIN PROTEINS AND NUCLEIC ACIDS FOR NEURODEGENERATIVE DISEASE

5. With regard to the **abstract,**

   [X] the text is approved as submitted by the applicant.

   [ ] the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. ____1____

   [X] as suggested by the applicant.   [ ] None of the figures.

   [ ] because the applicant failed to suggest a figure.

   [ ] because this figure better characterizes the invention.

Form PCT/ISA/210 (first sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7   C07K14/47   C12N15/12   C12N5/10   C07K16/18   G01N33/53
         C12Q1/68   A61K38/16   A61K48/00   A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7   C12N   C07K   G01N   C12Q   A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

GENSEQ, EMBL, EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! 16 January 2002 (2002-01-16) LANIGAN,T.M. AND GUAN, K.L.: "Homo sapiens connector enhancer of KSR2A mRNA, complete cds." Database accession no. AF418269 XP002210679 --- -/--	11,13, 14,16, 20,26, 28,29

[X] Further documents are listed in the continuation of box C.

[ ] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
18 June 2003	30/06/2003

| Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL – 2280 HV Rijswijk
 Tel. (+31–70) 340–2040, Tx. 31 651 epo nl,
 Fax: (+31–70) 340–3016 | Authorized officer

 ALCONADA RODRIG.., A |

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE GENSEQ 'Online! 8 November 2000 (2000-11-08) TAKAI,Y. ET AL.: "Rat MAGUIN 1 protein" Database accession no. AAY92942 XP002210736 -& DATABASE WPI Section Ch, Week 200033 Derwent Publications Ltd., London, GB; Class B04, AN 2000-387785 XP002210680 & WO 00 29572 A (KAGAKU GIJUTSU SHINKO JIGYODAN), 25 May 2000 (2000-05-25) abstract ---	11,13, 14,16, 20,26, 28,29
X	DATABASE GENSEQ 'Online! 8 November 2000 (2000-11-08) TAKAI, Y. ET AL.: "Rat MAGUIN 2 protein" Database accession no. AAY92943 XP002210737 -& DATABASE WPI Section Ch, Week 200033 Derwent Publications Ltd., London, GB; Class B04, AN 2000-387785 XP002210680 & WO 00 29572 A (KAGAKU GIJUTSU SHINKO JIGYODAN), 25 May 2000 (2000-05-25) abstract -----	11,13, 14,16, 20,26, 28,29

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

FURTHER INFORMATION CONTINUED FROM   PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.:   12-15 (in part) and 19, 21-25 (complete)

Present claim 12 relates to a method of treating or preventing a
neurodegenerative disease, said method comprising adminstering to said
subject an amount of an agent, wherein said agent is defined by reference
to a desirable characterisitc or property, namely, that said agent
directly or indirectly modulates the activity or level of the (i) gene
coding for human MAGUIN-1 and/or human MAGUIN-2; and/or (ii) a
transcription product of a gene coding for human MAGUIN-1 or human
MAGUIN-2 and/or (iii) a translation product of a gene coding for human
MAGUIN-1 and/or human MAGUIN-2 and/or a fragment, or derivative, or
variant of (i) to (iii). The claims cover the methods that involve the
adminastration of an agent having this characteristic or property,
whereas the application provides support within the meaning of Article 6
PCT and disclosure within the meaning of Article 5 PCT for only a very
limited number of such agents. In the present case, the claims so lack
support, and the application so lacks disclosure, that a meaningful
search of the claimed scope is impossible. Independent of the above
reasoning, the claims also lack clarity (Article 6 PCT). An attempt is
made to define the agent by reference to a result to be achieved. Again,
this lack of clarity in the present case is such as to render a
meaningful search over the whole of the claimed scope impossible.
Consequently, the search has been carried out for those parts of the
claims which appear to be clear, supported and disclosed, namely those
parts relating to the methods which make use of the agent, wherein the
agent comprises the human MAGUIN-1 or MAGUIN-2 polypeptide sequences or
the corresponding polynucleotide sequence in sense or antisense
orientation (see page 14 from the description).

The same objection applies to claim 13, which refers to the above
mentioned agent or modulator as such, to claim 14 which refers to
pharmaceutical compositions comprising said modulator and to claim 15,
which refers to the second medical use of said modulator.

Present claim 19 relates to a method for the identification of a compound
for inhibition of binding between a ligand and human MAGUIN-1 or
MAGUIN-2, wherein said method implies contacting MAGUIN-1 or MAGUIN-2
with a detectable ligand in the presence of the compound to be tested.
The claim cover all possible MAGUIN ligands, whereas the application does
not provides support within the meaning of Article 6 PCT or disclosure
within the meaning of Article 5 PCT for any of such MAGUIN ligandss. In
the present case, the claim so lacks support, and the application so
lacks disclosure, that a meaningful search of the claim is impossible.
Independent of the above reasoning, the claim also lack clarity (Article
6 PCT). An attempt is made to define the product by reference to a result
to be achieved. Again, this lack of clarity in the present case is such
as to render a meaningful search over the whole of the claimed scope
impossible. Consequently, the search has been not carried out for those
claims.

Claims 21-25 relate to methods of producing medicaments and medicaments

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

obtained by said method, wherein said medicaments contain a compound
which is defined by reference to a desirable characterisitic or property,
namely, that the compund can be identified by the methods of claim 18-20.
The claims cover all compounds having this characteristic or property,
whereas the application provides support within the meaning of Article 6
PCT and disclosure within the meaning of Article 5 PCT for none of such
compounds. In the present case, the claims so lack support, and the
application so lacks disclosure, that a meaningful search over the whole
of the claimed scope is impossible. Independent of the above reasoning,
the claims also lack clarity (Article 6 PCT). An attempt is made to
define the compound by reference to a result to be achieved. Again, this
lack of clarity in the present case is such as to render a meaningful
search of the claim impossible. Consequently, the search has not been
carried out for those claims.

The applicant's attention is drawn to the fact that claims, or parts of
claims, relating to inventions in respect of which no international
search report has been established need not be the subject of an
international preliminary examination (Rule 66.1(e) PCT). The applicant
is advised that the EPO policy when acting as an International
Preliminary Examining Authority is normally not to carry out a
preliminary examination on matter which has not been searched. This is
the case irrespective of whether or not the claims are amended following
receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 12 and 17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [X] Claims Nos.:   12-15 (in part) and 19, 21-25 (complete)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest   [ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

PATENT COOPERATION TREATY

PCT

20 SEP 2004

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

(Rationalised Report according to the Notice of the President of the EPO published in the OJ11/2001)

Applicant's or agent's file reference 030640wo/Me/sto	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/EP03/02857	International filing date *(day/month/year)* 19/03/2003	Priority date *(day/month/year)* 21/03/2002

International Patent Classification (IPC) or national classification and IPC
C07K14/47

| Applicant |
|---|
| EVOTEC NEUROSCIENCES GMBH ET AL. |

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of ____2____ sheets, including this cover sheet.

   ☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consists of a total of _____ sheets.

3. This report contains indications relating to the following items:

   I ☒ Basis of the report

   II ☐ Priority

   III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

   IV ☐ Lack of unity of invention

   V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

   VI ☐ Certain documents cited

   VII ☐ Certain defects in the international application

   VIII ☐ Certain observations on the international application

Date of submission of the demand 20/10/2003	Date of completion of this report 16/02/2004
Name and mailing address of the IPEA/ European Patent Office, Gitschiner Str. 103 D-10969 Berlin - Germany Tel.: (+49-30) 25901-0 Fax: (+49-30) 25901-840	Authorized officer DE BUNDEL E R J Tel. (+49-89) 2399 2828

I.   **Basis of the report**

The basis of this international preliminary examination is the application as originally filed.

III.   **Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

The question of whether the claimed invention appears to be novel, to involve an inventive step, or to be industrially applicable has not been the subject of the international preliminary examination in respect of the claims which have not been searched (Article 17(2)(a) or (3) and Rule 66.1(e) PCT); see also international search report).

V.   **Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability**

To the extent that the international preliminary examination has been carried out (see item III above), the following is pointed out:

In light of the documents cited in the international search report, it is considered that the invention as defined in at least some of the claims, which have been the subject of an international search report, does not appear to meet the criteria mentioned in Article 33(1) PCT, i.e. does not appear to be novel and/or to involve an inventive step (see international search report, in particular the documents cited X and/or Y and corresponding claim references).

508/343

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

20 SEP 2004

(71) Applicant (for all designated States except US): EVOTEC NEUROSCIENCES GMBH [DE/DE]; Schnackenburgallee 114, 22525 Hamburg (DE).

(72) Inventors; and
(75) Inventors/Applicants (for US only): VON DER KAMMER, Heinz [DE/DE]; Verbindungsstr. 6d, 22607 Hamburg (DE). HANES, Jozef [SK/DE]; Dornkamp 15, 22869 Schenefeld (DE). POHLNER, Johannes [DE/DE]; Quittenweg 11, 22175 Hamburg (DE).

(74) Agents: MEYERS, Hans-Wilhelm et al.; Postfach 10 22 41, 50462 Köln (DE).

[Continued on next page]

(54) Title: DIAGNOSTIC AND THERAPEUTIC USE OF HUMAN MAGUIN PROTEINS AND NUCLEIC ACIDS FOR NEURODEGENERATIVE DISEASES

Identification of Genes Involved in Alzheimer's Disease Pathology

(57) Abstract: The present invention discloses the differential expression of the human MAGUIN-1caveolae-associatedintegral membrane protein flotillin-1 and/or human MAGUIN-2 gene in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease,se or other neurodegenerative diseases in a subjectpatient, or for determining whether a subject is at increased risk of developing such a disease or other related neurodegenerative diseases. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using a human MAGUIN caveolae-associated integral membrane protein genegene.flotillin-1 A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

WO 03/080661 A1

Best Available Copy

DIAGNOSTIC AND THERAPEUTIC USE OF HUMAN MAGUIN PROTEINS AND NUCLEIC ACIDS FOR NEURODEGENERATIVE DISEASES

The present invention relates to methods of diagnosing, prognosticating and monitoring the progression of neurodegenerative diseases in a subject. Furthermore, methods of therapy control and screening for modulating agents of neurodegenerative diseases are provided. The invention also discloses pharmaceutical compositions, kits, and recombinant animal models.

Neurodegenerative diseases, in particular Alzheimer's disease (AD), have a strongly debilitating impact on a patient's life. Furthermore, these diseases constitute an enormous health, social, and economic burden. AD is the most common neurodegenerative disease, accounting for about 70% of all dementia cases, and it is probably the most devastating age-related neurodegenerative condition affecting about 10% of the population over 65 years of age and up to 45% over age 85 (for a recent review see Vickers et al., *Progress in Neurobiology* 2000, 60: 139-165). Presently, this amounts to an estimated 12 million cases in the US, Europe, and Japan. This situation will inevitably worsen with the demographic increase in the number of old people ("aging of the baby boomers") in developed countries. The neuropathological hallmarks that occur in the brains of individuals with AD are senile plaques, composed of amyloid-β protein, and profound cytoskeletal changes coinciding with the appearance of abnormal filamentous structures and the formation of neurofibrillary tangles.

The amyloid-β (Aβ) protein evolves from the cleavage of the amyloid precursor protein (APP) by different kinds of proteases. The cleavage by the β/γ-secretase leads to the formation of Aβ peptides of different lengths, typically a short more soluble and slow aggregating peptide consisting of 40 amino acids and a longer 42 amino acid peptide, which rapidly aggregates outside the cells, forming the characteristic amyloid plaques (Selkoe, *Physiological Rev* 2001, 81: 741-66; Greenfield et al., *Frontiers Bioscience* 2000, 5: D72-83). Two types of plaques, diffuse plaques and neuritic plaques, can be detected in the brain of AD patients, the latter ones being the classical, most prevalent type. They are primarily found in the cerebral cortex and hippocampus. The neuritic plaques have a diameter of 50μm to 200μm and are composed of insoluble fibrillar amyloids, fragments of dead neurons, of microglia and astrocytes, and other components such as neurotransmitters, apolipoprotein E, glycosaminoglycans, α1-antichymotrypsin and others. The generation of toxic Aβ deposits in the brain starts very early in the course of AD, and it is discussed to be a key player for the subsequent

CONFIRMATION COPY

destructive processes leading to AD pathology. The other pathological hallmarks of AD are neurofibrillary tangles (NFTs) and abnormal neurites, described as neuropil threads (Braak and Braak, *Acta Neuropathol* 1991, 82: 239-259). NFTs emerge inside neurons and consist of chemically altered tau, which forms paired helical filaments twisted around each other. Along the formation of NFTs, a loss of neurons can be observed. It is discussed that said neuron loss may be due to a damaged microtubule-associated transport system (Johnson and Jenkins, *J Alzheimers Dis* 1996, 1: 38-58; Johnson and Hartigan, *J Alzheimers Dis* 1999, 1: 329-351). The appearance of neurofibrillary tangles and their increasing number correlates well with the clinical severity of AD (Schmitt et al., *Neurology* 2000, 55: 370-376).

AD is a progressive disease that is associated with early deficits in memory formation and ultimately leads to the complete erosion of higher cognitive function. The cognitive disturbances include among other things memory impairment, aphasia, agnosia and the loss of executive functioning. A characteristic feature of the pathogenesis of AD is the selective vulnerability of particular brain regions and subpopulations of nerve cells to the degenerative process. Specifically, the temporal lobe region and the hippocampus are affected early and more severely during the progression of the disease. On the other hand, neurons within the frontal cortex, occipital cortex, and the cerebellum remain largely intact and are protected from neurodegeneration (Terry et al., *Annals of Neurology* 1981, 10: 184-92).

The age of onset of AD may vary within a range of 50 years, with early-onset AD occurring in people younger than 65 years of age, and late-onset of AD occurring in those older than 65 years. About 10% of all AD cases suffer from early-onset AD, with only 1-2% being familial, inherited cases.

Currently, there is no cure for AD, nor is there an effective treatment to halt the progression of AD or even to diagnose AD ante-mortem with high probability. Several risk factors have been identified that predispose an individual to develop AD, among them most prominently the epsilon 4 allele of the three different existing alleles (epsilon 2, 3, and 4) of the apolipoprotein E gene (ApoE) (Strittmatter et al., *Proc Natl Acad Sci USA* 1993, 90: 1977-81; Roses, *Ann NY Acad Sci* 1998, 855: 738-43). The polymorphic plasmaprotein ApoE plays a role in the intercellular cholesterol and phospholipid transport by binding low-density lipoprotein receptors, and it seems to play a role in neurite growth and regeneration. Efforts to detect further susceptibility genes and disease-linked polymorphisms, lead to the assumption that specific regions and genes on human chromosomes 10 and 12 may be associated with late-onset AD (Myers et al., *Science* 2000, 290: 2304-5; Bertram et al., *Science* 2000, 290: 2303; Scott et al., *Am J Hum Genet* 2000, 66: 922-32).

●

Although there are rare examples of early-onset AD which have been attributed to genetic defects in the genes for amyloid precursor protein (APP) on chromosome 21, presenilin-1 on chromosome 14, and presenilin-2 on chromosome 1, the prevalent form of late-onset sporadic AD is of hitherto unknown etiologic origin. The mutations found to date account for only half of the familial AD cases, which is less than 2% of all AD patients. The late onset and complex pathogenesis of neurodegenerative disorders pose a formidable challenge to the development of therapeutic and diagnostic agents. It is pivotal to expand the pool of potential drug targets and diagnostic markers. It is therefore an object of the present invention to provide insight into the pathogenesis of neurological diseases and to provide methods, materials, agents, compositions, and animal models which are suited inter alia for the diagnosis and development of a treatment of these diseases. This object has been solved by the features of the independent claims. The subclaims define preferred embodiments of the present invention.

Neurons conduct signals in the form of electrical impulses. The communication between the cells of a neuronal network involves several chemical steps, including the production, release, and transport of signal molecules and the recognition of such messengers by a receptor. These steps take place at the anatomical contact of an axon with the dendrites (axonodendritic), the cell body (axonosomatic), or rarely with the axon of another neuron, and also between neurons and cells of muscle- and gland tissue. Trillions of such specialized cell junctions (synapses) in the human brain are crucial for controlling mental activity and learning processes (Tessier-Lavigne and Goodman, *Science* 1996, 274: 1123-1133). A synapse is composed of the presynaptic element, the synaptic cleft with a spacing distance of about 20-30 nm and the postsynaptic component. They are responsible for altering the membrane potential of the postsynaptic neuron or other effector cells. The quality and intensity of information transferred relies on the number, location, and distribution of synapses. The basis of learning and memory is believed to be due to brain plasticity, i.e. to the plasticity of synapses. The storage and processing of information cause alterations in the structure, chemistry, and strength of synapses and the formation of new synapses (Poirazi and Mel, *Neuron* 2001, 29: 779-796). The postsynaptic density (PSD) is a specialized synaptic signaling assemblage, composed of a specific set of proteins which are assembled together and linked to the cytoplasmic face of the postsynaptic membrane. An important function of the postsynaptic density is the provision of a structural matrix consisting of cytoskeletal and regulatory proteins which localize and accumulate neurotransmitter receptors (e.g. glutamate receptors) and anchor signaling molecules at the postsynaptic membrane (Sheng and Kim, *Current Opinion Neurobiology* 1996, 6:

602-608). Neurotransmitter receptors convert the extracellular chemical signals into intracellular signals. Neurotransmitters are released from the presynaptic membrane into the synaptic cleft via exocytotic processes (vesicle formation). At the postsynaptic membrane they are bound by their specific receptors, resulting in the generation of second messengers. Thus, neurotransmitters function as mediators of nerve impulse transmission across the synapse. The PSD organizes and regulates postsynaptic signal transduction (Kim and Huganir, *Current Opinion Cell Biology* 1999, 11:248-254). To date, several components of the PSD have been identified, among them the prototypic synaptic scaffolding protein postsynaptic density (PSD)-95/synapse-associated protein (SAP) 90. PSD-95/SAP90 and its isoforms belong to a family of membrane-associated guanylate kinases (MAGUK) (Hirao et al., *Journal of Biological Chemistry* 1998, 273: 21105-21110; Hirao et al., *Journal of Biological Chemistry* 2000, 275: 2966-2972). The members of the MAGUK protein family are multiple PDZ-domain containing proteins which interact with many neuronal adhesion proteins, receptors (e.g. N-methyl-D-aspartate (NMDA)) and ion-channels (e.g. potassium channels) through these domains and mediate their assembling at the PSD (Kim et al., *Neuron* 1996, 17: 103-113).

In this context, a novel neuronal membrane-associated guanylate kinase-interacting protein, denoted MAGUIN, was found by Yao et al. (*Journal of Biological Chemistry* 1999, 274: 11889-11896). Using the PDZ-domain sequence of the neurospecific synaptic scaffolding molecule (S-SCAM) as bait, the authors screened a rat brain yeast two-hybrid library and obtained several positive clones, among them two clones subsequently named rat MAGUIN-1 and rat MAGUIN-2 (GenBank accession numbers AF102853 and AF102854, respectively). A Northern blot analysis of different rat tissues with a rat MAGUIN-1 probe revealed brain specific hybridization signals at 4.4 kDa and 5.4 kDa. MAGUIN proteins have a chimerical molecular structure consisting of several protein modules, an N-terminally located sterile alpha-motif (SAM) (aa 8-75), a PDZ-domain (aa 156-296) and a C-terminally located Pleckstrin-homology (PH)-domain (aa 571-667). The Sterile Alpha Motif (SAM) contains four different domain structures, spanning approximately 70 amino acids generating a compact five-helix bundle with a highly conserved hydrophobic core. This motif was found to be part of a number of types of proteins, including signal transduction proteins, playing a role in mediating protein-protein interactions or DNA binding (Schultz et al., *Protein Science* 1997, 6: 249-253). The term PDZ is named after three proteins (i.e. PSD-95/SAP90, *Drosophila* discs-large tumor suppressor protein (Dlg-A) and the tight junction protein ZO-1), originally identified as proteins sharing the same repeats of about 90 amino acids. These amino acids form a distinctive structure of two α helices and six β sheets which mediate the interaction with the carboxyl termini of various proteins. Often, PDZ-

domains of different proteins can heterodimerize with each other. The target proteins are transmembrane receptors, ion channels, or signaling proteins. PDZ-domain binding seems to be important In receptor clustering and in recruiting signal transduction molecules to the plasma membrane. PDZ-domain harboring proteins are for example tyrosine phosphatases and the previously described membrane-associated guanylate kinase-like proteins (Doyle et al., *Cell* 1996, 85: 1067-1076). The Pleckstrin-homology (PH)-domain forms an anti-parallel perpendicular β-sheet sandwich with a succeeding α-helical structure. The β-sheet-loops are important for high affinity binding to specific phosphatidylinositide phosphates, allowing signaling proteins containing the PH-domain to anchor to membranes, for example as studied for GTP binding proteins, protein kinases and phospholipase C isoforms (Lemmon et al., *Trends Cell Biology* 1997, 7: 237-242).

Rat MAGUIN-1 and rat MAGUIN-2 cover 3099 and 2691 nucleotides of coding sequence, respectively, (GenBank accession numbers AF102853, AF102854) which encode for proteins of 1032 aa amino acids (rat MAGUIN-1) (GenBank accession number aad04568) and 896 amino acids (rat MAGUIN-2) (GenBank accession number aad04567), respectively. Rat MAGUIN-2 lacks the 3' terminal PDZ binding motif of rat MAGUIN-1. In neurons, the rat MAGUIN proteins are localized in the cell body and in neurites where they are associated with the plasma-membrane via their PH-domains. Full-length rat MAGUIN-1 could be recovered from neuronal membrane fractions. Rat MAGUIN-1, but not rat MAGUIN-2, interacts via the PDZ-binding motif with the PDZ-domain of PSD-95/SAP90 and the synaptic scaffolding molecule (S-SCAM) (Hirao et al., *Journal of Biological Chemistry* 1998, 273: 21105-21110). S-SCAM has recently been identified as a multiple PDZ-domain containing protein, interacting with SAP90/PSD-95-associated protein (SAPAP), the NMDA receptor, and neuronal adhesion molecules. Additionally, interaction of the PH-domain of rat MAGUIN-1 with the kinase domain of Raf could be confirmed *in vitro* and *in vivo*, but their is no evidence for the activation of Raf or its recruitment to the plasma membrane by rat MAGUIN-1.

To date, the precise function of rat MAGUIN-1 and rat MAGUIN-2 is still not clear. Some clues for the role of rat MAGUIN-1 in the cellular context come from particular protein domains and motifs, specific brain expression patterns, and structural homologies to other proteins like CNK (connector enhancer of kinase suppressor of ras (ksr)), as described for the fruit fly. CNK binds kinase suppressor for Ras and Raf kinase, functions in the Ras/MAP kinase pathway, and has been found to play a profound role in the regulation of eye development (Therrien et al., *Cell* 1998, 95: 343-353). On the basis of the similarities between *Drosophila* CNK (contains SAM, PDZ and PH-domains) and rat MAGUIN-1, rat MAGUIN-1 is discussed as a rodent homolog to CNK. Thus, it is

likely that rat MAGUIN-1 assembles components of synaptic junctions and regulators of the MAP kinase pathway and links them to NMDA receptors and neuronal adhesion molecules. To date, no experiments have been described that show a relationship between a differential expression of human MAGUIN genes, neither on a transcriptional nor on a translational level, and the pathology of neurodegenerative disorders.

The disclosure in the present invention of the human MAGUIN-1 gene and the identification of a link of both human MAGUIN-1 and/or human MAGUIN-2 to neurodegenerative diseases, particularly Alzheimer's disease, offers new ways, inter alia, for the diagnosis and treatment of such diseases.

The singular forms "a", "an", and "the" as used herein and in the claims include plural reference unless the context dictates otherwise. For example "a cell" means as well a plurality of cells, and so forth. The term "and/or" as used in the present specification and in the claims implies that the phrases before and after this term are to be considered either as alternatives or in combination. For instance, the wording "determination of a level and/or an activity" means that either only a level, or only an activity, or both a level and an activity are determined. The term "level" as used herein is meant to comprise a gage of, or a measure of the amount of, or a concentration of a transcription product, for instance an mRNA, or a translation product, for instance a protein or polypeptide. The term "activity" as used herein shall be understood as a measure for the ability of a transcription product or a translation product to produce a biological effect or a measure for a level of biologically active molecules. The term "activity" also refers to enzymatic activity. The terms "level" and/or "activity" further refer to gene expression levels or gene activity. Gene expression can be defined as the utilization of the information contained in a gene by transcription and translation leading to the production of a gene product. "Dysregulation" shall mean an upregulation or downregulation of gene expression. A gene product comprises either RNA or protein and is the result of expression of a gene. The amount of a gene product can be used to measure how active a gene is. The term "gene" as used in the present specification and in the claims comprises both coding regions (exons) as well as non-coding regions (e.g. non-coding regulatory elements such as promotors or enhancers, introns, leader and trailer sequences). The term "ORF" is an acronym for "open reading frame" and refers to a nucleic acid sequence that does not possess a stop codon in at least one reading frame and therefore can potentially be translated into a sequence of amino acids. "Regulatory elements" as used in the present disclosure shall comprise inducible and non-inducible promotors, enhancers, operators and other elements that drive and regulate gene expression. The term "fragment" as used herein is meant to comprise e.g.

an alternatively spliced, or truncated, or otherwise cleaved transcription product or translation product. The term "derivative" as used herein refers to a mutant, or an RNA-edited, or a chemically modified, or otherwise altered transcription product, or to a mutant, or chemically modified, or otherwise altered translation product. For instance, a "derivative" may be generated by processes such as altered phosphorylation, or glycosylation, or acetylation, or lipidation, or by altered signal peptide cleavage or other types of maturation cleavage. These processes may occur post-translationally. The term "modulator" as used in the present invention and in the claims refers to a molecule capable of changing or altering the level and/or the activity of a gene, or a transcription product of a gene, or a translation product of a gene. Preferably, a "modulator" is capable of changing or altering the biological activity of a transcription product or a translation product of a gene. Said modulation, for instance, may be an increase or a decrease in enzyme activity, a change in binding characteristics, or any other change or alteration in the biological, functional, or immunological properties of said translation product of a gene.

The terms "agent", "reagent", or "compound" refer to any substance, chemical, composition or extract that have a positive or negative biological effect on a cell, tissue, body fluid, or within the context of any biological system, or any assay system examined. They can be agonists, antagonists, partial agonists or inverse agonists of a target. Such agents, reagents, or compounds may be nucleic acids, natural or synthetic peptides or protein complexes, or fusion proteins. They may also be antibodies, organic or anorganic molecules or compositions, small molecules, drugs and any combinations of any of said agents above. They may be used for testing, for diagnostic or for therapeutic purposes. The terms "oligonucleotide primer" or "primer" refer to short nucleic acid sequences which can anneal to a given target polynucleotide by hybridization of the complementary base pairs and can be extended by a polymerase. They may be chosen to be specific to a particular sequence or they may be randomly selected, e.g. they will prime all possible sequences in a mix. The length of primers used herein may vary from 10 nucleotides to 80 nucleotides. "Probes" are short nucleic acid sequences of the nucleic acid sequences described and disclosed herein or sequences complementary therewith. They may comprise full length sequences, or fragments, derivatives, isoforms, or variants of a given sequence. The identification of hybridization complexes between a "probe" and an assayed sample allows the detection of the presence of other similar sequences within that sample. As used herein, "homolog or homology" is a term used in the art to describe the relatedness of a nucleotide or peptide sequence to another nucleotide or peptide sequence, which is determined by the degree of identity and/or similarity between said sequences compared.

The term "variant" as used herein refers to any polypeptide and protein, in reference to polypeptides and proteins disclosed in the present invention, in which one or more amino acids are added and/or substituted and/or deleted and/or inserted at the N-terminus, and/or the C-terminus, and/or within the native amino acid sequences of the native polypeptides or proteins of the present invention. Furthermore, the term "variant" shall include any shorter or longer version of a polypeptide or protein. "Variants" shall also comprise a sequence that has at least about 80% sequence identity, more preferably at least about 90% sequence identity, and most preferably at least about 95% sequence identity with the amino acid sequences of SEQ ID NO. 1 and/or SEQ ID NO. 2, respectively. Derivatives, variants, and fragments may include, but are not limited to, a functional SAM, a functional PDZ and a functional PH domain or other functional modules within the polypeptide sequence of human MAGUIN-1 and/or human Maguin-2 proteins. "Variants" of a protein molecule shown in SEQ ID NO. 1 and/or SEQ ID NO. 2 may include, for example, proteins with conservative amino acid substitutions in highly conservative regions. For example, isoleucine, valine and leucine can each be substituted for one another. Aspartate and glutamate can be substituted for each other. Glutamine and asparagine can be substituted for each other. Serine and threonine can be substituted for each other. Amino acid substitutions in less conservative regions include, for example, isoleucine, valine and leucine, which can each be substituted for one another. Aspartate and glutamate can be substituted for each other. Glutamine and asparagine can be subsituted for each other. Serine and threonine can be substituted for each other. Glycine and alanine can be substituted for each other. Alanine and valine can be substituted for each other. Methionine can be substituted for each of leucine, isoleucine or valine, and vice versa. Lysine and arginine can be substituted for each other. One of aspartate and glutamate can be substituted for one of arginine or lysine, and vice versa. Histidine can be substituted for arginine or lysine, and vice versa. Glutamine and glutamate can be substituted for each other. Asparagine and aspartate can be substituted for each other. Other examples of protein modifications include glycosylation and further post-translational modifications. "Proteins and polypeptides" of the present invention include variants, fragments and chemical derivatives of the protein comprising SEQ ID NO. 1 and/or SEQ ID NO. 2. They can include proteins and polypeptides which can be isolated from nature or which can be produced by recombinant and/or synthetic means. Native proteins or polypeptides refer to naturally-occurring truncated or secreted forms, naturally occurring variant forms (e.g. splice variants) and naturally occurring allelic variants. As used herein, protein and polypeptide refers to a linear series of amino acid residues connected to one another by peptide bonds between the alpha-amino group and carboxy groups of adjacent amino

acid residues. Other covalent bonds, such as amide and disulfide bonds, may also be present.

The term "isolated" as used herein is considered to refer to molecules that are removed from their natural environment, i.e. isolated from a cell or from a living organism in which they normally occur, and that are separated or essentially purified from the coexisting components with which they are found to be associated in nature. This notion further means that the sequences encoding such molecules can be linked by the hand of man to polynucleotides, to which they are not linked in their natural state, and that such molecules can be produced by recombinant and/or synthetic means. Even if for said purposes those sequences may be introduced into living or non-living organisms by methods known to those skilled in the art, and even if those sequences are still present in said organisms, they are still considered to be isolated. In the present invention, the terms "risk", "susceptibility", and "predisposition" are tantamount and are used with respect to the probability of developing a neurodegenerative disease, preferably Alzheimer's disease.

The term 'AD' shall mean Alzheimer's disease. "AD-type neuropathology" as used herein refers to neuropathological, neurophysiological, histopathological and clinical hallmarks as described in the instant invention and as commonly known from state-of-the-art literature (see: Iqbal, Swaab, Winblad and Wisniewski, *Alzheimer's Disease and Related Disorders (Etiology, Pathogenesis and Therapeutics)*, Wiley & Sons, New York, Weinheim, Toronto, 1999; Scinto and Daffner, *Early Diagnosis of Alzheimer's Disease*, Humana Press, Totowa, New Jersey, 2000; Mayeux and Christen, *Epidemiology of Alzheimer's Disease: From Gene to Prevention*, Springer Press, Berlin, Heidelberg, New York, 1999; Younkin, Tanzi and Christen, *Presenilins and Alzheimer's Disease*, Springer Press, Berlin, Heidelberg, New York, 1998).

Neurodegenerative diseases or disorders according to the present invention comprise Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Pick's disease, fronto-temporal dementia, progressive nuclear palsy, corticobasal degeneration, cerebro-vascular dementia, multiple system atrophy, argyrophilic grain dementia and other tauopathies, and mild-cognitive impairment. Further conditions involving neurodegenerative processes are, for instance, age-related macular degeneration, narcolepsy, motor neuron diseases, prion diseases, traumatic nerve injury and repair, and multiple sclerosis.

In one aspect, the invention features a method of diagnosing or prognosticating a neurodegenerative disease in a subject, or determining whether a subject is at increased risk of developing said disease. The method comprises: determining a level,

or an activity, or both said level and said activity of (i) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or of (ii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample from said subject and comparing said level, and/or said activity to a reference value representing a known disease or health status, thereby diagnosing or prognosticating said neurodegenerative disease in said subject, or determining whether said subject is at increased risk of developing said neurodegenerative disease.

The invention also relates to the construction and the use of primers and probes which are unique to the nucleic acid sequences, or fragments, or variants thereof, as disclosed in the present invention. The oligonucleotide primers and/or probes can be labeled specifically with fluorescent, bioluminescent, magnetic, or radioactive substances. The invention further relates to the detection and the production of said nucleic acid sequences, or fragments and variants thereof, using said specific oligonucleotide primers in appropriate combinations. PCR-analysis, a method well known to those skilled in the art, can be performed with said primer combinations to amplify said gene specific nucleic acid sequences from a sample containing nucleic acids. Such sample may be derived either from healthy or diseased subjects. Whether an amplification results in a specific nucleic acid product or not, and whether a fragment of different length can be obtained or not, may be indicative for a neurodegenerative disease, in particular Alzheimer's disease. Thus, the invention provides nucleic acid sequences, oligonucleotide primers, and probes of at least 10 bases in length up to the entire coding and gene sequences, useful for the detection of gene mutations and single nucleotide polymorphisms in a given sample comprising nucleic acid sequences to be examined, which may be associated with neurodegenerative diseases, in particular Alzheimer's disease. This feature has utility for developing rapid DNA-based diagnostic tests, preferably also in the format of a kit.

In a further aspect, the invention features a method of monitoring the progression of a neurodegenerative disease in a subject. A level, or an activity, or both said level and said activity, of (i) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or of (ii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample from said subject is determined. Said level and/or said activity is compared to a reference value representing a known disease or health status. Thereby the progression of said neurodegenerative disease in said subject is monitored.

In still a further aspect, the invention features a method of evaluating a treatment for a neurodegenerative disease, comprising determining a level, or an activity, or both said level and said activity of (i) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or of (ii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample obtained from a subject being treated for said disease. Said level, or said activity, or both said level and said activity are compared to a reference value representing a known disease or health status, thereby evaluating the treatment for said neurodegenerative disease.

In a preferred embodiment of the herein claimed methods, kits, recombinant animals, molecules, assays, and uses of the instant invention, said gene coding for the membrane-associated guanylate kinase-interacting proteins is the gene coding for the human neuronal membrane-associated guanylate kinase-interacting protein 1 (SEQ ID NO. 5), also termed (MAGUIN-1), and the human neuronal membrane-associated guanylate kinase-interacting protein 2 (SEQ ID NO. 6).

In a further preferred embodiment of the herein claimed methods, kits, recombinant animals, molecules, assays, and uses of the instant invention, said neurodegenerative disease or disorder is Alzheimer's disease, and said subjects suffer from Alzheimer's disease.

The present invention discloses the differential expression and regulation of the human MAGUIN-1 and/or human MAGUIN-2 gene in specific brain regions of Alzheimer's disease patients. Consequently, human MAGUIN-1 and/or human MAGUIN-2 and their corresponding translation products may have a causative role in the regional selective neuronal degeneration typically observed in Alzheimer's disease. Alternatively, human MAGUIN-1 and/or human MAGUIN-2 may confer a neuroprotective function to the remaining surviving nerve cells. Based on these disclosures, the present invention has utility for the diagnostic evaluation and prognosis as well as for the identification of a predisposition to a neurodegenerative disease, in particular Alzheimer's disease. Furthermore, the present invention provides methods for the diagnostic monitoring of patients undergoing treatment for such a disease.

It is preferred that the sample to be analyzed and determined is selected from the group comprising brain tissue, or other tissues, or other body cells. The sample can also comprise cerebrospinal fluid or other body fluids including saliva, urine, serum plasma,

or mucus. Preferably, the methods of diagnosis, prognosis, monitoring the progression or evaluating a treatment for a neurodegenerative disease, according to the instant invention, can be practiced *ex corpore*, and such methods preferably relate to samples, for instance, body fluids or cells, removed, collected, or isolated from a subject or patient.

In further preferred embodiments, said reference value is that of a level, or an activity, or both said level and said activity of (i) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or of (ii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample from a subject not suffering from said neurodegenerative disease.

In preferred embodiments, an alteration in the level and/or activity of a transcription product of the gene coding for human MAGUIN-1 and/or human MAGUIN-2 and/or a translation product of the gene coding for human MAGUIN-1 and/or human MAGUIN-2 protein in a sample cell, or tissue, or body fluid from said subject relative to a reference value representing a known health status indicates a diagnosis, or prognosis, or increased risk of becoming diseased with a neurodegenerative disease, particularly Alzheimer's disease.

In preferred embodiments, measurement of the level of transcription products of a gene coding for human MAGUIN-1 and/or human MAGUIN-2 is performed in a sample from a subject using a quantitative PCR-analysis with primer combinations to amplify said gene specific sequences from cDNA obtained by reverse transcription of RNA extracted from a sample of a subject. A Northern blot with probes specific for said gene can also be applied. It might also be preferred to measure transcription products by means of chip-based micro-array technologies. These techniques are known to those of ordinary skill in the art (see Sambrook and Russell, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001; Schena M., *Microarray Biochip Technology*, Eaton Publishing, Natick, MA, 2000). An example of an immunoassay is the detection and measurement of enzyme activity as disclosed and described in the patent application WO 02/14543.

Furthermore, the level and/or an activity of a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or a fragment, or derivative, or variant of said translation product, and/or the level of activity of said translation product, and/or a fragment, or derivative, or variant thereof, can be detected using an immunoassay, an

activity assay, and/or a binding assay. These assays can measure the amount of binding between said protein molecule and an anti-protein antibody by the use of enzymatic, chromodynamic, radioactive, magnetic, or luminescent labels which are attached to either the anti-protein antibody or a secondary antibody which binds the anti-protein antibody. In addition, other high affinity ligands may be used. Immunoassays which can be used include e.g. ELISAs, Western blots and other techniques known to those of ordinary skill in the art (see Harlow and Lane, *Using Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1999 and Edwards R, *Immunodiagnostics: A Practical Approach*, Oxford University Press, Oxford; England, 1999). All these detection techniques may also be employed in the format of microarrays, protein-arrays, antibody microarrays, tissue microarrays, electronic biochip or protein-chip based technologies (see Schena M., *Microarray Biochip Technology*, Eaton Publishing, Natick, MA, 2000).

In a preferred embodiment, the level, or the activity, or both said level and said activity of (i) a transcription product of human MAGUIN-1 and/or human MAGUIN-2, and/or of (ii) a translation product of human MAGUIN-1 and/or human MAGUIN-2, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a series of samples taken from said subject over a period of time is compared, in order to monitor the progression of said disease. In further preferred embodiments, said subject receives a treatment prior to one or more of said sample gatherings. In yet another preferred embodiment, said level and/or activity is determined before and after said treatment of said subject.

In another aspect, the invention features a kit for diagnosing or prognosticating neurodegenerative diseases, in particular Alzheimer's disease, in a subject, or determining the propensity or predisposition of a subject to develop a neurodegenerative disease, in particular Alzheimer's disease, said kit comprising:

(a) at least one reagent which is selected from the group consisting of (i) reagents that selectively detect a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2 (ii) reagents that selectively detect a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2; and

(b) instruction for diagnosing, or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, or determining the propensity or predisposition of a subject to develop such a disease by

- detecting a level, or an activity, or both said level and said activity, of said transcription product and/or said translation product of a gene coding for

human MAGUIN-1 and/or human MAGUIN-2, in a sample from said subject; and

- diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, or determining the propensity or predisposition of said subject to develop such a disease,

wherein a varied level, or activity, or both said level and said activity, of said transcription product and/or said translation product compared to a reference value representing a known health status; or a level, or activity, or both said level and said activity, of said transcription product and/or said translation product similar or equal to a reference value representing a known disease status, indicates a diagnosis or prognosis of a neurodegenerative disease, in particular Alzheimer's disease, or an increased propensity or predisposition of developing such a disease. The kit, according to the present invention, may be particularly useful for the identification of individuals that are at risk of developing a neurodegenerative disease, in particular Alzheimer's disease. Consequently, the kit, according to the invention, may serve as a means for targeting identified individuals for early preventive measures or therapeutic intervention prior to disease onset, before irreversible damage in the course of the disease has been inflicted. Furthermore, in preferred embodiments, the kit featured in the invention is useful for monitoring a progression of a neurodegenerative disease, in particular Alzheimer's disease, in a subject, as well as monitoring success or failure of therapeutic treatment for such a disease of said subject.

In another aspect, the invention features a method of treating or preventing a neurodegenerative disease, in particular Alzheimer's disease, in a subject comprising the administration to said subject in a therapeutically or prophylactically effective amount of an agent or agents which directly or indirectly affect a level, or an activity, or both said level and said activity, of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iii) a translation product of said gene, and/or (iv) a fragment, or derivative, or variant of (i) to (iii). Said agent may comprise a small molecule, or it may also comprise a peptide, an oligopeptide, or a polypeptide. Said peptide, oligopeptide, or polypeptide may comprise an amino acid sequence shown in SEQ ID NO.1 and/or SEQ ID NO.2, or a fragment, or derivative, or variant thereof. An agent for treating or preventing a neurodegenerative disease, in particular AD, according to the instant invention, may also consist of a nucleotide, an oligonucleotide, or a polynucleotide. Said oligonucleotide or polynucleotide may comprise a nucleotide sequence of the gene coding for human MAGUIN-1 and/or human MAGUIN-2 protein, either in sense orientation or in antisense orientation.

In preferred embodiments, the method comprises the application of per se known methods of gene therapy and/or antisense nucleic acid technology to administer said agent or agents. In general, gene therapy includes several approaches: molecular replacement of a mutated gene, addition of a new gene resulting in the synthesis of a therapeutic protein, and modulation of endogenous cellular gene expression by recombinant expression methods or by drugs. Gene-transfer techniques are described in detail (see e.g. Behr, *Acc Chem Res* 1993, 26: 274-278 and Mulligan, *Science* 1993, 260: 926-931; the contents of which are incorporated herein by reference) and include direct gene-transfer techniques such as mechanical microinjection of DNA into a cell as well as indirect techniques employing biological vectors (like recombinant viruses, especially retroviruses) or model liposomes, or techniques based on transfection with DNA coprecipitation with polycations, cell membrane pertubation by chemical (solvents, detergents, polymers, enzymes) or physical means (mechanic, osmotic, thermic, electric shocks). The postnatal gene transfer into the central nervous system has been described in detail (see e.g. Wolff, *Curr Opin Neurobiol* 1993, 3: 743-748).

In particular, the invention features a method of treating or preventing a neurodegenerative disease by means of antisense nucleic acid therapy, i.e. the down-regulation of an inappropriately expressed or defective gene by the introduction of antisense nucleic acids or derivatives thereof into certain critical cells (see e.g. Gillespie, *DN&P* 1992, 5: 389-395; Agrawal and Akhtar, *Trends Biotechnol* 1995, 13: 197-199; Crooke, *Biotechnology* 1992, 10: 882-6). Apart from hybridization strategies, the application of ribozymes, i.e. RNA molecules that act as enzymes, destroying RNA that carries the message of disease has also been described (see e.g. Barinaga, *Science* 1993, 262: 1512-1514). In preferred embodiments, the subject to be treated is a human, and therapeutic antisense nucleic acids or derivatives thereof are directed against human MAGUIN-1 and/or human MAGUIN-2. It is preferred that cells of the central nervous system, preferably the brain, of a subject are treated in such a way. Cell penetration can be performed by known strategies such as coupling of antisense nucleic acids and derivatives thereof to carrier particles, or the above described techniques. Strategies for administering targeted therapeutic oligodeoxynucleotides are known to those of skill in the art (see e.g. Wickstrom, *Trends Biotechnol* 1992, 10: 281-287). In some cases, delivery can be performed by mere topical application. Further approaches are directed to intracellular expression of antisense RNA. In this strategy, cells are transformed *ex vivo* with a recombinant gene that directs the synthesis of an RNA that is complementary to a region of target nucleic acid. Therapeutical use of intracellularly expressed antisense RNA is procedurally similar to gene therapy. A recently developed

method of regulating the intracellular expression of genes by the use of double-stranded RNA, known variously as RNA interference (RNAi), can be another effective approach for nucleic acid therapy (Hannon, *Nature* 2002, 418: 244-251).

In further preferred embodiments, the method comprises grafting donor cells into the central nervous system, preferably the brain, of said subject, or donor cells preferably treated so as to minimize or reduce graft rejection, wherein said donor cells are genetically modified by insertion of at least one transgene encoding said agent or agents. Said transgene might be carried by a viral vector, in particular a retroviral vector. The transgene can be inserted into the donor cells by a nonviral physical transfection of DNA encoding a transgene, in particular by microinjection. Insertion of the transgene can also be performed by electroporation, chemically mediated transfection, in particular calcium phosphate transfection, or liposomal mediated transfection (see Mc Celland and Pardee, *Expression Genetics: Accelerated and High-Throughput Methods*, Eaton Publishing, Natick, MA, 1999).

In preferred embodiments, said agent for treating and preventing a neurodegenerative disease, in particular AD, is a therapeutic protein which can be administered to said subject, preferably a human, by a process comprising introducing subject cells into said subject, said subject cells having been treated *in vitro* to insert a DNA segment encoding said therapeutic protein, said subject cells expressing *in vivo* in said subject a therapeutically effective amount of said therapeutic protein. Said DNA segment can be inserted into said cells *in vitro* by a viral vector, in particular a retroviral vector.

Methods of treatment, according to the present invention, comprise the application of therapeutic cloning, transplantation, and stem cell therapy using embryonic stem cells or embryonic germ cells and neuronal adult stem cells, combined with any of the previously described cell- and gene therapeutic methods. Stem cells may be totipotent or pluripotent. They may also be organ-specific. Strategies for repairing diseased and/or damaged brain cells or tissue comprise (I) taking donor cells from an adult tissue. Nuclei of those cells are transplanted into unfertilized egg cells from which the genetic material has been removed. Embryonic stem cells are isolated from the blastocyst stage of the cells which underwent somatic cell nuclear transfer. Use of differentiation factors then leads to a directed development of the stem cells to specialized cell types, preferably neuronal cells (Lanza et al., *Nature Medicine* 1999, 9: 975-977), or (ii) purifying adult stem cells, isolated from the central nervous system, or from bone marrow (mesenchymal stem cells), for in vitro expansion and subsequent grafting and transplantation, or (iii) directly inducing endogenous neural stem cells to proliferate,

migrate, and differentiate into functional neurons (Peterson DA, *Curr. Opin. Pharmacol.* 2002, 2: 34-42). Adult neural stem cells are of great potential for repairing damaged or diseased brain tissues, as the germinal centers of the adult brain are free of neuronal damage or dysfunction (Colman A, *Drug Discovery World* 2001, 7: 66-71).

In preferred embodiments, the subject for treatment or prevention, according to the present invention, can be a human, an experimental animal, e.g. a mouse or a rat, a domestic animal, or a non-human primate. The experimental animal can be an animal model for a neurodegenerative disorder, e.g. a transgenic mouse and/or a knock-out mouse with a neurodegenerative phenotype, in particular with an Alzheimer's-type neuropathology.

In a further aspect, the invention features a modulator of an activity, or a level, or both said activity and said level of at least one substance which is selected from the group consisting of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2 and/or (iii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iv) a fragment, or derivative, or variant of (i) to (iii).

In an additional aspect, the invention features a pharmaceutical composition comprising said modulator and preferably a pharmaceutical carrier. Said carrier refers to a diluent, adjuvant, excipient, or vehicle with which the modulator is administered.

In a further aspect, the invention features a modulator of an activity, or a level, or both said activity and said level of at least one substance which is selected from the group consisting of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iv) a fragment, or derivative, or variant of (i) to (iii) for use in a pharmaceutical composition.

In another aspect, the invention provides for the use of a modulator of an activity, or a level, or both said activity and said level of at least one substance which is selected from the group consisting of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2 and/or (iii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iv) a fragment, or derivative, or variant of

(i) to (iii) for a preparation of a medicament for treating or preventing a neurodegenerative disease, in particular Alzheimer's disease.

In one aspect, the present invention also provides a kit comprising one or more containers filled with a therapeutically or prophylactically effective amount of said pharmaceutical composition.

In a further aspect, the invention features a recombinant, non-human animal comprising a non-native gene sequence coding for human MAGUIN-1 and/or human MAGUIN-2, or a fragment, or a variant, or a derivative thereof. The generation of said recombinant, non-human animal comprises (i) providing a gene targeting construct containing said gene sequence and a selectable marker sequence, and (ii) introducing said targeting construct into a stem cell of a non-human animal, and (iii) introducing said non-human animal stem cell into a non-human embryo, and (iv) transplanting said embryo into a pseudopregnant non-human animal, and (v) allowing said embryo to develop to term, and (vi) identifying a genetically altered non-human animal whose genome comprises a modification of said gene sequence in both alleles, and (vii) breeding the genetically altered non-human animal of step (vi) to obtain a genetically altered non-human animal whose genome comprises a modification of said endogenous gene, wherein said gene is mis-expressed, or under-expressed, or over-expressed, and wherein said disruption or alteration results in said non-human animal exhibiting a predisposition to developing symptoms of neuropathology similar to a neurodegenerative disease, in particular Alzheimer's disease. Strategies and techniques for the generation and construction of such an animal are known to those of ordinary skill in the art (see e.g. Capecchi, *Science* 1989, 244: 1288-1292 and Hogan et al., 1994, *Manipulating the Mouse Embryo: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York and Jackson and Abbott, *Mouse Genetics and Transgenics: A Practical Approach*, Oxford University Press, Oxford, England, 1999). It is preferred to make use of such a recombinant non-human animal as an animal model for investigating neurodegenerative diseases, in particular Alzheimer's disease. Such an animal may be useful for screening, testing and validating compounds, agents and modulators in the development of diagnostics and therapeutics to treat neurodegenerative diseases, in particular Alzheimer's disease.

In another aspect, the invention features an assay for screening for a modulator of neurodegenerative diseases, in particular Alzheimer's disease, or related diseases and disorders of one or more substances selected from the group consisting of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription

product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iv) a fragment, or derivative, or variant of (i) to (iii). This screening method comprises (a) contacting a cell with a test compound, and (b) measuring the activity, or the level, or both the activity and the level of one or more substances recited in (i) to (iv), and (c) measuring the activity, or the level, or both the activity and the level of said substances in a control cell not contacted with said test compound, and (d) comparing the levels of the substance in the cells of step (b) and (c), wherein an alteration in the activity and/or level of said substances in the contacted cells indicates that the test compound is a modulator of said diseases and disorders.

In one further aspect, the invention features a screening assay for a modulator of neurodegenerative diseases, in particular Alzheimer's disease, or related diseases and disorders of one or more substances selected from the group consisting of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iv) a fragment, or derivative, or variant of (i) to (iii), comprising (a) administering a test compound to a test animal which is predisposed to developing or has already developed symptoms of a neurodegenerative disease or related diseases or disorders, and (b) measuring the activity and/or level of one or more substances recited in (i) to (iv), and (c) measuring the activity and/or level of said substances in a matched control animal which is equally predisposed to developing or has already developed said symptoms and to which animal no such test compound has been administered, and (d) comparing the activity and/or level of the substance in the animals of step (b) and (c), wherein an alteration in the activity and/or level of substances in the test animal indicates that the test compound is a modulator of said diseases and disorders.

In a preferred embodiment, said test animal and/or said control animal is a recombinant, non-human animal which expresses the gene coding for human MAGUIN-1 and/or human MAGUIN-2, or a fragment, or derivative, or a variant thereof, under the control of a transcriptional regulatory element which is not the native human MAGUIN-1 and/or human MAGUIN-2 gene transcriptional control regulatory element.

In another embodiment, the present invention provides a method for producing a medicament comprising the steps of (i) identifying a modulator of neurodegenerative diseases by a method of the aforementioned screening assays and (ii) admixing the

modulator with a pharmaceutical carrier. However, said modulator may also be identifiable by other types of screening assays.

In another aspect, the present invention provides for an assay for testing a compound, preferably for screening a plurality of compounds, for inhibition of binding between a ligand and human MAGUIN-1 and/or human MAGUIN-2, or a fragment, or derivative, or variant thereof. Said screening assay comprises the steps of (i) adding a liquid suspension of said human MAGUIN-1 and/or human MAGUIN-2, or a fragment, or derivative, or variant thereof, to a plurality of containers, and (ii) adding a compound or a plurality of compounds to be screened for said inhibition to said plurality of containers, and (iii) adding fluorescently labelled ligand to said containers, and (iv) incubating said human MAGUIN-1 and/or human MAGUIN-2, or said fragment, or derivative, or variant thereof, and said compound or plurality of compounds, and said fluorescently labelled ligand, and (v) measuring the amounts of fluorescence associated with said human MAGUIN-1 and/or human MAGUIN-2, or with said fragment, or derivative, or variant thereof, and (vi) determining the degree of inhibition by one or more of said compounds of binding of said ligand to said human MAGUIN-1 and/or human MAGUIN-2, or said fragment, or derivative, or variant thereof. Instead of utilizing a fluorescently labelled ligand, it might in some aspects be preferred to use any other detectable label known to the person skilled in the art, e.g. radioactive labels, and detect it accordingly. Said method may be useful for the identification of novel compounds as well as for evaluating compounds which have been improved or otherwise optimized in their ability to inhibit the binding of a ligand to a gene product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, or a fragment, or derivative, or variant thereof. One example of a fluorescent binding assay, in this case based on the use of carrier particles, is disclosed and described in patent application WO 00/52451. A further example is the competitive assay method as described in patent WO 02/01226. Preferred signal detection methods for screening assays of the instant invention are described in the following patent applications: WO 96/13744, WO 98/16814, WO 98/23942, WO 99/17086, WO 99/34195, WO 00/66985, WO 01/59436, WO 01/59416.

In one further embodiment, the present invention provides a method for producing a medicament comprising the steps of (i) identifying a compound as an inhibitor of binding between a ligand and a gene product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2 by the aforementioned inhibitory binding assay and (ii) admixing the compound with a pharmaceutical carrier. However, said compound may also be identifiable by other types of screening assays.

In another aspect, the invention features an assay for testing a compound, preferably for screening a plurality of compounds to determine the degree of binding of said compounds to human MAGUIN-1 and/or human MAGUIN-2, or to a fragment, a variant, or derivative thereof. Said screening assay comprises (i) adding a liquid suspension of said human MAGUIN-1 and/or human MAGUIN-2, or a fragment, or a variant, or derivative thereof, to a plurality of containers, and (ii) adding a fluorescently labelled compound or a plurality of fluorescently labelled compounds to be screened for said binding to said plurality of containers, and (iii) incubating said human MAGUIN-1 and/or human MAGUIN-2, or said fragment, or variant, or derivative thereof, and said fluorescently labelled compound or fluorescently labelled compounds, and (iv) measuring the amounts of fluorescence associated with said human MAGUIN-1 and/or human MAGUIN-2, or with said fragment, or variant, or derivative thereof, and (v) determining the degree of binding by one or more of said compounds to said human MAGUIN-1 and/or human MAGUIN-2, or said fragment, or variant, or derivative thereof. In this type of assay it might be preferred to use a fluorescent label. However, any other type of detectable label might also be employed. Said method may be useful for the identification of novel compounds as well as for evaluating compounds which have been improved or otherwise optimized in their ability to bind to a human MAGUIN-1 and/or human MAGUIN-2 gene product, or fragment, or variant, or derivative thereof.

In one further embodiment, the present invention provides a method for producing a medicament comprising the steps of (i) identifying a compound as a binder to a gene product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2 by the aforementioned binding assays and (ii) admixing the compound with a pharmaceutical carrier. However, said compound may also be identifiable by other types of screening assays.

In another embodiment, the present invention provides for a medicament obtainable by any of the methods according to the herein claimed screening assays. In one further embodiment, the instant invention provides for a medicament obtained by any of the methods according to the herein claimed screening assays.

The present invention features protein molecules shown in SEQ ID NO. 1, and SEQ ID NO. 2, or fragments, or derivatives, or variants thereof, for use as diagnostic targets for detecting a neurodegenerative disease, preferably Alzheimer's disease.

The present invention further features protein molecules shown in SEQ ID NO. 1 and SEQ ID NO. 2, or fragments, or derivatives, or variants thereof, for use as screening

targets for reagents or compounds preventing, or treating, or ameliorating a neurodegenerative disease, preferably Alzheimer's disease.

The invention further features an antibody specifically immunoreactive with an immunogen, wherein said immunogen is a translation product of the human MAGUIN-1 gene shown in SEQ ID NO. 1, or a fragment, or a variant, or a derivative thereof. The immunogen may comprise immunogenic or antigenic epitopes or portions of a translation product of said gene, wherein said immunogenic or antigenic portion of a translation product is a polypeptide, and wherein said polypeptide elicits an antibody response in an animal, and wherein said polypeptide is immunospecifically bound by said antibody. Methods for generating antibodies are well known in the art (see Harlow et al., *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1988). The term "antibody", as employed in the present invention, encompasses all forms of antibodies known in the art, such as polyclonal, monoclonal, chimeric, recombinatorial, anti-idiotypic, humanized, or single chain antibodies, as well as fragments thereof (see Dubel and Breitling, *Recombinant Antibodies*, Wiley-Liss, New York, NY, 1999). Antibodies of the present invention are useful, for instance, in a variety of diagnostic and therapeutic methods, based on state-in-the-art techniques (see Harlow and Lane, *Using Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1999 and Edwards R., *Immunodiagnostics: A Practical Approach*, Oxford University Press, Oxford, England, 1999) such as enzyme-immuno assays (e.g. enzyme-linked immunosorbent assay, ELISA), radioimmuno assays, chemoluminescence-immuno assays, Western-blot, immunoprecipitation and antibody microarrays. These methods involve the detection of translation products of the human MAGUIN-1 gene.

The invention also features an antibody specifically immunoreactive with an immunogen, wherein said immunogen is a translation product of the human MAGUIN-2 gene shown in SEQ ID NO. 2, or a fragment, a variant, or a derivative thereof.

In a preferred embodiment of the present invention, said antibodies can be used for detecting the pathological state of a cell in a sample from a subject, comprising immunocytochemical staining of said cell with said antibody, wherein an altered degree of staining, or an altered staining pattern in said cell compared to a cell representing a known health status indicates a pathological state of said cell. The invention is particularly suited to detect pathological structures in the brain of a subject. It is also especially suited to detect pathological cells of the muscular system, prostate, stomach, testis, ovary, adrenal glands, mammary glands, liver, spleen, lung, trachea or placenta.

Preferably, the pathological state relates to a neurodegenerative disease, in particular to Alzheimer's disease. Immunocytochemical staining of a cell can be carried out by a number of different experimental methods well known in the art. It might be preferred, however, to apply an automated method for the detection of antibody binding, wherein the determination of the degree of staining of a cell, or the determination of the cellular or subcellular staining pattern of a cell, or the topological distribution of an antigen on the cell surface or among organelles and other subcellular structures within the cell, are carried out according to the method described in US patent 6150173.

Other features and advantages of the invention will be apparent from the following description of figures and examples which are illustrative only and not intended to limit the remainder of the disclosure in any way.

Figure 1 depicts the brain regions with selective vulnerability to neuronal loss and degeneration in Alzheimer's disease. Primarily, neurons within the inferior temporal lobe, the entorhinal cortex, the hippocampus, and the amygdala are subject to degenerative processes in Alzheimer's disease (Terry et al., *Annals of Neurology* 1981, 10:184-192). These brain regions are mostly involved in the processing of learning and memory functions. In contrast, neurons within the frontal cortex, the occipital cortex, and the cerebellum remain largely intact and preserved from neurodegenerative processes in Alzheimer's disease. Brain tissues from the frontal cortex (F), the temporal cortex (T), and the hippocampus (H) of Alzheimer's disease patients and healthy, age-matched control individuals were used for the herein disclosed examples. For illustrative purposes, the image of a normal healthy brain was taken from a publication by Strange (*Brain Biochemistry and Brain Disorders*, Oxford University Press, Oxford, 1992, p.4).

Figure 2 discloses the initial identification of the differential expression of the human MAGUIN-1 gene in a fluorescence differential display screen. The figure shows a clipping of a large preparative fluorescent differential display gel. PCR products from the frontal cortex (F) and the temporal cortex (T) of two healthy control subjects and six Alzheimer's diseased patients were loaded in duplicate onto a denaturing polyacrylamide gel (from left to right). PCR products were obtained by amplification of the individual cDNAs with the corresponding one-base-anchor oligonucleotide and the specific Cy3 labelled random primers. The arrow indicates the lane where significant differences in intensity of the signals for human MAGUIN-1 transcript derived from frontal cortex, compared to the signals for human MAGUIN-1 transcript derived from the temporal cortex of Alzheimer's patients exist. The differential expression reflects a down-regulation of human MAGUIN RNA expression in the temporal cortex in

comparison to the frontal cortex of AD patients. Comparing the signals derived from frontal cortex and temporal cortex of healthy non-AD control subjects with each other, no distinction in signal intensity, i.e. no altered expression level can be detected.

Figure 3 and Figure 4 illustrate the verification of the differential expression of human MAGUIN-1 in AD brain tissues by quantitative RT-PCR analysis. Quantification of RT-PCR products from RNA samples collected from the frontal cortex (F) and the temporal cortex (T) of AD patients (Figure 3a) and samples from the frontal cortex (F) and the hippocampus (H) of AD patients (Figure 4a) was performed by the LightCycler rapid thermal cycling technique. Likewise, samples of healthy, age-matched control individuals were compared (Figure 3b for frontal cortex and temporal cortex, Figure 4b for frontal cortex and hippocampus). The data were normalized to the combined average values of a set of standard genes which showed no significant differences in their gene expression levels. Said set of standard genes consisted of genes for cyclophilin B, the ribosomal protein S9, the transferrin receptor, GAPDH, and beta-actin. The figure depicts the kinetics of amplification by plotting the cycle number against the amount of amplified material as measured by its fluorescence. Note that the amplification kinetics of Maguin-1 cDNA from both, the frontal and temporal cortices of a normal control individual, and from the frontal cortex and hippocampus of a normal control individual, respectively, during the exponential phase of the reaction are juxtaposed (Figures 3b and 4b, arrowheads), whereas in Alzheimer's disease (Figures 3a and 4a, arrowheads) there is a significant separation of the corresponding curves, indicating a differential expression of Maguin-1 in the respective analyzed brain regions.

Figure 5 and Figure 6 illustrate the verification of the differential expression of human MAGUIN-2 in AD brain tissues by quantitative RT-PCR analysis. Quantification of RT-PCR products from RNA samples collected from the frontal cortex (F) and the temporal cortex (T) of AD patients (Figure 5a) and samples from the frontal cortex (F) and the hippocampus (H) of AD patients (Figure 6a) was performed by the LightCycler rapid thermal cycling technique. Likewise, samples of healthy, age-matched control individuals were compared (Figure 5b for frontal cortex and temporal cortex, Figure 6b for frontal cortex and hippocampus). The data were normalized to the combined average values of a set of standard genes which showed no significant differences in their gene expression levels. Said set of standard genes consisted of genes for cyclophilin B, the ribosomal protein S9, the transferrin receptor, GAPDH, and beta-actin. The figure depicts the kinetics of amplification by plotting the cycle number against the amount of amplified material as measured by its fluorescence. Note that the amplification kinetics of Maguin-2 cDNA from both, the frontal and temporal cortices of a normal control

individual, and from the frontal cortex and hippocampus of a normal control individual, respectively, during the exponential phase of the reaction are juxtaposed (Figures 5b and 6b, arrowheads), whereas in Alzheimer's disease (Figures 5a and 6a, arrowheads) there is a significant separation of the corresponding curves, indicating a differential expression of Maguin-2 in the respective analyzed brain regions.

Figure 7 discloses the amino acid sequence of the human MAGUIN-1 protein comprising 1034 amino acids; SEQ ID NO. 1. The protein harbors several distinct functional domains which are located as follows: amino acid residues 8 to 75 form the 'Sterile Alpha Motif' (SAM), amino acid residues 156 to 296 constitute the PDZ domain, and the Pleckstrin-homology (PH) domain consists of amino acid residues 572 to 667.

Figure 8 shows an alignment of the amino acid sequence of SEQ ID NO.1, human MAGUIN-1, with the rat MAGUIN-1 amino acid sequence (GenBank accession number aad04568). The full length human MAGUIN-1 protein consists of 1034 amino acids (residues given in the single-letter amino acid code).

Figure 9 discloses the amino acid sequence of the human MAGUIN-2 protein comprising 898 amino acids; SEQ ID NO. 2. The protein harbors several distinct functional domains which are located as follows: amino acid residues 8 to 75 form the 'Sterile Alpha Motif' (SAM), amino acid residues 156 to 296 constitute the PDZ domain, and the Pleckstrin-homology (PH) domain consists of amino acid residues 572 to 667.

Figure 10 shows an alignment of the amino acid sequence of SEQ ID NO. 2, human MAGUIN-2, with rat MAGUIN-2 amino acid sequence (GenBank accession number aad04567). The full length human MAGUIN-2 protein consists of 898 amino acids (residues given in the single-letter amino acid code).

Figure 11 represents the nucleotide sequence of SEQ ID NO. 3, the coding sequence of the human MAGUIN-1 gene, comprising 3105 nucleotides.

Figure 12 represents the nucleotide sequence of SEQ ID NO. 4, the coding sequence of the human MAGUIN-2 gene, comprising 2697 nucleotides.

Figure 13 shows SEQ ID NO. 5, the nucleotide sequence of the human MAGUIN-1 cDNA, comprising 5749 nucleotides.

Figure 14 shows SEQ ID NO. 6, the nucleotide sequence of the human MAGUIN-2 cDNA; comprising 4350 nucleotides.

Figure 15 depicts SEQ ID NO. 7, the nucleotide sequence of the 50 bp MAGUIN-1 cDNA fragment, identified and obtained by fluorescence differential display and subsequent cloning.

Figure 16 outlines the sequence alignment of SEQ ID NO. 7, the 50 bp human MAGUIN-1 cDNA fragment, with the 3'UTR nucleotide sequence of SEQ ID NO. 5 (nucleotide 5693 to 5742), the nucleotide sequence of human MAGUIN-1 cDNA.

Figure 17 charts the schematic alignment of SEQ ID NO. 7, the human MAGUIN-1 cDNA fragment, SEQ ID NO. 6, the human MAGUIN-2 cDNA sequence and the nucleotide sequence of SEQ ID NO. 5, the nucleotide sequence of human MAGUIN-1 cDNA, derived from the alignment of EST nucleotide sequences as found in the GenBank genetic sequence database. EST numbers are written on the left side, all sequences are 5' to 3' directed.

Figure 18 depicts human cerebral cortex labeled with an affinity-purified rabbit anti-Maguin-1 antiserum raised against a peptide corresponding to amino acids 914-928 (green signals). Strong immunoreactivity of human Maguin-1 was detected in neuronal cell bodies (indicated by arrowheads) and in neurites, whereas glial cells were immuno-negative (see arrows). The same immunostaining pattern was observed by using another antiserum raised against a peptide mapping to amino acids 973-987 of Maguin-1. Blue signals indicate nuclei stained with DAPI.

Table 1 lists the gene expression levels in the frontal cortex relative to the temporal cortex for the human MAGUIN-1 gene in seven Alzheimer's disease patients, herein identified by internal reference numbers P010, P011, P012, P014, P016, P017, P019 (1.42 to 4.14 fold) and five healthy, age-matched control individuals, herein identified by internal reference numbers C005, C008, C011, C012, C014 (0.30 to 1.36 fold). The values shown are reciprocal values according to the formula described herein.

Table 2 lists the gene expression levels in the frontal cortex relative to the hippocampus for the human MAGUIN-1 gene in six Alzheimer's disease patients, herein identified by internal reference numbers P010, P011, P012, P014, P016, P019 (1.21 to 3.07 fold) and three healthy, age-matched control individuals, herein identified by internal reference

numbers C004, C005, C008 (0.39 to 1.74 fold). The values shown are reciprocal values according to the formula described herein.

Table 3 lists the gene expression levels in the frontal cortex relative to the temporal cortex for the human MAGUIN-2 gene in seven Alzheimer's disease patients, herein identified by internal reference numbers P010, P011, P012, P014, P016, P017, P019 (1.77 to 11.73 fold) and five healthy, age-matched control individuals, herein identified by internal reference numbers C005, C008, C011, C012, C014 (0.30 to 1.42 fold). The values shown are reciprocal values according to the formula described herein.

Table 4 lists the gene expression levels in the frontal cortex relative to the hippocampus for the human MAGUIN-2 gene in six Alzheimer's disease patients, herein identified by internal reference numbers P010, P011, P012, P014, P016, P019 (0.72 to 9.08 fold) and three healthy, age-matched control individuals, herein identified by internal reference numbers C004, C005, C008 (0.46 to 1.69 fold). The values shown are reciprocal values according to the formula described herein.

EXAMPLE I:

(i)   Brain tissue dissection from patients with Alzheimer's disease:
Brain tissues from Alzheimer's disease patients and age-matched control subjects were collected within 6 hours post-mortem and immediately frozen on dry ice. Sample sections from each tissue were fixed in paraformaldehyde for histopathological confirmation of the diagnosis. Brain areas for differential expression analysis were identified (see Figure 1) and stored at – 80 °C until RNA extractions were performed.

(ii)   Isolation of total RNA:
Total RNA was extracted from post-mortem brain tissue by using the RNeasy kit (Qiagen) according to the manufacturer's protocol. The accurate RNA concentration and the RNA quality were determined with the DNA LabChip system using the Agilent 2100 Bioanalyzer (Agilent Technologies). For additional quality testing of the prepared RNA, i.e. exclusion of partial degradation and testing for DNA contamination, specifically designed intronic GAPDH oligonucleotides and genomic DNA as reference control were utilised to generate a melting curve with the LightCycler technology as described in the manufacturer's protocol (Roche).

(iii)   cDNA synthesis and identification of differentially expressed genes by

fluorescence differential display (FDD):

In order to identify changes in gene expression in different tissues we employed a modified and improved differential display (DD) screening method. The original DD screening method is known to those skilled in the art (Liang and Pardee, *Science* 1995, 267:1186-7). This technique compares two populations of RNA and provides clones of genes that are expressed in one population but not in the other. Several samples can be analyzed simultaneously and both up- and down-regulated genes can be identified in the same experiment. By adjusting and refining several steps in the DD method as well as modifying technical parameters, e.g. increasing redundancy, evaluating optimized reagents and conditions for reverse transcription of total RNA, optimizing polymerase chain reactions (PCR) and separation of the products thereof, a technique was developed which allows for highly reproducible and sensitive results. The applied and improved DD technique was described in detail by von der Kammer et al. (*Nucleic Acids Research* 1999, 27: 2211-2218). A set of 64 specifically designed random primers were developed (standard set) to achieve a statistically comprehensive analysis of all possible RNA species. Further, the method was modified to generate a preparative DD slab-gel technique, based on the use of fluorescently labelled primers. In the present invention, RNA populations from carefully selected post-mortem brain tissues (frontal and temporal cortex) of Alzheimer's disease patients and age-matched control subjects were compared.

As starting material for the DD analysis we used total RNA, extracted as described above (ii). Equal amounts of 0.05 µg RNA each were transcribed into cDNA in 20 µl reactions containing 0.5 mM each dNTP, 1 µl Sensiscript^{TM} Reverse Transcriptase and 1x RT buffer (Qiagen), 10 U RNase inhibitor (Qiagen) and 1 µM of either one-base-anchor oligonucleotides $HT_{11}A$, $HT_{11}G$ or $HT_{11}C$ (Liang et al., *Nucleic Acids Research* 1994, 22: 5763-5764; Zhao et al., *Biotechniques* 1995, 18: 842-850). Reverse transcription was performed for 60 min at 37 °C with a final denaturation step at 93 °C for 5 min. 2 µl of the obtained cDNA each was subjected to a polymerase chain reaction (PCR) employing the corresponding one-base-anchor oligonucleotide (1 µM) along with either one of the Cy3 labelled random DD primers (1 µM), 1x GeneAmp PCR buffer (Applied Biosystems), 1.5 mM $MgCl_2$ (Applied Biosystems), 2 µM dNTP-Mix (dATP, dGTP, dCTP, dTTP Amersham Pharmacia Biotech), 5 % DMSO (Sigma), 1 U AmpliTaq DNA Polymerase (Applied Biosystems) in a 20 µl final volume. PCR conditions were set as follows: one round at 94 °C for 30 sec for denaturing, cooling 1 °C/sec down to 40 °C, 40 °C for 4 min for low-stringency annealing of primer, heating 1 °C/sec up to 72 °C, 72 °C for 1 min for extension. This round was followed by 39 high-stringency cycles: 94

°C for 30 sec, cooling 1 °C/sec down to 60 °C, 60 °C for 2 min, heating 1 °C/sec up to 72 °C, 72 °C for 1 min. One final step at 72 °C for 5 min was added to the last cycle (PCR cycler: Multi Cycler PTC 200, MJ Research). 8 µl DNA loading buffer were added to the 20 µl PCR product preparation, denatured for 5 min and kept on ice until loading onto a gel. 3.5 µl each were separated on 0.4 mm thick, 6 %-polyacrylamide (Long Ranger)/ 7 M urea sequencing gels in a slab-gel system (Hitachi Genetic Systems) at 2000 V, 60W, 30 mA, for 1 h 40 min. Following completion of the electrophoresis, gels were scanned with a FMBIO II fluorescence-scanner (Hitachi Genetic Systems), using the appropriate FMBIO II Analysis 8.0 software. A full-scale picture was printed, differentially expressed bands marked, excised from the gel, transferred into 1.5 ml containers, overlayed with 200 µl sterile water and kept at –20°C until extraction.

Elution and reamplification of differential display products: The differential bands were extracted from the gel by boiling in 200 µl H2O for 10 min, cooling down on ice and precipitation from the supernatant fluids by using ethanol (Merck) and glycogen/sodium acetate (Merck) at – 20 °C over night, and subsequent centrifugation at 13.000 rpm for 25 min at 4 °C. Pellets were washed twice in ice-cold ethanol (80%), resuspended in 10 mM Tris pH 8.3 (Merck) and dialysed against 10 % glycerol (Merck) for 1 h at room temperature on a 0.025 µm VSWP membrane (Millipore). The obtained preparations were used as templates for reamplification by 15 high-stringency cycles in 25-µl PCR mixtures containing the corresponding primer pairs as used for the differential display PCR (see above) under identical conditions, with the exception of the initial round at 94 °C for 5 min, followed by 15 cycles of: 94 °C for 45 sec, 60 °C for 45 sec, ramp 1°C/sec to 70 °C for 45 sec, and one final step at 72 °C for 5 min.

Cloning and sequencing of differential display products: Re-amplified cDNAs were analyzed with the DNA LabChip system (Agilent 2100 Bioanalyzer, Agilent Technologies) and were ligated into the pCR-Blunt II-TOPO vector and transformed into *E.coli* Top10F' cells (Zero Blunt TOPO PCR Cloning Kit, Invitrogen) according to the manufacturer's instructions. Cloned cDNA fragments were sequenced by commercially available sequencing facilities. The results of one such fluorescence differential display experiment for the human MAGUIN-1 gene are shown in Figure 2.

(iv)   Confirmation of differential expression by quantitative RT-PCR:
Positive corroboration of differential expression of the human MAGUIN-1 gene and human MAGUIN-2 gene was performed using the LightCycler technology (Roche). This technique features rapid thermal cyling for the polymerase chain reaction as well as real-time measurement of fluorescent signals during amplification and therefore allows for highly accurate quantification of RT-PCR products by using a kinetic, rather than an endpoint approach. The ratios of human MAGUIN-1 and human MAGUIN-2 cDNA each

from the temporal cortex and frontal cortex, and from the hippocampus and frontal cortex, respectively, were determined (relative quantification).

First, a standard curve was generated to determine the efficiency of the PCR with specific primers for human MAGUIN-1:

5'-CAGCAAGCAGTTGACGGGA-3'

and 5'-GCCACGAGTCTTGTCAAATTCA -3'

and human MAGUIN-2:

5'-GGGCCTCCCAAAGGGATAT-3'

and 5'-CCCAATGTAGAAAGCTCGCATT-3'.

PCR amplification (95 °C and 1 sec, 56 °C and 5 sec, and 72 °C and 5 sec) was performed in a volume of 20 µl containing Lightcycler-FastStart DNA Master SYBR Green I mix (contains FastStart Taq DNA polymerase, reaction buffer, dNTP mix with dUTP instead of dTTP, SYBR Green I dye, and 1 mM $MgCl_2$; Roche), 0.5 µM primers, 2 µl of a cDNA dilution series (final concentration of 40, 20, 10, 5, 1 and 0.5 ng human total brain cDNA; Clontech) and depending on the primers used, additional 3 mM $MgCl_2$. Melting curve analysis revealed a single peak at approximately 80°C and 80.6°C with no visible primer dimers. Quality and size of the PCR product were determined with the DNA LabChip system (Agilent 2100 Bioanalyzer, Agilent Technologies). A single peak at the expected size of 121 bp for human MAGUIN-1 and 67 bp for human MAGUIN-2 was observed in the electropherogram of the sample.

In an analogous manner, the PCR protocol was applied to determine the PCR efficiency of a set of reference genes which were selected as a reference standard for quantification. In the present invention, the mean value of five such reference genes was determined: (1) cyclophilin B, using the specific primers 5'-ACTGAAGCACTACGGGCCTG-3' and 5'-AGCCGTTGGTGTCTTTGCC-3' except for $MgCl_2$ (an additional 1 mM was added instead of 3 mM). Melting curve analysis revealed a single peak at approximately 87 °C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band of the expected size (62 bp). (2) Ribosomal protein S9 (RPS9), using the specific primers 5'-GGTCAAATTTACCCTGGCCA-3' and 5'- TCTCATCAAGCGTCAGCAGTTC-3' (exception: additional 1 mM $MgCl_2$ was added instead of 3 mM). Melting curve analysis revealed a single peak at approximately 85°C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (62 bp). (3) beta-actin, using the specific primers 5'-TGGAACGGTGAAGGTGACA-3' and 5'-GGCAAGGGACTTCCTGTAA-3'. Melting curve analysis revealed a single peak at approximately 87°C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (142 bp). (4) GAPDH, using the specific primers 5'-CGTCATGGGTGTGAACCATG-

3' and 5'-GCTAAGCAGTTGGTGGTGCAG-3'. Melting curve analysis revealed a single peak at approximately 83°C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (81 bp). (5) Transferrin receptor TRR, using the specific primers 5'-GTCGCTGGTCAGTTCGTGATT-3' and 5'-AGCAGTTGGCTGTTGTACCTCTC-3'. Melting curve analysis revealed a single peak at approximately 83°C with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (80 bp).

For calculation of the values, first the logarithm of the cDNA concentration was plotted against the threshold cycle number C_t for human MAGUIN-1 and human MAGUIN-2, respectively, and the five reference standard genes. The slopes and the intercepts of the standard curves (i.e. linear regressions) were calculated for all genes. In a second step, cDNAs from temporal cortex and frontal cortex, and from hippocampus and frontal cortex, for human MAGUIN-1 and human MAGUIN-2, respectively, were analyzed in parallel and normalized to cyclophilin B. The C_t values were measured and converted to ng total brain cDNA using the corresponding standard curves:

$$10 \char94 ((C_t \text{ value - intercept}) / \text{slope}) \qquad [\text{ng total brain cDNA}]$$

The values for temporal cortex and frontal cortex of human MAGUIN-1 and human MAGUIN-2 cDNAs, and the values for hippocampus and frontal cortex of human MAGUIN-1 and human MAGUIN-2 cDNAs, respectively, were normalized to cyclophilin B, and the ratios were calculated using the following formulas:

$$\text{Ratio} = \frac{\text{human MAGUIN-1(MAGUIN-2) temporal [ng] / cyclophilin B temporal [ng]}}{\text{human MAGUIN-1(MAGUIN-2) frontal [ng] / cyclophilin B frontal [ng]}}$$

$$\text{Ratio} = \frac{\text{human MAGUIN-1(MAGUIN-2) hippocampus [ng] / cyclophilin B hippocampus [ng]}}{\text{human MAGUIN-1(MAGUIN-2) frontal [ng] / cyclophilin B frontal [ng]}}$$

In a third step, the set of reference standard genes was analyzed in parallel to determine the mean average value of the temporal to frontal ratios, and of the hippocampal to frontal ratios, respectively, of expression levels of the reference standard genes for each individual brain sample. As cyclophilin B was analyzed in step

2 and step 3, and the ratio from one gene to another gene remained constant in different runs, it was possible to normalize the values for human MAGUIN-1 and human MAGUIN-2 to the mean average value of the set of reference standard genes instead of normalizing to one single gene alone. The calculation was performed by dividing the ratio shown above by the deviation of cyclophilin B from the mean value of all housekeeping genes. The results of such quantitative RT-PCR analysis for the human MAGUIN-1 gene are shown in Figure 3 and 4 and for the human MAGUIN-2 gene in Figure 5 and 6.

(v) <u>Sequence Analysis</u>

Searching the EST database of the GenBank database for sequence similarities to the identified differentially expressed human cDNA fragment, SEQ ID NO. 7, as stated in the present invention, it was found that SEQ ID NO. 7 was identical to portions of the human EST sequences ai817268 and bf115709, (shown in Figure 17). These human ESTs showed high homology to rat (*Rattus norvegicus*) MAGUIN-1. Aligning human ESTs in addition to the identified expressed SEQ ID NO. 7, a complete EST cluster representing the human MAGUIN-1 cDNA, SEQ ID NO. 5, was constructed. The amino acid sequence of a large open reading frame with the potential to encode a protein of 1034 amino acid residues was deduced (SEQ ID NO. 1). The human MAGUIN-1 protein, as denoted herein, is highly homologous to the rat MAGUIN-1 protein. In addition, it encodes a protein (SEQ ID NO. 1) harboring a number of structurally and functionally important domains. One SAM, one PDZ, and one PH domain are located from amino acid residues 8 to 75 (SAM), amino acid residues 156 to 296 (PDZ), and amino acid residues 572 to 667 (PH) (refer to Figure 7).

(vi) <u>Immunohistochemistry:</u>

For immunofluorescence staining of Maguin-1 in human brain, frozen sections were prepared from post-mortem pre-central gyrus of a donor person (Cryostat Leica CM3050S) and fixed in acetone for 10 min. After washing in PBS, the sections were pre-incubated with blocking buffer (10% normal goat serum, 0.2% Triton X-100 in PBS) for 30min, and then incubated with affinity-purified rabbit anti-Maguin-1 antisera (1:20-1:50 diluted in blocking buffer, custom-made by Davids Biotechnologie, Regensburg) overnight at 4°C. After rinsing three times in 0.2% Triton X-100/PBS, the sections were incubated with FITC-conjugated goat anti-rabbit IgG (1:150 diluted in 1% BSA/PBS) for 2 hours at room temperature, and then again washed in PBS. Staining of the nuclei was performed by incubation of the sections with 5µM DAPI in PBS for 3min (blue signal). In order to block the autofluoresence of lipofuscin in human brain, the sections were treated with 1% Sudan Black B in 70% ethanol for 2-10 min at room temperature,

sequentially dipped in 70% ethanol, destilled water and PBS. The sections were coverslipped by 'Vectrashield mounting medium' (Vector Laboratories, Burlingame, CA) and observed under an inverted microscope (IX81, Olympus Optical). The digital images were captured with the appropriate software (AnalySiS, Olympus Optical).

●   34   ●

CLAIMS

1.   A method of diagnosing or prognosticating a neurodegenerative disease in a subject, or determining whether a subject is at increased risk of developing said disease, comprising:

    determining a level and/or an activity of

    (i)   a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or

    (ii)   a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or

    (iii)   a fragment, or derivative, or variant of said transcription or translation product,

in a sample from said subject and comparing said level and/or said activity to a reference value representing a known disease or health status, thereby diagnosing or prognosticating said neurodegenerative disease in said subject, or determining whether said subject is at increased risk of developing said neurodegenerative disease.

2. A method of monitoring the progression of a neurodegenerative disease in a subject, comprising:

    determining a level and/or an activity of

    (i)   a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or

    (ii)   a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or

    (iii)   a fragment, or derivative, or variant of said transcription or translation product,

in a sample from said subject and comparing said level and/or said activity to a reference value representing a known disease or health status, thereby monitoring the progression of said neurodegenerative disease in said subject.

3. A method of evaluating a treatment for a neurodegenerative disease, comprising:

    determining a level and/or an activity of

    (i)   a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or

    (ii)   a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or

(iii)   a fragment, or derivative, or variant of said transcription or translation product,

in a sample from a subject being treated for said disease and comparing said level and/or said activity to a reference value representing a known disease or health status, thereby evaluating said treatment for said neurodegenerative disease.

4.   The method according to any of claims 1 to 3 wherein said neurodegenerative disease is Alzheimer's disease.

5.   The method according to any of claims 1 to 4 wherein said sample is a cell, or a tissue, or a body fluid, in particular cerebrospinal fluid or blood.

6.   The method according to any of claims 1 to 5 wherein said reference value is that of a level and/or an activity of

(i) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or

(ii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or

(iii) a fragment, or derivative, or variant of said transcription or translation product,

in a sample from a subject not suffering from said neurodegenerative disease.

7. The method according to any of claims 1 to 6 wherein an alteration in the level and/or activity of a transcription product of the gene coding for human MAGUIN-1 and/or human MAGUIN-2 and/or a translation product of the gene coding for human MAGUIN-1 and/or human MAGUIN-2 and/or a fragment, or derivative, or variant thereof, in a sample cell, or tissue, or body fluid, in particular cerebrospinal fluid, from said subject relative to a reference value representing a known health status indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.

8.   The method according to any of claims 1 to 7, further comprising   comparing a level and/or an activity of

(i)   a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or

(ii)   a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or

(iii)   a fragment, or derivative, or variant of said transcription or translation product,

in a series of samples taken from said subject over a period of time.

9.   The method according to claim 8, wherein said subject receives a treatment prior to one or more of said sample gatherings.

10.   The method according to claim 9 wherein said level and/or activity is determined before and after said treatment of said subject.

11. A kit for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or determining the propensity or predisposition of a subject to develop such a disease, said kit comprising:
   (a) at least one reagent which is selected from the group consisting of
      (i) reagents that selectively detect a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and
      (ii) reagents that selectively detect a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2 and
   (b) an instruction for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, or determining the propensity or predisposition of a subject to develop such a disease by
      (i) detecting a level, or an activity, or both said level and said activity, of said transcription product and/or said translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2 in a sample from said subject; and
      (ii) diagnosing or prognosticating a neurodegenerative disease, in   particular Alzheimer's disease, or determining the propensity or   predisposition of said subject to develop such a disease,
      wherein a varied level, or activity, or both said level and said activity, of said transcription product and/or said translation product compared to a reference value representing a known health status; or a level, or activity, or both said level and said activity, of said transcription product and/or said translation product similar or equal to a reference value representing a known disease status indicates a diagnosis or prognosis of a neurodegenerative disease, in particular Alzheimer's disease, or an increased propensity or predisposition of developing such a disease.

12.   A method of treating or preventing a neurodegenerative disease, in particular Alzheimer's disease, in a subject comprising administering to said subject in a therapeutically or prophylactically effective amount an agent or agents which directly or

indirectly affect an activity and/or a level of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iv) a fragment, or derivative, or variant of (i) to (iii).

13.   A modulator of an activity and/or of a level of at least one substance which is selected from the group consisting of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iv) a fragment, or derivative, or variant of (i) to (iii).

14.   A pharmaceutical composition comprising a modulator according to claim 13.

15.   Use of a modulator of an activity and/or of a level of at least one substance which is selected from the group consisting of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iv) a fragment, or derivative, or variant of (i) to (iii) for a preparation of a medicament for treating or preventing a neurodegenerative disease, in particular Alzheimer's disease.

16.   A recombinant, non-human animal comprising a non-native gene sequence coding for human MAGUIN-1 and/or human MAGUIN-2 or a fragment, or a derivative, or a variant thereof, said animal being obtainable by:
   (i)   providing a gene targeting construct comprising said gene sequence and a selectable marker sequence, and
   (ii)   introducing said targeting construct into a stem cell of a non-human animal, and
   (iii)   introducing said non-human animal stem cell into a non-human embryo, and
   (iv)   transplanting said embryo into a pseudopregnant non-human animal, and
   (v)   allowing said embryo to develop to term, and
   (vi)   identifying a genetically altered non-human animal whose genome comprises a modification of said gene sequence in both alleles, and
   (vii)   breeding the genetically altered non-human animal of step (vi) to obtain a genetically altered non-human animal whose genome comprises a modification of said endogenous gene, wherein said disruption results in said

non-human animal exhibiting a predisposition to developing symptoms of a neurodegenerative disease or related diseases or disorders.

17.   Use of the recombinant, non-human animal according to claim 16 for screening, testing, and validating compounds, agents, and modulators in the development of diagnostics and therapeutics to treat neurodegenerative diseases, in particular Alzheimer's disease.

18. An assay for screening for a modulator of neurodegenerative diseases, in particular Alzheimer's disease, or related diseases or disorders of one or more substances selected from the group consisting of

(i)   a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or

(ii)   a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or

(iii)   a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or

(iv)   a fragment, or derivative, or variant of (i) to (iii), said method comprising:

(a) contacting a cell with a test compound;

(b) measuring the activity and/or level of one or more substances recited in (i) to (iv);

(c) measuring the activity and/or level of one or more substances recited in (i) to (iv) in a control cell not contacted with said test compound; and

(d) comparing the levels and/or activities of the substance in the cells of step (b) and (c), wherein an alteration in the activity and/or level of substances in the contacted cells indicates that the test compound is a modulator of said diseases or disorders.

19. A method of testing a compound, preferably of screening a plurality of compounds, for inhibition of binding between a ligand and human MAGUIN-1 and/or human MAGUIN-2, or fragments, or derivatives, or variants thereof, said method comprising the steps of:

(i)   adding a liquid suspension of said human MAGUIN-1 and/or human MAGUIN-2, or fragments, or derivatives, or variants thereof, to a plurality of containers;

(ii)   adding a compound, preferably a plurality of compounds, to be screened for said inhibition of binding to said plurality of containers;

(iii)   adding a detectable ligand, in particular a fluorescently detectable ligand, to said containers;

(iv)   incubating the liquid suspension of said human MAGUIN-1 and/or human MAGUIN-2, or said fragments, or derivatives, or variants thereof, and said compound, preferably said plurality of compounds, and said ligand;

(v)   measuring amounts of detectable ligand or fluorescence associated with said human MAGUIN-1 and/or human MAGUIN-2, or with said fragments, or derivatives, or variants thereof; and

(vi)   determining the degree of inhibition by one or more of said compounds of binding of said ligand to said human MAGUIN-1 and/or human MAGUIN-2, or said fragments, or derivatives, or variants thereof.

20. A method of testing a compound, preferably of screening a plurality of compounds, to determine the degree of binding of said compound or compounds to human MAGUIN-1 and/or human MAGUIN-2, or to fragments, or derivatives, or variants thereof, said method comprising the steps of:

(i)   adding a liquid suspension of said human MAGUIN-1 and/or human MAGUIN-2, or fragments, or derivatives, or variants thereof, to a plurality of containers;

(ii)   adding a detectable compound, preferably a plurality of detectable compounds, in particular fluorescently detectable compounds, to be screened for said binding to said plurality of containers;

(iii)   incubating the liquid suspension of said human MAGUIN-1 and/or human MAGUIN-2, or said fragments, or derivatives, or variants thereof, and said compound, preferably said plurality of compounds;

(iv)   measuring amounts of detectable compound or fluorescence associated with said human MAGUIN-1 and/or human MAGUIN-2, or with said fragments, or derivatives, or variants thereof; and

(v)   determining the degree of binding by one or more of said compounds to said human MAGUIN-1 and/or human MAGUIN-2, or said fragments, or derivatives, or variants thereof.

21. A method for producing a medicament comprising the steps of (i) identifying a modulator of neurodegenerative diseases, in particular Alzheimer's disease, by a method according to claim 18 and (ii) admixing the modulator with a pharmaceutical carrier.

22. A method for producing a medicament comprising the steps of (i) identifying a compound as an inhibitor of binding between a ligand and a human MAGUIN-1 and/or human MAGUIN-2 gene product by a method according to claim 19 and (ii) admixing the compound with a pharmaceutical carrier.

23. A method for producing a medicament comprising the steps of (i) identifying a compound as a binder to a human MAGUIN-1 and/or human MAGUIN-2 gene product by a method according to claim 20 and (ii) admixing the compound with a pharmaceutical carrier.

24. A medicament obtainable by any of the methods according to claim 21 to 23.

25. A medicament obtained by any of the methods according to claim 21 to 23.

26. A protein molecule shown in SEQ ID NO.1 or SEQ ID NO.2, or a fragment, or derivative, or variant thereof, for use as a diagnostic target for detecting a neurodegenerative disease, preferably Alzheimer's disease.

27. A protein molecule shown in SEQ ID NO. 1 or SEQ ID NO.2, or a fragment, or derivative, or variant thereof, for use as a screening target for reagents or compounds preventing, or treating, or ameliorating a neurodegenerative disease, preferably Alzheimer's disease.

28. An antibody specifically immunoreactive with an immunogen, wherein said immunogen is a protein molecule shown in SEQ ID NO. 1, or a   fragment, or derivative, or variant thereof.

29. An antibody specifically immunoreactive with an immunogen, wherein said immunogen is a protein molecule shown in SEQ ID NO. 2, or a   fragment, or derivative, or variant thereof.

30. Use of an antibody of claim 28 or 29, for detecting the pathological state of a cell in a sample from a subject, comprising immunocytochemical staining of said cell with said antibody, wherein an altered degree of staining, or an altered staining pattern in said cell compared to a cell representing a known health status indicates a pathological state of said cell.

Fig. 1: Identification of Genes Involved in Alzheimer's Disease Pathology

Fig. 2: Identification of differentially expressed genes in a fluorescence differential display screen

Fig. 3: Verification of differential expression of human MAGUIN-1 by quantitative RT-PCR

Fig. 4: Verification of differential expression of Maguin-1 by quantitative RT-PCR

Fig. 5: Verification of differential expression of human MAGUIN-2 by quantitative RT-PCR

Fig. 6: Verification of differential expression of Maguin-2 by quantitative RT-PCR

Fig. 7: SEQ ID NO. 1:
amino acid sequence of
human MAGUIN-1 protein

Length: 1034 aa

```
   1 MALIMEPVSK WSPSQVVDWM KGLDDCLQQY IKNFEREKIS GDQLLRITHQ

  51 ELEDLGVSRI GHQELILEAV DLLCALNYGL ETENLKTLSH KLNASAKNLQ

 101 NFITGRRRSG HYDGRTSRKL PNDFLTSVVD LIGAAKSLLA WLDRSPFAAV

 151 TDYSVTRNNV IQLCLELTTI VQQDCTVYET ENKILHVCKT LSGVCDHIIS

 201 LSSDPLVSQS AHLEVIQLAN IKPSEGLGMY IKSTYDGLHV ITGTTENSPA

 251 DRCKKIHAGD EVIQVNHQTV VGWQLKNLVN ALREDPSGVI LTLKKRPQSM

 301 LTSAPALLKN MRWKPLALQP LIPRSPTSSV ATPSSTISTP TKRDSSALQD

 351 LYIPPPPAEP YIPRDEKGNL PCEDLRGHMV GKPVHKGSES PNSFLDQEYR

 401 KRFNIVEEDT VLYCYEYEKG RSSSQGRRES TPTYGKLRPI SMPVEYNWVG

 451 DYEDPNKMKR DSRRENSLLR YMSNEKIAQE EYMFQRNSKK DTGKKSKKKG

 501 DKSNSPTHYS LLPSLQMDAL RQDIMGTPVP ETTLYHTFQQ SSLQHKSKKK

 551 NKGPIAGKSK RRISCKDLGR GDCEGWLWKK KDAKSYFSQK WKKYWFVLKD

 601 ASLYWYINEE DEKAEGFISL PEFKIDRASE CRKKYAFKAC HPKIKSFYFA

 651 AEHLDDMNRW LNRINMLTAG YAERERIKQE QDYWSESDKE EADTPSTPKQ

 701 DSPPPPYDTY PRPPSMSCAS PYVEAKHSRL SSTETSQSQS SHEEFRQEVT

 751 GSSAVSPIRK TASQRRSWQD LIETPLTSSG LHYLQTLPLE DSVFSDSAAI

 801 SPEHRRQSTL PTQKCHLQDH YGPYPLAESE RMQVLNGNGG KPRSFTLPRD

 851 SGFNHCCLNA PVSACDPQDD VQPPEVEEEE EEEEEGEAA GENIGEKSES

 901 REEKLGDSLQ DLYRALEQAS LSPLGEHRIS TKMEYKLSFI KRCNDPVMNE

 951 KLHRLRILKS TLKAREGEVA IIDKVLDNPD LTSKEFQQWK QMYLDLFLDI

1001 CQNTTSNDPL SISSEVDVIT SSLAHTHSYI ETHV*
```

Fig. 8: Alignment of SEQ ID NO. 1, human MAGUIN-1, with rat MAGUIN-1

Length: 1034 aa

```
  1 MALIMEPVSKWSPSQVVDWMKGLDDCLQQYIKNFEREKISGDQLLRITHQ  50
    |||||||||||||||||||||||||||||||||||||||||||||||||
  1 MALIMEPVSKWSPSQVVDWMKGLDDCLQQYIKNFEREKISGDQLLRITHQ  50

 51 ELEDLGVSRIGHQELILEAVDLLCALNYGLETENLKTLSHKLNASAKNLQ 100
    |||||||||||||||||||||||||||||||||||||||||||||||||
 51 ELEDLGVSRIGHQELILEAVDLLCALNYGLETENLKTLSHKLNASAKNLQ 100

101 NFITGRRRSGHYDGRTSRKLPNDFLTSVVDLIGAAKSLLAWLDRSPFAAV 150
    |||||||||||||||||||||||||||||||||||||||||||||||||
101 NFITGRRRSGHYDGRTSRKLPNDFLTSVVDLIGAAKSLLAWLDRSPFAAV 150

151 TDYSVTRNNVIQLCLELTTIVQQDCTVYETENKILHVCKTLSGVCDHIIS 200
    |||||||||||||||||||||||||||||||||||||||||||||||||
151 TDYSVTRNNVIQLCLELTTIVQQDCTVYETENKILHVCKTLSGVCDHIIS 200

201 LSSDPLVSQSAHLEVIQLANIKPSEGLGMYIKSTYDGLHVITGTTENSPA 250
    |||||||||||||||||||||||||||||||||||||||||||||||||
201 LSSDPLVSQSAHLEVIQLANIKPSEGLGMYIKSTYDGLHVITGTTENSPA 250

251 DRCKKIHAGDEVIQVNHQTVVGWQLKNLVNALREDPSGVILTLKKRPQSM 300
    |||||||||||||||||||||||||||||||||||||||||||||||||
251 DRCKKIHAGDEVIQVNHQTVVGWQLKNLVNALREDPSGVILTLKKRPQSM 300

301 LTSAPALLKNMRWKPLALQPLIPRSPTSSVATPSSTISTPTKRDSSALQD 350
    |||||||||||||||||||||||||||||||||||||||||||||||||
301 LTSAPALLKNMRWKPLALQPLIPRSPTSSVATPSSTISTPTKRDSSALQD 350

351 LYIPPPPAEPYIPRDEKGNLPCEDLRGHMVGKPVHKGSESPNSFLDQEYR 400
    |||||||||||||||||||||||||||||||||||||||||||||||||
351 LYIPPPPAEPYIPRDEKGNLPCEDLRGHMVGKPVHKGSESPNSFLDQEYR 400

401 KRFNIVEEDTVLYCYEYEKGRSSSQGRRESTPTYGKLRPISMPVEYNWVG 450
    |||||||||||||||||||||||||||||||||||||||||||||||||
401 KRFNIVEEDTVLYCYEYEKGRSSSQGRRESTPTYGKLRPISMPVEYNWVG 450

451 DYEDPNKMKRDSRRENSLLRYMSNEKIAQEEYMFQRNSKKDTGKKSKKKG 500
    |||||||||||||||||||||||||||||||||||||||||||||||||
451 DYEDPNKMKRDSRRENSLLRYMSNEKIAQEEYMFQRNSKKDTGKKSKKKG 500
```

```
501 DKSNSPTHYSLLPSLQMDALRQDIMGTPVPETTLYHTFQQSSLQHKSKKK 550
    |||:||||||||||||||||||||||||||||||||||||||||||||||
501 DKSTSPTHYSLLPSLQMDALRQDIMGTPVPETTLYHTFQQSSLQHKSKKK 550

551 NKGPIAGKSKRRISCKDLGRGDCEGWLWKKKDAKSYFSQKWKKYWFVLKD 600
    |||:||||||||||||||||||||||||||||||||||||||||||||||
551 NKGAIAGKSKRRISCKDLGRGDCEGWLWKKKDAKSYFSQKWKKYWFVLKD 600

601 ASLYWYINEEDEKAEGFISLPEFKIDRASECRKKYAFKACHPKIKSFYFA 650
    |||||||||||||||||||||||||||||||||||||||||||||||||
601 ASLYWYINEEDEKAEGFISLPEFKIDRASECRKKYAFKACHPKIKSFYFA 650

651 AEHLDDMNRWLNRINMLTAGYAERERIKQEQDYWSESDKEEADTPSTPKQ 700
    |||||||||||||||||||||||||||||||||||||||||||||||||
651 AEHLDDMNRWLNRINMLTAGYAERERIKQEQDYWSESDKEEADTPSTPKQ 700

701 DSPPPPYDTYPRPPSMSCASPYVEAKHSRLSSTETSQSQSSHEEFRQEVT 750
    |||||||||||||||||||||||||||||||||||||||||||||||||
701 DSPPPPYDTYPRPPSMSCASPYVEAKHSRLSSTETSQSQSSHEEFRQEVT 750

751 GSSAVSPIRKTASQRRSWQDLIETPLTSSGLHYLQTLPLEDSVFSDSAAI 800
    |||||||||||||||||||||||||||||||||||||||||||||||||
751 GSSAVSPIRKTASQRRSWQDLIETPLTSSGLHYLQTLPLEDSVFSDSAAI 800

801 SPEHRRQSTLPTQKCHLQDHYGPYPLAESERMQVLNGNGGKPRSFTLPRD 850
    |||||||||||||||||||||||||||||||||||||||||||||||||
801 SPEHRRQSTLPTQKCHLQDHYGPYPLAESERMQVLNGNGGKPRSFTLPRD 850

851 SGFNHCCLNAPVSACDPQDDVQPPEVEEEEEEEEEGEAAGENIGEKSES 900
    |||||||||||||||||||||||:||||||||||||    |||||||||:|:
851 SGFNHCCLNAPVSACDPQDDIQPPEVEEEEEEEE..EAAGENIGEKNEN 898

901 REEKLGDSLQDLYRALEQASLSPLGEHRISTKMEYKLSFIKRCNDPVMNE 950
    |||||||||||||||||||||||:||||||||||||||:|||||||||||
899 REEKLGDSLQDLYRALEEASLSPLGEHRISTKIEYKLSFIKRCNDPVMNE 948

951 KLHRLRILKSTLKAREGEVAIIDKVLDNPDLTSKEFQQWKQMYLDLFLDI 1000
    ||||||||||||||||||||||||||||||||||||||||||||||||||
949 KLHRLRILKSTLKAREGEVAIIDKVLDNPDLTSKEFQQWKQMYLDLFLDI 998

1001 CQNTTSNDPLSISSEVDVITSSLAHTHSYIETHV 1034
     |||||||||||||||||||||||||:|||||||||
 999 CQNTTSNDPLSISSEVDVITSSLTHTHSYIETHV 1032
```

Fig. 9: SEQ ID NO. 2: amino acid sequence of human MAGUIN-2 protein

Length: 898 aa

```
  1 MALIMEPVSK WSPSQVVDWM KGLDDCLQQY IKNFEREKIS GDQLLRITHQ

 51 ELEDLGVSRI GHQELILEAV DLLCALNYGL ETENLKTLSH KLNASAKNLQ

101 NFITGRRRSG HYDGRTSRKL PNDFLTSVVD LIGAAKSLLA WLDRSPFAAV

151 TDYSVTRNNV IQLCLELTTI VQQDCTVYET ENKILHVCKT LSGVCDHIIS

201 LSSDPLVSQS AHLEVIQLAN IKPSEGLGMY IKSTYDGLHV ITGTTENSPA

251 DRCKKIHAGD EVIQVNHQTV VGWQLKNLVN ALREDPSGVI LTLKKRPQSM

301 LTSAPALLKN MRWKPLALQP LIPRSPTSSV ATPSSTISTP TKRDSSALQD

351 LYIPPPPAEP YIPRDEKGNL PCEDLRGHMV GKPVHKGSES PNSFLDQEYR

401 KRFNIVEEDT VLYCYEYEKG RSSSQGRRES TPTYGKLRPI SMPVEYNWVG

451 DYEDPNKMKR DSRRENSLLR YMSNEKIAQE EYMFQRNSKK DTGKKSKKKG

501 DKSNSPTHYS LLPSLQMDAL RQDIMGTPVP ETTLYHTFQQ SSLQHKSKKK

551 NKGPIAGKSK RRISCKDLGR GDCEGWLWKK KDAKSYFSQK WKKYWFVLKD

601 ASLYWYINEE DEKAEGFISL PEFKIDRASE CRKKYAFKAC HPKIKSFYFA

651 AEHLDDMNRW LNRINMLTAG YAERERIKQE QDYWSESDKE EADTPSTPKQ

701 DSPPPPYDTY PRPPSMSCAS PYVEAKHSRL SSTETSQSQS SHEEFRQEVT

751 GSSAVSPIRK TASQRRSWQD LIETPLTSSG LHYLQTLPLE DSVFSDSAAI

801 SPEHRRQSTL PTQKCHLQDH YGPYPLAESE RMQVLNGNGG KPRSFTLPRD

851 SGFNHCCLNA PVSACDPQDD VQPPEVEEEE EEEEEGEAA GENIGEKS*
```

Figure 10: Alignment of SEQ ID NO. 2,
         human MAGUIN-2, with
         rat MAGUIN-2

Length: 898 aa

```
  1 MALIMEPVSKWSPSQVVDWMKGLDDCLQQYIKNFEREKISGDQLLRITHQ  50
    |||||||||||||||||||||||||||||||||||||||||||||||||
  1 MALIMEPVSKWSPSQVVDWMKGLDDCLQQYIKNFEREKISGDQLLRITHQ  50

 51 ELEDLGVSRIGHQELILEAVDLLCALNYGLETENLKTLSHKLNASAKNLQ 100
    |||||||||||||||||||||||||||||||||||||||||||||||||
 51 ELEDLGVSRIGHQELILEAVDLLCALNYGLETENLKTLSHKLNASAKNLQ 100

101 NFITGRRRSGHYDGRTSRKLPNDFLTSVVDLIGAAKSLLAWLDRSPFAAV 150
    |||||||||||||||||||||||||||||||||||||||||||||||||
101 NFITGRRRSGHYDGRTSRKLPNDFLTSVVDLIGAAKSLLAWLDRSPFAAV 150

151 TDYSVTRNNVIQLCLELTTIVQQDCTVYETENKILHVCKTLSGVCDHIIS 200
    |||||||||||||||||||||||||||||||||||||||||||||||||
151 TDYSVTRNNVIQLCLELTTIVQQDCTVYETENKILHVCKTLSGVCDHIIS 200

201 LSSDPLVSQSAHLEVIQLANIKPSEGLGMYIKSTYDGLHVITGTTENSPA 250
    |||||||||||||||||||||||||||||||||||||||||||||||||
201 LSSDPLVSQSAHLEVIQLANIKPSEGLGMYIKSTYDGLHVITGTTENSPA 250

251 DRCKKIHAGDEVIQVNHQTVVGWQLKNLVNALREDPSGVILTLKKRPQSM 300
    |||||||||||||||||||||||||||||||||||||||||||||||||
251 DRCKKIHAGDEVIQVNHQTVVGWQLKNLVNALREDPSGVILTLKKRPQSM 300

301 LTSAPALLKNMRWKPLALQPLIPRSPTSSVATPSSTISTPTKRDSSALQD 350
    |||||||||||||||||||||||||||||||||||||||||||||||||
301 LTSAPALLKNMRWKPLALQPLIPRSPTSSVATPSSTISTPTKRDSSALQD 350

351 LYIPPPPAEPYIPRDEKGNLPCEDLRGHMVGKPVHKGSESPNSFLDQEYR 400
    |||||||||||||||||||||||||||||||||||||||||||||||||
351 LYIPPPPAEPYIPRDEKGNLPCEDLRGHMVGKPVHKGSESPNSFLDQEYR 400

401 KRFNIVEEDTVLYCYEYEKGRSSSQGRRESTPTYGKLRPISMPVEYNWVG 450
    |||||||||||||||||||||||||||||||||||||||||||||||||
401 KRFNIVEEDTVLYCYEYEKGRSSSQGRRESTPTYGKLRPISMPVEYNWVG 450

451 DYEDPNKMKRDSRRENSLLRYMSNEKIAQEEYMFQRNSKKDTGKKSKKKG 500
    |||||||||||||||||||||||||||||||||||||||||||||||||
451 DYEDPNKMKRDSRRENSLLRYMSNEKIAQEEYMFQRNSKKDTGKKSKKKG 500
```

```
501 DKSNSPTHYSLLPSLQMDALRQDIMGTPVPETTLYHTFQQSSLQHKSKKK 550
    |||:||||||||||||||||||||||||||||||||||||||||||||||
501 DKSTSPTHYSLLPSLQMDALRQDIMGTPVPETTLYHTFQQSSLQHKSKKK 550

551 NKGPIAGKSKRRISCKDLGRGDCEGWLWKKKDAKSYFSQKWKKYWFVLKD 600
    |||:||||||||||||||||||||||||||||||||||||||||||||||
551 NKGAIAGKSKRRISCKDLGRGDCEGWLWKKKDAKSYFSQKWKKYWFVLKD 600

601 ASLYWYINEEDEKAEGFISLPEFKIDRASECRKKYAFKACHPKIKSFYFA 650
    ||||||||||||||||||||||||||||||||||||||||||||||||||
601 ASLYWYINEEDEKAEGFISLPEFKIDRASECRKKYAFKACHPKIKSFYFA 650

651 AEHLDDMNRWLNRINMLTAGYAERERIKQEQDYWSESDKEEADTPSTPKQ 700
    ||||||||||||||||||||||||||||||||||||||||||||||||||
651 AEHLDDMNRWLNRINMLTAGYAERERIKQEQDYWSESDKEEADTPSTPKQ 700

701 DSPPPPYDTYPRPPSMSCASPYVEAKHSRLSSTETSQSQSSHEEFRQEVT 750
    ||||||||||||||||||||||||||||||||||||||||||||||||||
701 DSPPPPYDTYPRPPSMSCASPYVEAKHSRLSSTETSQSQSSHEEFRQEVT 750

751 GSSAVSPIRKTASQRRSWQDLIETPLTSSGLHYLQTLPLEDSVFSDSAAI 800
    ||||||||||||||||||||||||||||||||||||||||||||||||||
751 GSSAVSPIRKTASQRRSWQDLIETPLTSSGLHYLQTLPLEDSVFSDSAAI 800

801 SPEHRRQSTLPTQKCHLQDHYGPYPLAESERMQVLNGNGGKPRSFTLPRD 850
    ||||||||||||||||||||||||||||||||||||||||||||||||||
801 SPEHRRQSTLPTQKCHLQDHYGPYPLAESERMQVLNGNGGKPRSFTLPRD 850

851 SGFNHCCLNAPVSACDPQDDVQPPEVEEEEEEEEEGEAAGENIGEKS 898
    |||||||||||||||||||||:|||||||||||||  |||||||||||
851 SGFNHCCLNAPVSACDPQDDIQPPEVEEEEEEEEE..EAAGENIGEKS 896
```

Fig. 11: SEQ ID NO. 3: nucleotide sequence of human MAGUIN-1 coding sequence

Length: 3105 bp

```
   1 ATGGCTCTGA TAATGGAACC GGTGAGCAAA TGGTCTCCGA GTCAAGTAGT GGACTGGATG
  61 AAAGGTCTTG ATGACTGTTT GCAGCAGTAT ATTAAGAACT TTGAGAGGGA GAAGATCAGT
 121 GGGGACCAGC TGCTGCGCAT TACACATCAG GAGCTAGAAG ATCTGGGGGT CAGCCGCATT
 181 GGCCATCAGG AACTGATCTT GGAAGCAGTT GACCTTCTGT GTGCATTGAA TTATGGCTTG
 241 GAAACAGAAA ATCTAAAAAC CCTTTCTCAC AAGTTGAATG CATCTGCCAA AAATCTGCAG
 301 AATTTTATAA CAGGAAGGAG AAGGAGTGGC CATTATGATG GGAGGACCAG CCGAAAATTG
 361 CCAAACGACT TTCTGACCTC AGTTGTGGAT CTGATTGGAG CAGCCAAGAG TCTGCTTGCC
 421 TGGTTGGACA GGTCACCATT TGCTGCTGTG ACAGACTATT CAGTTACAAG AAATAATGTC
 481 ATACAACTCT GCCTGGAGTT AACAACAATT GTGCAACAGG ATTGTACTGT ATATGAAACA
 541 GAGAATAAAA TTCTTCACGT GTGTAAAACT CTTTCTGGAG TCTGTGACCA CATCATATCC
 601 CTGTCGTCAG ATCCTCTGGT TTCACAGTCT GCTCACCTGG AAGTGATTCA ACTGGCAAAC
 661 ATTAAACCAA GCGAAGGGCT GGGTATGTAT ATTAAATCTA CATATGATGG CCTCCATGTA
 721 ATTACTGGAA CCACAGAAAA TTCACCTGCA GATCGGTGCA AGAAAATCCA TGCTGGCGAT
 781 GAAGTGATTC AAGTTAATCA TCAGACTGTG GTGGGGTGGC AGTTGAAAAA TTTGGTGAAT
 841 GCACTACGAG AGGACCCGAG TGGTGTTATC TTAACTTTGA AAAAGCGACC TCAGAGCATG
 901 CTTACCTCAG CACCAGCTTT ACTGAAAAAT ATGAGATGGA AGCCCCTTGC TCTGCAGCCT
 961 CTTATACCTA GAAGTCCCAC AAGCAGCGTT GCCACGCCTT CCAGCACCAT CAGTACACCC
1021 ACCAAAAGAG ACAGTTCTGC CCTCCAGGAT CTCTACATTC CCCTCCTCC TGCAGAACCA
1081 TATATTCCCA GGGATGAAAA AGGAAACCTT CCTTGTGAAG ACCTCAGAGG ACATATGGTG
1141 GGCAAGCCAG TGCATAAGGG ATCTGAATCA CCAAATTCAT TTCTGGATCA GGAATATCGA
1201 AAGAGATTTA ATATTGTCGA AGAAGATACT GTCTTATATT GCTATGAATA TGAAAAAGGA
1261 AGATCAAGTA GTCAAGGAAG ACGAGAAAGC ACCCCAACTT ATGGCAAGCT ACGACCTATA
1321 TCTATGCCAG TGGAATATAA TTGGGTGGGG GACTATGAAG ATCCAAATAA GATGAAGAGA
1381 GATAGTAGAA GAGAAAACTC TCTACTTCGG TATATGAGCA ATGAAAAGAT TGCTCAAGAA
1441 GAATACATGT TTCAGAGAAA CAGCAAAAAG GACACAGGGA AGAAGTCAAA AAAGAAGGGT
1501 GATAAGAGTA ATAGCCCAAC TCACTATTCA TTGCTACCTA GTTTACAAAT GGATGCACTG
1561 AGACAAGACA TCATGGGCAC TCCTGTGCCA GAGACCACAC TATACCATAC ATTTCAGCAG
1621 TCCTCACTGC AGCACAAATC AAAGAAGAAA AACAAAGGTC CTATAGCAGG CAAGAGCAAA
1681 AGACGAATTT CTTGCAAAGA TCTTGGCCGT GGTGACTGTG AGGGCTGGCT TTGGAAAAAG
1741 AAAGATGCGA AGAGTTACTT TTCACAGAAA TGGAAAAAAT ATTGGTTTGT CCTAAAGGAT
1801 GCATCCCTTT ATTGGTATAT TAATGAGGAG GATGAAAAAG CAGAAGGATT CATTAGCCTG
1861 CCTGAATTTA AAATTGATAG AGCCAGTGAA TGCCGCAAAA AATATGCATT CAAAGCCTGT
1921 CATCCTAAAA TCAAAAGCTT TTATTTTGCT GCTGAACATC TTGATGATAT GAACAGGTGG
1981 CTTAACAGAA TTAATATGCT GACTGCAGGA TATGCAGAAA GAGAGAGGAT TAAGCAGGAA
2041 CAAGATTACT GGAGTGAGAG TGACAAGGAA GAAGCAGATA CTCCATCAAC ACCAAAACAA
2101 GATAGCCCTC CACCCCCATA TGATACATAC CCACGACCTC CCTCGATGAG TTGCGCCAGT
2161 CCTTATGTGG AAGCAAAACA TAGCCGACTT TCCTCCACGG AGACTTCTCA GTCTCAGTCT
2221 TCTCATGAGG AGTTTCGCCA GGAAGTAACT GGGAGCAGTG CAGTGTCTCC CATTCGCAAG
2281 ACAGCCAGTC AGCGCCGCTC CTGGCAGGAT TTAATTGAGA CGCCACTGAC AAGTTCAGGC
2341 TTACACTATC TTCAGACTCT GCCCCTGGAG GATTCTGTCT TCTCTGACTC CGCGGCCATC
2401 TCCCCAGAGC ACAGGCGGCA GTCTACCCTG CCAACTCAGA AATGCCACCT GCAGGATCAC
2461 TATGGGCCAT ACCCCTTAGC TGAGAGTGAG AGGATGCAAG TGCTAAATGG AAATGGGGGC
2521 AAGCCTCGAA GTTTTACTCT GCCTCGAGAT AGCGGGTTCA ACCATTGCTG TCTGAATGCT
2581 CCAGTTAGTG CCTGTGACCC ACAGGATGAC GTGCAACCCC CAGAGGTGGA GGAAGAGGAG
2641 GAGGAGGAGG AGGAGGAAGG GGAGGCAGCA GGGAAAAACA TAGGAGAAAA AAGTGAAAGC
2701 AGAGAAGAAA AGTTAGGAGA CTCATTGCAA GATTTATACA GGGCACTGGA GCAGGCCAGT
2761 CTGTCACCAC TAGGAGAACA TCGTATTTCA ACCAAGATGG AATACAAGCT ATCATTTATA
2821 AAAAGATGTA ATGATCCTGT AATGAATGAA AAACTACACC GGCTGAGAAT TCTCAAAAGC
2881 ACTTTAAAGG CCAGAGAAGG GGAAGTAGCC ATTATCGATA AGTCCTAGA CAATCCAGAC
2941 TTGACATCTA AAGAATTCCA ACAATGGAAG CAGATGTACC TCGACCTTTT CTTGGATATC
3001 TGTCAAAATA CCACCTCAAA TGACCCACTG AGTATTTCTT CTGAAGTAGA TGTAATCACT
3061 TCCTCTCTAG CACACACTCA TTCATACATT GAAACGCATG TCTAA
```

Fig. 12: SEQ ID NO. 4: nucleotide sequence of human MAGUIN-2 coding sequence

Length: 2697 bp

```
   1  ATGGCTCTGA TAATGGAACC GGTGAGCAAA TGGTCTCCGA GTCAAGTAGT
  51  GGACTGGATG AAAGGTCTTG ATGACTGTTT GCAGCAGTAT ATTAAGAACT
 101  TTGAGAGGGA GAAGATCAGT GGGGACCAGC TGCTGCGCAT TACACATCAG
 151  GAGCTAGAAG ATCTGGGGGT CAGCCGCATT GGCCATCAGG AACTGATCTT
 201  GGAAGCAGTT GACCTTCTGT GTGCATTGAA TTATGGCTTG GAAACAGAAA
 251  ATCTAAAAAC CCTTTCTCAC AAGTTGAATG CATCTGCCAA AAATCTGCAG
 301  AATTTTATAA CAGGAAGGAG AAGGAGTGGC CATTATGATG GGAGGACCAG
 351  CCGAAAATTG CCAAACGACT TTCTGACCTC AGTTGTGGAT CTGATTGGAG
 401  CAGCCAAGAG TCTGCTTGCC TGGTTGGACA GGTCACCATT TGCTGCTGTG
 451  ACAGACTATT CAGTTACAAG AAATAATGTC ATACAACTCT GCCTGGAGTT
 501  AACAACAATT GTGCAACAGG ATTGTACTGT ATATGAAACA GAGAATAAAA
 551  TTCTTCACGT GTGTAAAACT CTTTCTGGAG TCTGTGACCA CATCATATCC
 601  CTGTCGTCAG ATCCTCTGGT TTCACAGTCT GCTCACCTGG AAGTGATTCA
 651  GCTGGCAAAC ATTAAACCAA GCGAAGGGCT GGGTATGTAT ATTAAATCTA
 701  CATATGATGG CCTCCATGTA ATTACTGGAA CCACAGAAAA TTCACCTGCA
 751  GATCGGTGCA AGAAAATCCA TGCTGGCGAT GAAGTGATTC AAGTTAATCA
 801  TCAGACTGTG GTGGGGTGGC AGTTGAAAAA TTTGGTGAAT GCACTACGAG
 851  AGGACCCGAG TGGTGTTATC TTAACTTTGA AAAAGCGACC TCAGAGCATG
 901  CTTACCTCAG CACCAGCTTT ACTGAAAAAT ATGAGATGGA AGCCCCTTGC
 951  TCTGCAGCCT CTTATACCTA GAAGTCCCAC AAGCAGCGTT GCCACGCCTT
1001  CCAGCACCAT CAGTACACCC ACCAAAGAG ACAGTTCTGC CCTCCAGGAT
1051  CTCTACATTC CCCCTCCTCC TGCAGAACCA TATATTCCCA GGGATGAAAA
1101  AGGAAACCTT CCTTGTGAAG ACCTCAGAGG ACATATGGTG GGCAAGCCAG
1151  TGCATAAGGG ATCTGAATCA CCAAATTCAT TTCTGGATCA GGAATATCGA
1201  AAGAGATTTA ATATTGTCGA AGAAGATACT GTCTTATATT GCTATGAATA
1251  TGAAAAGGA AGATCAAGTA GTCAAGGAAG ACGAGAAAGC ACCCCAACTT
1301  ATGGCAAGCT ACGACCTATA TCTATGCCAG TGGAATATAA TTGGGTGGGG
1351  GACTATGAAG ATCCAAATAA GATGAAGAGA GATAGTAGAA GAGAAAACTC
1401  TCTACTTCGG TATATGAGCA ATGAAAAGAT TGCTCAAGAA GAATACATGT
1451  TTCAGAGAAA CAGCAAAAAG GACACAGGGA AGAAGTCAAA AAAGAAGGGT
1501  GATAAGAGTA ATAGCCCAAC TCACTATTCA TTGCTACCTA GTTTACAAAT
1551  GGATGCACTG AGACAAGACA TCATGGGCAC TCCTGTGCCA GAGACCACAC
1601  TATACCATAC ATTTCAGCAG TCCTCACTGC AGCACAAATC AAAGAAGAAA
1651  AACAAAGGTC CTATAGCAGG CAAGAGCAAA AGACGAATTT CTTGCAAAGA
1701  TCTTGGCCGT GGTGACTGTG AGGGCTGGCT TTGGAAAAAG AAAGATGCGA
1751  AGAGTTACTT TTCACAGAAA TGGAAAAAAT ATTGGTTTGT CCTAAAGGAT
1801  GCATCCCTTT ATTGGTATAT TAATGAGGAG GATGAAAAAG CAGAAGGATT
1851  CATTAGCCTG CCTGAATTTA AAATTGATAG AGCCAGTGAA TGCCGCAAAA
1901  AATATGCATT CAAAGCCTGT CATCCTAAAA TCAAAAGCTT TTATTTTGCT
1951  GCTGAACATC TTGATGATAT GAACAGGTGG CTTAACAGAA TTAATATGCT
2001  GACTGCAGGA TATGCAGAAA GAGAGAGGAT TAAGCAGGAA CAAGATTACT
2051  GGAGTGAGAG TGACAAGGAA GAAGCAGATA CTCCATCAAC ACCAAAACAA
2101  GATAGCCCTC CACCCCATA TGATACATAC CCACGACCTC CCTCGATGAG
2151  TTGCGCCAGT CCTTATGTGG AAGCAAAACA TAGCCGACTT TCCTCCACGG
2201  AGACTTCTCA GTCTCAGTCT TCTCATGAGG AGTTTCGCCA GGAAGTAACT
2251  GGGAGCAGTG CAGTGTCTCC CATTCGCAAG ACAGCCAGTC AGCGCCGCTC
2301  CTGGCAGGAT TTAATTGAGA CGCCCACTGAC AAGTTCAGGC TTACACTATC
2351  TTCAGACTCT GCCCCTGGAG GATTCTGTCT TCTCTGACTC CGCGGCCATC
2401  TCCCCAGAGC ACAGGCGGCA GTCTACCCTG CCAACTCAGA AATGCCACCT
2451  GCAGGATCAC TATGGGCCAT ACCCCTTAGC TGAGAGTGAG AGGATGCAAG
2501  TGCTAAATGG AAATGGGGGC AAGCCTCGAA GTTTTACTCT GCCTCGAGAT
2551  AGCGGGTTCA ACCATTGCTG TCTGAaTGCT CCAGTTAGTG CCTGTGACCC
2601  ACAGGATGAC GTGCAACCCC CAGAGGTGGA GGAAGAGGAG GAGGAGGAGG
2651  AGGAGGAAGG GGAGGCAGCA GGGGAAAACA TAGGAGAAAA AAGCTAA
```

Fig. 13: SEQ ID NO. 5: nucleotide sequence of human MAGUIN-1 cDNA

Length: 5749 bp

```
   1 CGGGCAGCTA GTCGTGCTCG GGGCTTCACT CCCGCGCGTG AGGCGAGCGG GCAAGTTGGC
  61 TGAGGGCGTG CGGCAGAGGC TGCTTCCCTC GGCGACGCGA CCCCTCAGCA ACTCAAGCTA
 121 TGAACTGAAG CTCCCTAGGG ACGGAGACCG GAGCGGAGCG GCGGAGGCAG CAGCAGCAGC
 181 AGCAGCAGCA GCAGCAGCAG CAGCCGCCGC CGCCGCCGCC TTAGCGGGAA CTGAGCAGAC
 241 CCGGCGCGGA GCCACGACTC CTGCACGTTT ACCTCCCTGT CGCCGTTCCT GCCGCGCGGTT
 301 GGCTAAAAGA CGTTACAGCC GCGAGACCCG ACACACAAAA GCCGCTTTCT CCGCGCCGCC
 361 CGCCCAGGGA GGCTGCGGCC AGCAAGGGAC CCCACCTGAG AGCAGCTCGG GCTGCTGAGT
 421 TCGTTTTGTG TCTGAGCTCT GCGCTCTGCA CGGAACCGAC CCCGTACCCA TGGCTCTGAT
 481 AATGGAACCG GTGAGCAAAT GGTCTCCGAG TCAAGTAGTG GACTGGATGA AAGGTCTTGA
 541 TGACTGTTTG CAGCAGTATA TTAAGAACTT TGAGAGGGAG AAGATCAGTG GGGACCAGCT
 601 GCTGCGCATT ACACATCAGG AGCTAGAAGA TCTGGGGGTC AGCCGCATTG GCCATCAGGA
 661 ACTGATCTTG GAAGCAGTTG ACCTTCTGTG TGCATTGAAT TATGGCTTGG AAACAGAAAA
 721 TCTAAAAACC CTTTCTCACA AGTTGAATGC ATCTGCCAAA AATCTGCAGA ATTTTATAAC
 781 AGGAAGGAGA AGGAGTGGCC ATTATGATGG GAGGACCAGC CGAAAATTGC CAAACGACTT
 841 TCTGACCTCA GTTGTGGATC TGATTGGAGC AGCCAAGAGT CTGCTTGCCT GGTTGGACAG
 901 GTCACCATTT GCTGCTGTGA CAGACTATTC AGTTACAAGA AATAATGTCA TACAACTCTG
 961 CCTGGAGTTA ACAACAATTG TGCAACAGGA TTGTACTGTA TATGAAACAG AGAATAAAAT
1021 TCTTCACGTG TGTAAAACTC TTTCTGGAGT CTGTGACCAC ATCATATCCC TGTCGTCAGA
1081 TCCTCTGGTT TCACAGTCTG CTCACCTGGA AGTGATTCAA CTGGCAAACA TTAAACCAAG
1141 CGAAGGGCTG GGTATGTATA TTAAATCTAC ATATGATGGC CTCCATGTAA TTACTGGAAC
1201 CACAGAAAAT TCACCTGCAG ATCGGTGCAA GAAAATCCAT GCTGGCGATG AAGTGATTCA
1261 AGTTAATCAT CAGACTGTGG TGGGGTGGCA GTTGAAAAAT TTGGTGAATG CACTACGAGA
1321 GGACCGAGT GGTGTTATCT TAACTTTGAA AAAGCGACCT CAGAGCATGC TTACCTCAGC
1381 ACCAGCTTTA CTGAAAAATA TGAGATGGAA GCCCCTTGCT CTGCAGCCTC TTATACCTAG
1441 AAGTCCCACA AGCAGCGTTG CCACGCCTTC CAGCACCATC AGTACACCCA CCAAAAGAGA
1501 CAGTTCTGCC CTCCAGGATC TCTACATTCC CCCTCCTCCT GCAGAACCAT ATATTCCCAG
1561 GGATGAAAAA GGAAACCTTC CTTGTGAAGA CCTCAGAGGA CATATGGTGG GCAAGCCAGT
1621 GCATAAGGGA TCTGAATCAC CAAATTCATT TCTGGATCAG GAATATCGAA AGAGATTTAA
1681 TATTGTCGAA GAAGATACTG TCTTATATTG CTATGAATAT GAAAAAGGAA GATCAAGTAG
1741 TCAAGGAAGA CGAGAAAGCA CCCCAACTTA TGGCAAGCTA CGACCTATAT CTATGCCAGT
1801 GGAATATAAT TGGGTGGGGG ACTATGAAGA TCCAAATAAG ATGAAGAGAG ATAGTAGAAG
1861 AGAAAACTCT CTACTTCGGT ATATGAGCAA TGAAAAGATT GCTCAAGAAG AATACATGTT
1921 TCAGAGAAAC AGCAAAAAGG ACACAGGGAA GAAGTCAAAA AAGAAGGGTG ATAAGAGTAA
1981 TAGCCCAACT CACTATTCAT TGCTACCTAG TTTACAAATG GATGCACTGA GACAAGACAT
2041 CATGGGCACT CCTGTGCCAG AGACCACACT ATACCATACA TTTCAGCAGT CCTCACTGCA
2101 GCACAAATCA AAGAAGAAAA ACAAAGGTCC TATAGCAGGC AAGAGCAAAA GACGAATTTC
2161 TTGCAAAGAT CTTGGCCGTG GTGACTGTGA GGGCTGGCTT TGGAAAAAGA AAGATGCGAA
2221 GAGTTACTTT TCACAGAAAT GGAAAAAATA TTGGTTTGTC CTAAAGGATG CATCCCTTTA
2281 TTGGTATATT AATGAGGAGG ATGAAAAAGC AGAAGGATTC ATTAGCCTGC CTGAATTTAA
2341 AATTGATAGA GCCAGTGAAT GCCGCAAAAA ATATGCATTC AAAGCCTGTC ATCCTAAAAT
2401 CAAAAGCTTT TATTTTGCTG CTGAACATCT TGATGATATG AACAGGTGGC TTAACAGAAT
2461 TAATATGCTG ACTGCAGGAT ATGCAGAAAG AGAGAGGATT AAGCAGGAAC AAGATTACTG
2521 GAGTGAGAGT GACAAGGAAG AAGCAGATAC TCCATCAACA CCAAAACAAG ATAGCCCTCC
2581 ACCCCCATAT GATACATACC CACGACCTCC CTCGATGAGT TGCGCCAGTC CTTATGTGGA
2641 AGCAAAACAT AGCCGACTTT CCTCCACGGA GACTTCTCAG TCTCAGTCTT CTCATGAGGA
2701 GTTTCGCCAG GAAGTAACTG GGAGCAGTGC AGTGTCTCCC ATTCGCAAGA CAGCCAGTCA
2761 GCGCCGCTCC TGGCAGGATT TAATTGAGAC GCCACTGACA AGTTCAGGCT TACACTATCT
2821 TCAGACTCTG CCCCTGGAGG ATTCTGTCTT CTCTGACTCC GCGGCCATCT CCCCAGAGCA
```

```
2881 CAGGCGGCAG TCTACCCTGC CAACTCAGAA ATGCCACCTG CAGGATCACT ATGGGCCATA
2941 CCCCTTAGCT GAGAGTGAGA GGATGCAAGT GCTAAATGGA AATGGGGGCA AGCCTCGAAG

3001 TTTTACTCTG CCTCGAGATA GCGGGTTCAA CCATTGCTGT CTGAATGCTC CAGTTAGTGC
3061 CTGTGACCCA CAGGATGACG TGCAACCCCC AGAGGTGGAG GAAGAGGAGG AGGAGGAGGA
3121 GGAGGAAGGG GAGGCAGCAG GGGAAAACAT AGGAGAAAAA AGTGAAAGCA GAGAAGAAAA
3181 GTTAGGAGAC TCATTGCAAG ATTTATACAG GGCACTGGAG CAGGCCAGTC TGTCACCACT
3241 AGGAGAACAT CGTATTTCAA CCAAGATGGA ATACAAGCTA TCATTTATAA AAAGATGTAA
3301 TGATCCTGTA ATGAATGAAA AACTACACCG GCTGAGAATT CTCAAAAGCA CTTTAAAGGC
3361 CAGAGAAGGG GAAGTAGCCA TTATCGATAA AGTCCTAGAC AATCCAGACT TGACATCTAA
3421 AGAATTCCAA CAATGGAAGC AGATGTACCT CGACCTTTTC TTGGATATCT GTCAAAATAC
3481 CACCTCAAAT GACCCACTGA GTATTTCTTC TGAAGTAGAT GTAATCACTT CCTCTCTAGC
3541 ACACACTCAT TCATACATTG AAACGCATGT CTAAATGTAT TCTGCCTTCA GACCATCTAG
3601 TACCTGCTGG TACTCTGAAC AAGTATATAA GGTAGTTTTT ATATCAATGT GTGGAACACT
3661 TGACAAGCTA TACTTTAATG TTACCAAACT ATATGAAACA AACCATATAT GGTCACAATA
3721 CCACTATCTT TAATGAGCAT TTGTATATTT TATATGCAAC AGTGCTCAGC TTATGTTTAC
3781 CATGTGCAAA ATCAACTGTC TTTAATGACT TAAAATTAAC TTTTGCAAAC AATTCTAAAT
3841 ACAGGTGGTC TTCAAGTAGT AAAACCACAA AAGGCAGTTT TCTATCTATG GTCATCTTTT
3901 CTCCCTTTAA GTTAATTTTA TATAAACAAG ACTTCAAAAG TAAATCACAT TTTTTCAGGT
3961 GCAGACATCC TTGTGGGTGG GAAAGAATTT AAACCTTTTT TATATTTATT AAAATGTTCT
4021 AAGAATTTTC TTAAACATTG CACAAAGTTT AATGCTGTAG TTTTATTTTT GTGAAATGTA
4081 GATGCGCATA CAAGAGCTAA GCAAAATAGA AGAGCATCGA CATAAGAAAA GTTCAGGTAT
4141 CTAATATTCG TCTTAATAGT CTATTAACTT GTGAAAGCTA AGTTAATGGA AATATTATTC
4201 CAAATCTATG AGAACACTTG GTGTATCAGG GCAAAGCTTT GTAAGATGTT TTTGTAACTA
4261 AGACCAAAAT TGAAGATAGA GCTGCTTTAT TTTCTTGGTT TAAATCTTCC TTTATTTTTG
4321 TAGTGATGAG ATGCTGATTG TGTACAGAAG AATTTGAGAG GGGATTTTTA AAAACTGACT
4381 TAACACACCC AGAAAGGCAG CTAACAGCTA TATATATATA TAAATTTCAG CCCAAACTCA
4441 TGTTTTTAAA CTCCAACTCT TAAAAGACAA CAAGGTATAA ACTGAAATGA ATCAACTTTC
4501 CACTTAGTTT CCAATTTTCC CCTAGTCCAC TAATTAAACT TAGGTAATTA TACTTCAGGT
4561 AGGGAAGTAC AATATGTTTA GTTTCAGGCT GATGTGTGTT ATAAAAAACA ACACTGAAAA
4621 ATAAAAATGT ACTTCCCTTC TAAGGAGCAA GCAGGTGATG GTCATTCAAA GAGATGTCAC
4681 ATTGAATTAT GAGAGAAACA ATTTAGAGGT TTTTTTCCTG GCTTCATGAA TTGTTCTATA
4741 GAGTGGATGA AGTCTAAGGA AAAGTCCTCT TCATATATTT CCATTTATAA GCGTCTTGTT
4801 TTTGAAAGTG ATCACAGCAT GAAAATGACT GTGCTGCTTT TTAGTGTCTG GCTGCATAAT
4861 GTACAAGTCA CAATTTGCTG TTTTTTTCAG GAGGAGAAAG GGAACCTCCT TTACTATTCT
4921 ATATCCTAAA ATCTACTTCT AATCAGCTTT ATACTGTTGC CTGTACAGCT CAGTGAATGT
4981 ACTTTCATCT TTAAGAGTTC AGATATATGC CAGTGAATAT TTTTGCTGTA GAGGAGAAAG
5041 TAAAAACTCC ACAGCGGGGA TCTTTTTCTT TGCTTTTGAA ACCACCATTG AATCACTATC
5101 GTTTTGCAGA CTTTGCACAA CTGTACAGGA GAGTGGCCTT TCTACAGCAC ATTTTCAGTA
5161 ATCCTATATT TAGTCAAAAT GGATGAGAAA TCATGTATTA ATGTTTGTAT GGAATTTTGG
5221 GTCCAGTGTA ATATTTTTAT CATTTAAAAA GAACTCTATT TGTAAAAACA TTTATTTACT
5281 GCATGGATAT TGACGCACAT TAAATTTGTG GGATTTTGTA TATGTAAAAA AAAAAAAAAA
5341 AAAAAAAAAC AAAAAACCTC TTGTCCTAAA ATGAAGTGTG CTTGTTAACA GGTGTTTAGA
5401 CTTATTGATG TTTACTAGAC CAAATGTGTA TGTTCACTTA AAAATATATG TACCTGATGG
5461 ATGTGTCATG TTTACAGTGG CCAGGTTGTG GCCTGTAAAC AGCAAGCAGT TGACGGGAAG
5521 ACTAGCTCTG TTGCTACTAA GCAGCTTTTA CTTTTGTAAA GTCAGCTCTG TTGTTTTAAA
5581 TGGTAAAAAT TAAACTAATG AATTTGACAA GACTCGTGGC TAGCCTAGCA TGAAAGAGAC
5641 CTTTTAACAC TATATAATAT CTGTACATTT TATTGCATTC GTTTCAAATC TAGGAGAGAG
5701 GCAGCACTGT AAACTGAAGT CAAATAAATT CAGCTCTTAA TGAATCCTT
```

Fig. 14: SEQ ID NO. 6: nucleotide sequence of human MAGUIN-2 cDNA

Length: 4350 bp

```
    1  GTGCTCGGGG CTTCACTCCC GCGCGTGAGG CGAGCGGGCA AGTTGGCTGA
   51  GGGCGTGCGG CAGAGGCTGC TTCCCTCGGC GACGCGACCC CTCAGCAACT
  101  CAAGCTATGA ACTGAAGCTC CCTAGGGACG GAGACCGGAG CGGAGCGGCG
  151  GAGGCAGCAG CAGCAGCAGC AGCAGCAGCA GCAGCAGCAG CCGCCGCCGC
  201  CGCCGCCTTA GCGGGAACTG AGCAGACCCG GCGCGGAGCC ACGACTCCTG
  251  CACGTTTACC TCCCTGTCGC CGTTCCTGCC GGCGGTTGGC TAAAAGACGT
  301  TACAGCCGCG AGACCCGACA CACAAAGCC GCTTTCTCCG CGCCGCCCGC
  351  CCAGGGAGGC TGCGGCCAGC AAGGGACCCC ACCTGAGAGC AGCTCGGGCT
  401  GCTGAGTTCG TTTTGTGTCT GAGCTCTGCG CTCTGCACGG AACCGACCCC
  451  GTACCCATGG CTCTGATAAT GGAACCGGTG AGCAAATGGT CTCCGAGTCA
  501  AGTAGTGGAC TGGATGAAAG GTCTTGATGA CTGTTTGCAG CAGTATATTA
  551  AGAACTTTGA GAGGGAGAAG ATCAGTGGGG ACCAGCTGCT GCGCATTACA
  601  CATCAGGAGC TAGAAGATCT GGGGGTCAGC CGCATTGGCC ATCAGGAACT
  651  GATCTTGGAA GCAGTTGACC TTCTGTGTGC ATTGAATTAT GGCTTGGAAA
  701  CAGAAAATCT AAAAACCCTT TCTCACAAGT TGAATGCATC TGCCAAAAAT
  751  CTGCAGAATT TTATAACAGG AAGGAGAAGG AGTGGCCATT ATGATGGGAG
  801  GACCAGCCGA AAATTGCCAA ACGACTTTCT GACCTCAGTT GTGGATCTGA
  851  TTGGAGCAGC CAAGAGTCTG CTTGCCTGGT TGGACAGGTC ACCATTTGCT
  901  GCTGTGACAG ACTATTCAGT TACAAGAAAT AATGTCATAC AACTCTGCCT
  951  GGAGTTAACA ACAATTGTGC AACAGGATTG TACTGTATAT GAAACAGAGA
 1001  ATAAAATTCT TCACGTGTGT AAAACTCTTT CTGGAGTCTG TGACCACATC
 1051  ATATCCCTGT CGTCAGATCC TCTGGTTTCA CAGTCTGCTC ACCTGGAAGT
 1101  GATTCAGCTG GCAAACATTA AACCAAGCGA AGGGCTGGGT ATGTATATTA
 1151  AATCTACATA TGATGGCCTC CATGTAATTA CTGGAACCAC AGAAAATTCA
 1201  CCTGCAGATC GGTGCAAGAA AATCCATGCT GGCGATGAAG TGATTCAAGT
 1251  TAATCATCAG ACTGTGGTGG GGTGGCAGTT GAAAAATTTG GTGAATGCAC
 1301  TACGAGAGGA CCCGAGTGGT GTTATCTTAA CTTTGAAAAA GCGACCTCAG
 1351  AGCATGCTTA CCTCAGCACC AGCTTTACTG AAAAATATGA GATGGAAGCC
 1401  CCTTGCTCTG CAGCCTCTTA TACCTAGAAG TCCCACAAGC AGCGTTGCCA
 1451  CGCCTTCCAG CACCATCAGT ACACCCACCA AAAGAGACAG TTCTGCCCTC
 1501  CAGGATCTCT ACATTCCCCC TCCTCCTGCA GAACCATATA TTCCCAGGGA
 1551  TGAAAAGGA AACCTTCCTT GTGAAGACCT CAGAGGACAT ATGGTGGGCA
 1601  AGCCAGTGCA TAAGGGATCT GAATCACCAA ATTCATTTCT GGATCAGGAA
 1651  TATCGAAAGA GATTTAATAT TGTCGAAGAA GATACTGTCT TATATTGCTA
 1701  TGAATATGAA AAAGGAAGAT CAAGTAGTCA AGGAAGACGA GAAAGCACCC
 1751  CAACTTATGG CAAGCTACGA CCTATATCTA TGCCAGTGGA ATATAATTGG
 1801  GTGGGGGACT ATGAAGATCC AAATAAGATG AAGAGAGATA GTAGAAGAGA
 1851  AAACTCTCTA CTTCGGTATA TGAGCAATGA AAAGATTGCT CAAGAAGAAT
 1901  ACATGTTTCA GAGAAACAGC AAAAAGGACA CAGGGAAGAA GTCAAAAAAG
 1951  AAGGGTGATA AGAGTAATAG CCCAACTCAC TATTCATTGC TACCTAGTTT
 2001  ACAAATGGAT GCACTGAGAC AAGACATCAT GGGCACTCCT GTGCCAGAGA
 2051  CCACACTATA CCATACATTT CAGCAGTCCT CACTGCAGCA CAAATCAAAG
 2101  AAGAAAAACA AAGGTCCTAT AGCAGGCAAG AGCAAAAGAC GAATTTCTTG
 2151  CAAAGATCTT GGCCGTGGTG ACTGTGAGGG CTGGCTTTGG AAAAAGAAAG
 2201  ATGCGAAGAG TTACTTTTCA CAGAAATGGA AAAAATATTG GTTTGTCCTA
 2251  AAGGATGCAT CCCTTTATTG GTATATTAAT GAGGAGGATG AAAAAGCAGA
```

```
2301  AGGATTCATT  AGCCTGCCTG  AATTTAAAAT  TGATAGAGCC  AGTGAATGCC
2351  GCAAAAAATA  TGCATTCAAA  GCCTGTCATC  CTAAAATCAA  AAGCTTTTAT

2401  TTTGCTGCTG  AACATCTTGA  TGATATGAAC  AGGTGGCTTA  ACAGAATTAA
2451  TATGCTGACT  GCAGGATATG  CAGAAAGAGA  GAGGATTAAG  CAGGAACAAG
2501  ATTACTGGAG  TGAGAGTGAC  AAGGAAGAAG  CAGATACTCC  ATCAACACCA
2551  AAACAAGATA  GCCCTCCACC  CCCATATGAT  ACATACCCAC  GACCTCCCTC
2601  GATGAGTTGC  GCCAGTCCTT  ATGTGGAAGC  AAAACATAGC  CGACTTTCCT
2651  CCACGGAGAC  TTCTCAGTCT  CAGTCTTCTC  ATGAGGAGTT  TCGCCAGGAA
2701  GTAACTGGGA  GCAGTGCAGT  GTCTCCCATT  CGCAAGACAG  CCAGTCAGCG
2751  CCGCTCCTGG  CAGGATTTAA  TTGAGACGCC  ACTGACAAGT  TCAGGCTTAC
2801  ACTATCTTCA  GACTCTGCCC  CTGGAGGATT  CTGTCTTCTC  TGACTCCGCG
2851  GCCATCTCCC  CAGAGCACAG  GCGGCAGTCC  ACCCTGCCAA  CTCAGAAATG
2901  CCACCTGCAG  GATCACTATG  GGCCATACCC  CTTAGCTGAG  AGTGAGAGGA
2951  TGCAAGTGCT  AAATGGAAAT  GGGGGCAAGC  CTCGAAGTTT  TACTCTGCCT
3001  CGAGATAGCG  GGTTCAACCA  TTGCTGTCTG  AaTGCTCCAG  TTAGTGCCTG
3051  TGACCCACAG  GATGACGTGC  AACCCCCAGA  GGTGGAGGAA  GAGGAGGAGG
3101  AGGAGGAGGA  GGAAGGGGAG  GCAGCAGGGG  AAAACATAGG  AGAAAAAAGC
3151  TAATACACTG  CGAGAGTTGG  TAGAACCTCT  CCATGCCAAA  TCGGATCCAC
3201  TTCTGTTGGC  ACTCAACCCA  TTGGACTCAC  AGATTGATAA  GCTAATGTTT
3251  AGAGAATTTA  GATCGGAGAG  AGTCGGTACG  GCGCAGACTC  AACATCAACC
3301  TCTTGCAAGC  AACTAAAATG  GCCTCGTCCT  TGCTGTTTAT  AACAGAAAAC
3351  AGACTTGTAA  AAAGCTTAGA  TCATCAAGTG  TTTTGGATTG  GGGGCCTCCC
3401  AAAGGGATAT  AAGAGGGGCA  GGCCACTCTT  AAGAAGAATG  CGAGCTTTCT
3451  ACATTGGGAC  TAGCATAAGA  TCAAAGCCAA  TCAAGATGGA  GCACAGTAAC
3501  AGAAAACTGC  GGTTTCTGTG  GGAGAACAGA  AGGGGAAAGG  GTCTTAACTG
3551  GGAAAGGGCT  CTGTGTGGTA  ACACCTCAGT  TGTGTTCTCC  TGACACCAGG
3601  AAAAGAGAGG  GATCAGCTTC  AATAACTAGA  AAATTCTGGC  TGTTTAATGG
3651  ACTCTTTGGT  GGCCTCTTTA  AGGCAAAGCA  GAGAAAGCAA  ATTATGTATT
3701  AAGTGTATTT  TGCATTTTTA  AAACTTGACG  TGCTGTATTG  TACTAAATTA
3751  AGTGTAATCT  ATTAAGGCAA  GGTATACACA  ATTTGCTTTG  AAACTTACTA
3801  TGTTTATTCT  ATTATAAAGT  GTATTCAGGT  GCAACACAGA  GACTGCTTTC
3851  GGTGACATTA  ATGAAGAAAA  TTTCTCATGC  CAGGCTTTAT  TATAGAATCT
3901  TCAGCTAAAA  TCCTAACTTT  CTCCTTATTT  CTTGGCACTT  GTATACAAGT
3951  GGTGTTGCCT  CTTAGGGCAG  GCATGAGCTA  TTCTTTTCTG  TAAAATATTT
4001  TGAATCTATA  GGCTGTGGGT  TTCATTTTTG  AAAGTATTT  TGTCTGGATG
4051  TCTTTCAAAC  TAGCTTCAGA  TATTATTTAA  TACTATGTAA  CTGGGTCCCC
4101  TATGGCTCAA  TCAATATTGC  TTATTTTTCT  TCTGTAGTGG  ATGTGAAATT
4151  TCCTTTAGTT  GGATAAGATA  CACTGTAATA  ATTTTAATGC  TAATTAATGA
4201  TATTTCATAC  TGTGCAATGA  ACAGATAATT  TAACACTGTA  TTTTGAAATG
4251  TTTTTTTCTT  CCTGTCACCG  CAGTGTGTGG  TATTGCATAA  TGTGAATACC
4301  TGTAAAAATA  TAAATTACTT  AAAAATAAAA  ATATGACCAA  TTGGTATCAG
```

Figure 15: SEQ ID NO. 7

Length: 50 bp

1   GGAGAGAGGCAGCACTGTAAACTGAAGTCAAATAAATTCAGCTCTTAATG

Fig. 16: Alignment of SEQ ID NO. 7
with human MAGUIN-1 cDNA

Length: 50 bp

```
   1 GGAGAGAGGCAGCACTGTAAACTGAAGTCAAATAAATTCAGCTCTTAATG 50
     ||||||||||||||||||||||||||||||||||||||||||||||||||
5693 GGAGAGAGGCAGCACTGTAAACTGAAGTCAAATAAATTCAGCTCTTAATG 5742
```

Fig. 17: Schematic alignment of SEQ ID NO. 5, SEQ ID NO. 6 and SEQ ID NO. 7 with Genome Database EST-cluster

Fig. 18: Images of the human cerebral cortex labeled with anti-Maguin-1 antiserum and with DAPI

Table 1:

sample	Δ (fold) (frontal / temporal cortex)
patient P012	2.46
patient P016	2.78
patient P010	4.14
patient P011	2.20
patient P014	1.48
patient P017	1.42
patient P019	1.68
control C011	1.28
control C012	1.29
control C014	0.30
control C005	1.36
control C008	1.15

Table 2:

sample	Δ (fold) (frontal cortex / hippocampus)
patient P012	1.37
patient P016	3.07
patient P010	2.99
patient P011	2.28
patient P014	1.21
patient P019	1.48
control C005	1.74
control C008	0.39
control C004	0.87

Table 3:

sample	Δ (fold) (frontal / temporal cortex)
patient P012	2.68
patient P016	2.72
patient P010	11.73
patient P011	2.44
patient P014	1.77
patient P017	3.43
patient P019	4.02
control C011	1.42
control C012	1.22
control C014	0.30
control C005	0.92
control C008	0.81

Table 4:

sample	Δ (fold) (frontal cortex / hippocampus)
patient P012	1.57
patient P016	4.38
patient P010	9.08
patient P011	4.53
patient P014	0.72
patient P019	1.37
control C005	1.84
control C008	0.46
control C004	1.69

SEQUENCE LISTING

<110> Evotec NeuroSciences GmbH

<120> DIAGNOSTIC AND THERAPEUTIC USE OF HUMAN MAGUIN PROTEINS
AND NUCLEIC ACIDS FOR NEURODEGENERATIVE DISEASES

<130> 030640wo ME/BM

<140> 02006353.3
<141> 2002-03-21

<160> 24

<170> PatentIn Ver. 2.1

<210> 1
<211> 1034
<212> PRT
<213> Homo sapiens

<400> 1
Met Ala Leu Ile Met Glu Pro Val Ser Lys Trp Ser Pro Ser Gln Val
 1   5   10   15

Val Asp Trp Met Lys Gly Leu Asp Asp Cys Leu Gln Gln Tyr Ile Lys
            20   25   30

Asn Phe Glu Arg Glu Lys Ile Ser Gly Asp Gln Leu Leu Arg Ile Thr
        35   40   45

His Gln Glu Leu Glu Asp Leu Gly Val Ser Arg Ile Gly His Gln Glu
    50   55   60

Leu Ile Leu Glu Ala Val Asp Leu Leu Cys Ala Leu Asn Tyr Gly Leu
65   70   75   80

Glu Thr Glu Asn Leu Lys Thr Leu Ser His Lys Leu Asn Ala Ser Ala
                85   90   95

Lys Asn Leu Gln Asn Phe Ile Thr Gly Arg Arg Arg Ser Gly His Tyr
            100   105   110

Asp Gly Arg Thr Ser Arg Lys Leu Pro Asn Asp Phe Leu Thr Ser Val
            115   120   125

Val Asp Leu Ile Gly Ala Ala Lys Ser Leu Leu Ala Trp Leu Asp Arg
        130   135   140

Ser Pro Phe Ala Ala Val Thr Asp Tyr Ser Val Thr Arg Asn Asn Val
145   150   155   160

Ile Gln Leu Cys Leu Glu Leu Thr Thr Ile Val Gln Gln Asp Cys Thr
                165   170   175

```
Val Tyr Glu Thr Glu Asn Lys Ile Leu His Val Cys Lys Thr Leu Ser
            180                 185                 190

Gly Val Cys Asp His Ile Ile Ser Leu Ser Ser Asp Pro Leu Val Ser
            195                 200                 205

Gln Ser Ala His Leu Glu Val Ile Gln Leu Ala Asn Ile Lys Pro Ser
    210                 215                 220

Glu Gly Leu Gly Met Tyr Ile Lys Ser Thr Tyr Asp Gly Leu His Val
225                 230                 235                     240

Ile Thr Gly Thr Thr Glu Asn Ser Pro Ala Asp Arg Cys Lys Lys Ile
                245                 250                 255

His Ala Gly Asp Glu Val Ile Gln Val Asn His Gln Thr Val Val Gly
            260                 265                 270

Trp Gln Leu Lys Asn Leu Val Asn Ala Leu Arg Glu Asp Pro Ser Gly
            275                 280                 285

Val Ile Leu Thr Leu Lys Lys Arg Pro Gln Ser Met Leu Thr Ser Ala
    290                 295                 300

Pro Ala Leu Leu Lys Asn Met Arg Trp Lys Pro Leu Ala Leu Gln Pro
305                 310                 315                     320

Leu Ile Pro Arg Ser Pro Thr Ser Ser Val Ala Thr Pro Ser Ser Thr
                325                 330                 335

Ile Ser Thr Pro Thr Lys Arg Asp Ser Ser Ala Leu Gln Asp Leu Tyr
                340                 345                 350

Ile Pro Pro Pro Pro Ala Glu Pro Tyr Ile Pro Arg Asp Glu Lys Gly
            355                 360                 365

Asn Leu Pro Cys Glu Asp Leu Arg Gly His Met Val Gly Lys Pro Val
    370                 375                 380

His Lys Gly Ser Glu Ser Pro Asn Ser Phe Leu Asp Gln Glu Tyr Arg
385                 390                 395                     400

Lys Arg Phe Asn Ile Val Glu Glu Asp Thr Val Leu Tyr Cys Tyr Glu
                405                 410                 415

Tyr Glu Lys Gly Arg Ser Ser Ser Gln Gly Arg Arg Glu Ser Thr Pro
            420                 425                 430

Thr Tyr Gly Lys Leu Arg Pro Ile Ser Met Pro Val Glu Tyr Asn Trp
            435                 440                 445

Val Gly Asp Tyr Glu Asp Pro Asn Lys Met Lys Arg Asp Ser Arg Arg
    450                 455                 460
```

```
Glu Asn Ser Leu Leu Arg Tyr Met Ser Asn Glu Lys Ile Ala Gln Glu
465               470           475               480

Glu Tyr Met Phe Gln Arg Asn Ser Lys Lys Asp Thr Gly Lys Lys Ser
                485               490               495

Lys Lys Lys Gly Asp Lys Ser Asn Ser Pro Thr His Tyr Ser Leu Leu
            500               505               510

Pro Ser Leu Gln Met Asp Ala Leu Arg Gln Asp Ile Met Gly Thr Pro
        515               520               525

Val Pro Glu Thr Thr Leu Tyr His Thr Phe Gln Gln Ser Ser Leu Gln
    530               535               540

His Lys Ser Lys Lys Lys Asn Lys Gly Pro Ile Ala Gly Lys Ser Lys
545               550               555               560

Arg Arg Ile Ser Cys Lys Asp Leu Gly Arg Gly Asp Cys Glu Gly Trp
                565               570               575

Leu Trp Lys Lys Lys Asp Ala Lys Ser Tyr Phe Ser Gln Lys Trp Lys
            580               585               590

Lys Tyr Trp Phe Val Leu Lys Asp Ala Ser Leu Tyr Trp Tyr Ile Asn
            595               600               605

Glu Glu Asp Glu Lys Ala Glu Gly Phe Ile Ser Leu Pro Glu Phe Lys
    610               615               620

Ile Asp Arg Ala Ser Glu Cys Arg Lys Lys Tyr Ala Phe Lys Ala Cys
625               630               635               640

His Pro Lys Ile Lys Ser Phe Tyr Phe Ala Ala Glu His Leu Asp Asp
                645               650               655

Met Asn Arg Trp Leu Asn Arg Ile Asn Met Leu Thr Ala Gly Tyr Ala
            660               665               670

Glu Arg Glu Arg Ile Lys Gln Glu Gln Asp Tyr Trp Ser Glu Ser Asp
        675               680               685

Lys Glu Glu Ala Asp Thr Pro Ser Thr Pro Lys Gln Asp Ser Pro Pro
    690               695               700

Pro Pro Tyr Asp Thr Tyr Pro Arg Pro Pro Ser Met Ser Cys Ala Ser
705               710               715               720

Pro Tyr Val Glu Ala Lys His Ser Arg Leu Ser Ser Thr Glu Thr Ser
                725               730               735

Gln Ser Gln Ser Ser His Glu Glu Phe Arg Gln Glu Val Thr Gly Ser
            740               745               750
```

```
Ser Ala Val Ser Pro Ile Arg Lys Thr Ala Ser Gln Arg Arg Ser Trp
        755             760             765

Gln Asp Leu Ile Glu Thr Pro Leu Thr Ser Ser Gly Leu His Tyr Leu
    770             775             780

Gln Thr Leu Pro Leu Glu Asp Ser Val Phe Ser Asp Ser Ala Ala Ile
785             790             795             800

Ser Pro Glu His Arg Arg Gln Ser Thr Leu Pro Thr Gln Lys Cys His
            805             810             815

Leu Gln Asp His Tyr Gly Pro Tyr Pro Leu Ala Glu Ser Glu Arg Met
        820             825             830

Gln Val Leu Asn Gly Asn Gly Gly Lys Pro Arg Ser Phe Thr Leu Pro
        835             840             845

Arg Asp Ser Gly Phe Asn His Cys Cys Leu Asn Ala Pro Val Ser Ala
    850             855             860

Cys Asp Pro Gln Asp Asp Val Gln Pro Pro Glu Val Glu Glu Glu Glu
865             870             875             880

Glu Glu Glu Glu Glu Glu Gly Glu Ala Ala Gly Glu Asn Ile Gly Glu
            885             890             895

Lys Ser Glu Ser Arg Glu Glu Lys Leu Gly Asp Ser Leu Gln Asp Leu
        900             905             910

Tyr Arg Ala Leu Glu Gln Ala Ser Leu Ser Pro Leu Gly Glu His Arg
    915             920             925

Ile Ser Thr Lys Met Glu Tyr Lys Leu Ser Phe Ile Lys Arg Cys Asn
    930             935             940

Asp Pro Val Met Asn Glu Lys Leu His Arg Leu Arg Ile Leu Lys Ser
945             950             955             960

Thr Leu Lys Ala Arg Glu Gly Glu Val Ala Ile Ile Asp Lys Val Leu
            965             970             975

Asp Asn Pro Asp Leu Thr Ser Lys Glu Phe Gln Gln Trp Lys Gln Met
            980             985             990

Tyr Leu Asp Leu Phe Leu Asp Ile Cys Gln Asn Thr Thr Ser Asn Asp
        995             1000            1005

Pro Leu Ser Ile Ser Ser Glu Val Asp Val Ile Thr Ser Ser Leu Ala
    1010            1015            1020

His Thr His Ser Tyr Ile Glu Thr His Val
1025            1030
```

<210> 2
<211> 948
<212> PRT
<213> Homo sapiens

<400> 2
Phe Ile Gly Arg Glu Ser Glu Gln Ile Asp Asn Ala Met Ile Asn Ala
1   5   10   15

Cys Ile Asp Ser Glu Gln Glu Asn Cys Glu Phe His Met Ala Asn Met
            20   25   30

Ala Gly Ile Asn Pro Arg Thr Glu Ile Asn Leu Glu Asn Gly Thr His
        35   40   45

Ala Ala Met Ala Leu Ile Met Glu Pro Val Ser Lys Trp Ser Pro Ser
    50   55   60

Gln Val Val Asp Trp Met Lys Gly Leu Asp Asp Cys Leu Gln Gln Tyr
65   70   75   80

Ile Lys Asn Phe Glu Arg Glu Lys Ile Ser Gly Asp Gln Leu Leu Arg
                85   90   95

Ile Thr His Gln Glu Leu Glu Asp Leu Gly Val Ser Arg Ile Gly His
            100   105   110

Gln Glu Leu Ile Leu Glu Ala Val Asp Leu Leu Cys Ala Leu Asn Tyr
        115   120   125

Gly Leu Glu Thr Glu Asn Leu Lys Thr Leu Ser His Lys Leu Asn Ala
    130   135   140

Ser Ala Lys Asn Leu Gln Asn Phe Ile Thr Gly Arg Arg Arg Ser Gly
145   150   155   160

His Tyr Asp Gly Arg Thr Ser Arg Lys Leu Pro Asn Asp Phe Leu Thr
                165   170   175

Ser Val Val Asp Leu Ile Gly Ala Ala Lys Ser Leu Leu Ala Trp Leu
            180   185   190

Asp Arg Ser Pro Phe Ala Ala Val Thr Asp Tyr Ser Val Thr Arg Asn
        195   200   205

Asn Val Ile Gln Leu Cys Leu Glu Leu Thr Thr Ile Val Gln Gln Asp
    210   215   220

Cys Thr Val Tyr Glu Thr Glu Asn Lys Ile Leu His Val Cys Lys Thr
225   230   235   240

Leu Ser Gly Val Cys Asp His Ile Ile Ser Leu Ser Ser Asp Pro Leu

```
               245                250                   255
Val Ser Gln Ser Ala His Leu Glu Val Ile Gln Leu Ala Asn Ile Lys
            260                265                270

Pro Ser Glu Gly Leu Gly Met Tyr Ile Lys Ser Thr Tyr Asp Gly Leu
            275                280                285

His Val Ile Thr Gly Thr Thr Glu Asn Ser Pro Ala Asp Arg Cys Lys
        290                295                300

Lys Ile His Ala Gly Asp Glu Val Ile Gln Val Asn His Gln Thr Val
305                310                315                320

Val Gly Trp Gln Leu Lys Asn Leu Val Asn Ala Leu Arg Glu Asp Pro
                325                330                335

Ser Gly Val Ile Leu Thr Leu Lys Lys Arg Pro Gln Ser Met Leu Thr
                340                345                350

Ser Ala Pro Ala Leu Leu Lys Asn Met Arg Trp Lys Pro Leu Ala Leu
            355                360                365

Gln Pro Leu Ile Pro Arg Ser Pro Thr Ser Ser Val Ala Thr Pro Ser
    370                375                380

Ser Thr Ile Ser Thr Pro Thr Lys Arg Asp Ser Ser Ala Leu Gln Asp
385                390                395                400

Leu Tyr Ile Pro Pro Pro Pro Ala Glu Pro Tyr Ile Pro Arg Asp Glu
                405                410                415

Lys Gly Asn Leu Pro Cys Glu Asp Leu Arg Gly His Met Val Gly Lys
                420                425                430

Pro Val His Lys Gly Ser Glu Ser Pro Asn Ser Phe Leu Asp Gln Glu
            435                440                445

Tyr Arg Lys Arg Phe Asn Ile Val Glu Glu Asp Thr Val Leu Tyr Cys
    450                455                460

Tyr Glu Tyr Glu Lys Gly Arg Ser Ser Ser Gln Gly Arg Arg Glu Ser
465                470                475                480

Thr Pro Thr Tyr Gly Lys Leu Arg Pro Ile Ser Met Pro Val Glu Tyr
                485                490                495

Asn Trp Val Gly Asp Tyr Glu Asp Pro Asn Lys Met Lys Arg Asp Ser
                500                505                510

Arg Arg Glu Asn Ser Leu Leu Arg Tyr Met Ser Asn Glu Lys Ile Ala
        515                520                525

Gln Glu Glu Tyr Met Phe Gln Arg Asn Ser Lys Lys Asp Thr Gly Lys
```

```
              530                      535                      540
Lys Ser Lys Lys Lys Gly Asp Lys Ser Asn Ser Pro Thr His Tyr Ser
545                    550                    555                    560

Leu Leu Pro Ser Leu Gln Met Asp Ala Leu Arg Gln Asp Ile Met Gly
                    565                    570                    575

Thr Pro Val Pro Glu Thr Thr Leu Tyr His Thr Phe Gln Gln Ser Ser
              580                    585                    590

Leu Gln His Lys Ser Lys Lys Lys Asn Lys Gly Pro Ile Ala Gly Lys
              595                    600                    605

Ser Lys Arg Arg Ile Ser Cys Lys Asp Leu Gly Arg Gly Asp Cys Glu
         610              615                    620

Gly Trp Leu Trp Lys Lys Lys Asp Ala Lys Ser Tyr Phe Ser Gln Lys
625                    630                    635                    640

Trp Lys Lys Tyr Trp Phe Val Leu Lys Asp Ala Ser Leu Tyr Trp Tyr
                    645                    650                    655

Ile Asn Glu Glu Asp Glu Lys Ala Glu Gly Phe Ile Ser Leu Pro Glu
              660                    665                    670

Phe Lys Ile Asp Arg Ala Ser Glu Cys Arg Lys Lys Tyr Ala Phe Lys
              675                    680                    685

Ala Cys His Pro Lys Ile Lys Ser Phe Tyr Phe Ala Ala Glu His Leu
         690              695                    700

Asp Asp Met Asn Arg Trp Leu Asn Arg Ile Asn Met Leu Thr Ala Gly
705                    710                    715                    720

Tyr Ala Glu Arg Glu Arg Ile Lys Gln Glu Gln Asp Tyr Trp Ser Glu
                    725                    730                    735

Ser Asp Lys Glu Glu Ala Asp Thr Pro Ser Thr Pro Lys Gln Asp Ser
              740                    745                    750

Pro Pro Pro Pro Tyr Asp Thr Tyr Pro Arg Pro Pro Ser Met Ser Cys
              755                    760                    765

Ala Ser Pro Tyr Val Glu Ala Lys His Ser Arg Leu Ser Ser Thr Glu
         770              775                    780

Thr Ser Gln Ser Gln Ser Ser His Glu Glu Phe Arg Gln Glu Val Thr
785                    790                    795                    800

Gly Ser Ser Ala Val Ser Pro Ile Arg Lys Thr Ala Ser Gln Arg Arg
              805                    810                    815

Ser Trp Gln Asp Leu Ile Glu Thr Pro Leu Thr Ser Ser Gly Leu His
```

```
                  820                    825                    830

      Tyr Leu Gln Thr Leu Pro Leu Glu Asp Ser Val Phe Ser Asp Ser Ala
              835                    840                    845

      Ala Ile Ser Pro Glu His Arg Arg Gln Ser Thr Leu Pro Thr Gln Lys
              850                    855                    860

      Cys His Leu Gln Asp His Tyr Gly Pro Tyr Pro Leu Ala Glu Ser Glu
      865                    870                    875                    880

      Arg Met Gln Val Leu Asn Gly Asn Gly Gly Lys Pro Arg Ser Phe Thr
                  885                    890                    895

      Leu Pro Arg Asp Ser Gly Phe Asn His Cys Cys Leu Asn Ala Pro Val
                  900                    905                    910

      Ser Ala Cys Asp Pro Gln Asp Asp Val Gln Pro Pro Glu Val Glu Glu
                  915                    920                    925

      Glu Glu Glu Glu Glu Glu Glu Glu Gly Glu Ala Ala Gly Glu Asn Ile
          930                    935                    940

      Gly Glu Lys Ser
      945
```

```
<210> 3
<211> 3105
<212> DNA
<213> Homo sapiens

<400> 3
atggctctga taatggaacc ggtgagcaaa tggtctccga gtcaagtagt ggactggatg 60
aaaggtcttg atgactgttt gcagcagtat attaagaact ttgagaggga gaagatcagt 120
ggggaccagc tgctgcgcat tacacatcag gagctagaag atctgggggt cagccgcatt 180
ggccatcagg aactgatctt ggaagcagtt gaccttctgt gtgcattgaa ttatggcttg 240
gaaacagaaa atctaaaaac cctttctcac aagttgaatg catctgccaa aaatctgcag 300
aattttataa caggaaggag aaggagtggc cattatgatg ggaggaccag ccgaaaattg 360
ccaaacgact ttctgacctc agttgtggat ctgattggag cagccaagag tctgcttgcc 420
tggttggaca ggtcaccatt tgctgctgtg acagactatt cagttacaag aaataatgtc 480
atacaactct gcctggagtt aacaacaatt gtgcaacagg attgtactgt atatgaaaca 540
gagaataaaa ttcttcacgt gtgtaaaact ctttctggag tctgtgacca catcatatcc 600
ctgtcgtcag atcctctggt ttcacagtct gctcacctgg aagtgattca actggcaaac 660
attaaaccaa gcgaagggct gggtatgtat attaaatcta catatgatgg cctccatgta 720
attactggaa ccacagaaaa ttcacctgca gatcggtgca agaaaatcca tgctggcgat 780
gaagtgattc aagttaatca tcagactgtg gtggggtggc agttgaaaaa tttggtgaat 840
gcactacgag aggacccgag tggtgttatc ttaactttga aaaagcgacc tcagagcatg 900
cttacctcag caccagcttt actgaaaaat atgagatgga gcccccttgc tctgcagcct 960
cttataccta gaagtcccac aagcagcgtt gccacgcctt ccagcaccat cagtacaccc 1020
accaaaagag acagttctgc cctccaggat ctctacattc ccctcctcc tgcagaacca 1080
tatattccca gggatgaaaa aggaaacctt ccttgtgaag acctcagagg acatatggtg 1140
ggcaagccag tgcataaggg atctgaatca ccaaattcat ttctggatca ggaatatcga 1200
aagagattta atattgtcga agaagatact gtcttatatt gctatgaata tgaaaaagga 1260
```

```
agatcaagta gtcaaggaag acgagaaagc accccaactt atggcaagct acgacctata 1320
tctatgccag tggaatataa ttgggtgggg gactatgaag atccaaataa gatgaagaga 1380
gatagtagaa gagaaaactc tctacttcgg tatatgagca atgaaaagat tgctcaagaa 1440
gaatacatgt ttcagagaaa cagcaaaaag gacacaggga agaagtcaaa aaagaagggt 1500
gataagagta atagcccaac tcactattca ttgctaccta gtttacaaat ggatgcactg 1560
agacaagaca tcatgggcac tcctgtgcca gagaccacac tataccatac atttcagcag 1620
tcctcactgc agcacaaatc aaagaagaaa aacaaaggtc ctatagcagg caagagcaaa 1680
agacgaattt cttgcaaaga tcttggccgt ggtgactgtg agggctggct ttggaaaaag 1740
aaagatgcga agagttactt ttcacagaaa tggaaaaaat attggtttgt cctaaaggat 1800
gcatcccttt attggtatat taatgaggag gatgaaaaag cagaaggatt cattagcctg 1860
cctgaattta aaattgatag agccagtgaa tgccgcaaaa aatatgcatt caaagcctgt 1920
catcctaaaa tcaaaagctt ttattttgct gctgaacatc ttgatgatat gaacaggtgg 1980
cttaacagaa ttaatatgct gactgcagga tatgcagaaa gagagaggat taagcaggaa 2040
caagattact ggagtgagag tgacaaggaa gaagcagata ctccatcaac accaaaacaa 2100
gatagccctc caccccccata tgatacatac ccacgacctc cctcgatgag ttgcgccagt 2160
ccttatgtgg aagcaaaaca tagccgactt tcctccacgg agacttctca gtctcagtct 2220
tctcatgagg agtttcgcca ggaagtaact gggagcagtg cagtgtctcc cattcgcaag 2280
acagccagtc agcgccgctc ctggcaggat ttaattgaga cgccactgac aagttcaggc 2340
ttacactatc ttcagactct gcccctggag gattctgtct tctctgactc cgcggccatc 2400
tccccagagc acaggcggca gtctaccctg ccaactcaga aatgccacct gcaggatcac 2460
tatgggccat accccttagc tgagagtgag aggatgcaag tgctaaatgg aaatgggggc 2520
aagcctcgaa gttttactct gcctcgagat agcgggttca accattgctg tctgaatgct 2580
ccagttagtg cctgtgaccc acaggatgac gtgcaacccc cagaggtgga ggaagaggag 2640
gaggaggagg aggaggaagg ggaggcagca ggggaaaaca taggagaaaa aagtgaaagc 2700
agagaagaaa agttaggaga ctcattgcaa gatttataca gggcactgga gcaggccagt 2760
ctgtcaccac taggagaaca tcgtatttca accaagatgg aatacaagct atcatttata 2820
aaaagatgta atgatcctgt aatgaatgaa aaactacacc ggctgagaat tctcaaaagc 2880
actttaaagg ccagagaagg ggaagtagcc attatcgata aagtcctaga caatccagac 2940
ttgacatcta aagaattcca acaatggaag cagatgtacc tcgacctttt cttggatatc 3000
tgtcaaaata ccacctcaaa tgacccactg agtatttctt ctgaagtaga tgtaatcact 3060
tcctctctag cacacactca ttcatacatt gaaacgcatg tctaa              3105
```

<210> 4
<211> 2683
<212> DNA
<213> Homo sapiens

<400> 4

```
atggctctga taatggaacc ggtgagcaaa tggtctccga gtcaagtagt ggactggatg 60
aaaggtcttg atgactgttt gcagcagtat attaagaact ttgagaggga aagatcagt 120
ggggaccagc tgctgcgcat tacacatcag gagctagaag atctgggggt cagccgcatt 180
ggccatcagg aactgatctt ggaagcagtt gaccttctgt gtgcattgaa ttatggcttg 240
gaaacagaaa atctaaaaac cctttctcac aagttgaatg catctgccaa aaatctgcag 300
aattttataa caggaaggag aaggagtggc cattatgatg ggaggaccag ccgaaaattg 360
ccaaacgact ttctgacctc agttgtggat ctgattggag cagccaagag tctgcttgcc 420
tggttggaca ggtcaccatt tgctgctgtg acagactatt cagttacaag aaataatgtc 480
atacaactct gcctggagtt aacaacaatt gtgtactgt atatgaaaca 540
gagaataaaa ttcttcacgt gtgtaaaact ctttctggag tctgtgacca catcatatcc 600
ctgtcgtcag atcctctggt ttcacagtct gctcacctgg aagtgattca gctggcaaac 660
attaaaccaa gcgaagggct gggtatgtat attaaatcta catatgatgg cctccatgta 720
attactggaa ccacagaaaa ttcacctgca gatcggtgca agaaaatcca tgctggcgat 780
gaagtgattc aagttaatca tcagactgtg gtggggtggc agttgaaaaa tttggtgaat 840
gcactacgag aggacccgag tggtgttatc ttaactttga aaaagcgacc tcagagcatg 900
```

```
cttacctcag caccagcttt actgaaaaat atgagatgga agccccttgc tctgcagcct 960
cttataccta gaagtcccac aagcagcgtt gccacgcctt ccagcaccat cagtacaccc 1020
accaaaagag acagttctgc cctccaggat ctctacattc cccctcctcc tgcagaacca 1080
tatattccca gggatgaaaa aggaaacctt ccttgtgaag acctcagagg acatatggtg 1140
ggcaagccag tgcataaggg atctgaatca ccaaattcat ttctggatca ggaatatcga 1200
aagagattta atattgtcga agaagatact gtcttatatt gctatgaata tgaaaaagga 1260
agatcaagta gtcaaggaag acgagaaagc accccaactt atggcaagct acgacctata 1320
tctatgccag tggaatataa ttgggtgggg gactatgaag atccaaataa gatgaagaga 1380
gatagtagaa gagaaaactc tctacttcgg tatatgagca atgaaaagat tgctcaagaa 1440
gaatacatgt ttcagagaaa cagcaaaaag gacacaggga agaagtcaaa aaagaagggt 1500
gataagagta atagcccaac tcactattca ttgctaccta gtttacaaat ggatgcactg 1560
agacaagaca tcatgggcac tcctgtgcca gagaccacac tataccatac atttcagcag 1620
tcctcactgc agcacaaatc aaagaagaaa aacaaaggtc ctatagcagg caagagcaaa 1680
agacgaattt cttgcaaaga tcttggccgt ggtgactgtg agggctggct ttggaaaaag 1740
aaagatgcga agagttactt ttcacagaaa tggaaaaaat attggtttgt cctaaaggat 1800
gcatcccttt attggtatat taatgaggag gatgaaaaag cagaaggatt cattagcctg 1860
cctgaattta aaattgatag agccagtgaa tgccgcaaaa aatatgcatt caaagcctgt 1920
catcctaaaa tcaaaagctt ttattttgct gctgaacatc ttgatgatat gaacaggtgg 1980
cttaacagaa ttaatatgct gactgcagga tatgcagaaa gagagaggat taagcaggaa 2040
caagattact ggagtgagag tgacaaggaa gaagcagata ctccatcaac accaaaacaa 2100
gatagccctc cacccccata tgatacatac ccacgacctc cctcgatgag ttgcgccagt 2160
ccttatgtgg aagcaaaaca tagccgactt tcctccacgg agacttctca gtctcagtct 2220
tctcatgagg agtttcgcca ggaagtaact gggagcagtg cagtgtctcc cattcgcaag 2280
acagccagtc agcgccgctc ctggcaggat ttaattgaga cgccactgac aagttcaggc 2340
ttacactatc ttcagactct gcccctggag gattctgtct tctctgactc cgcggccatc 2400
tccccagagc acaggcggca gtctaccctg ccaactcaga aatgccacct gcaggatcac 2460
tatgggccat accccttagc tgagagtgag aggatgcaag tgctaaatgg aaatgggggc 2520
aagcctcgaa gtttttactct gcctcgagat agcgggttca accattgctg tctgaatgct 2580
ccagttagtg cctgtgaccc acaggatgac gtgcaacccc cagaggtgga ggaagaggag 2640
gaggaggagg aggaggaagg ggaggcagca ggggaaaaca tag               2683
```

<210> 5
<211> 5749
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: cDNA of human
     Maguin-1

<400> 5
```
cgggcagcta gtcgtgctcg gggcttcact cccgcgcgtg aggcgagcgg gcaagttggc 60
tgagggcgtg cggcagaggc tgcttccctc ggcgacgcga cccctcagca actcaagcta 120
tgaactgaag ctccctaggg acggagaccg gagcggagcg gcggaggcag cagcagcagc 180
agcagcagca gcagcagcag cagccgccgc cgccgccgcc ttagcgggaa ctgagcagac 240
ccggcgcgga gccacgactc ctgcacgttt acctccctgt cgccgttcct gccggcggtt 300
ggctaaaaga cgttacagcc gcgagacccg acacacaaaa gccgctttct ccgcgccgcc 360
cgcccaggga ggctgcggcc agcaagggac cccacctgag agcagctcgg gctgctgagt 420
tcgtttttgtg tctgagctct gcgctctgca cggaaccgac cccgtaccca tggctctgat 480
aatggaaccg gtgagcaaat ggtctccgag tcaagtagtg gactggatga aaggtcttga 540
tgactgtttg cagcagtata ttaagaactt gagagggag aagatcagtg gggaccagct 600
gctgcgcatt acacatcagg agctagaaga tctgggggtc agccgcattg ccatcagga 660
actgatcttg gaagcagttg accttctgtg tgcattgaat tatggcttgg aaacagaaaa 720
```

```
tctaaaaacc ctttctcaca agttgaatgc atctgccaaa aatctgcaga attttataac 780
aggaaggaga aggagtggcc attatgatgg gaggaccagc cgaaaattgc caaacgactt 840
tctgacctca gttgtggatc tgattggagc agccaagagt ctgcttgcct ggttggacag 900
gtcaccattt gctgctgtga cagactattc agttacaaga aataatgtca tacaactctg 960
cctggagtta acaacaattg tgcaacagga ttgtactgta tatgaaacag agaataaaat 1020
tcttcacgtg tgtaaaactc tttctggagt ctgtgaccac atcatatccc tgtcgtcaga 1080
tcctctggtt tcacagtctg ctcacctgga agtgattcaa ctggcaaaca ttaaaccaag 1140
cgaagggctg ggtatgtata ttaaatctac atatgatggc ctccatgtaa ttactggaac 1200
cacagaaaat tcacctgcag atcggtgcaa gaaaatccat gctggcgatg aagtgattca 1260
agttaatcat cagactgtgg tggggtggca gttgaaaaat ttggtgaatg cactacgaga 1320
ggacccgagt ggtgttatct taactttgaa aaagcgacct cagagcatgc ttacctcagc 1380
accagcttta ctgaaaaata tgagatggaa gccccttgct ctgcagcctc ttatacctag 1440
aagtcccaca agcagcgttg ccacgccttc cagcaccatc agtacaccca ccaaaagaga 1500
cagttctgcc ctccaggatc tctacattcc ccctcctcct gcagaaccat atattcccag 1560
ggatgaaaaa ggaaaccttc cttgtgaaga cctcagagga catatggtgg gcaagccagt 1620
gcataaggga tctgaatcac caaattcatt tctggatcag gaatatcgaa agagatttaa 1680
tattgtcgaa gaagatactg tcttatattg ctatgaatat gaaaaaggaa gatcaagtag 1740
tcaaggaaga cgagaaagca ccccaactta tggcaagcta cgacctatat ctatgccagt 1800
ggaatataat tgggtggggg actatgaaga tccaaataag atgaagagag atagtagaag 1860
agaaaactct ctacttcggt atatgagcaa tgaaaagatt gctcaagaag aatacatgtt 1920
tcagagaaac agcaaaaagg acacagggaa gaagtcaaaa aagaagggtg ataagagtaa 1980
tagcccaact cactattcat tgctacctag tttacaaatg gatgcactga gacaagacat 2040
catgggcact cctgtgccag agaccacact ataccataca tttcagcagt cctcactgca 2100
gcacaaatca aagaagaaaa acaaaggtcc tatagcaggc aagagcaaaa gacgaatttc 2160
ttgcaaagat cttggccgtg gtgactgtga gggctggctt tggaaaaaga aagatgcgaa 2220
gagttacttt tcacagaaat ggaaaaaata ttggtttgtc ctaaaggatg catcccttta 2280
ttggtatatt aatgaggagg atgaaaaagc agaaggattc attagcctgc ctgaatttaa 2340
aattgataga gccagtgaat gccgcaaaaa atatgcattc aaagcctgtc atcctaaaat 2400
caaaagcttt tattttgctg ctgaacatct tgatgatatg aacaggtggc ttaacagaat 2460
taatatgctg actgcaggat atgcagaaag agagaggatt aagcaggaac aagattactg 2520
gagtgagagt gacaaggaag aagcagatac tccatcaaca ccaaaacaag atagccctcc 2580
accccatat gatacatacc cacgacctcc ctcgatgagt tgcgccagtc cttatgtgga 2640
agcaaaacat agccgacttt cctccacgga gacttctcag tctcagtctt ctcatgagga 2700
gtttcgccag gaagtaactg ggagcagtgc agtgtctccc attcgcaaga cagccagtca 2760
gcgccgctcc tggcaggatt taattgagac gccactgaca agttcaggct tacactatct 2820
tcagactctg ccctggagg attctgtctt ctctgactcc gcggccatct ccccagagca 2880
caggcggcag tctaccctgc caactcagaa atgccacctg caggatcact atgggccata 2940
cccttagct gagagtgaga ggatgcaagt gctaaatgga aatgggggca agcctcgaag 3000
ttttactctg cctcgagata gcgggttcaa ccattgctgt ctgaatgctc cagttagtgc 3060
ctgtgaccca caggatgacg tgcaacccce agaggtggag gaagaggagg aggaggagga 3120
ggaggaaggg gaggcagcag gggaaaacat aggagaaaaa agtgaaagca gagaagaaaa 3180
gttaggagac tcattgcaag atttatacag ggcactggag caggccagtc tgtcaccact 3240
aggagaacat cgtatttcaa ccaagatgga atacaagcta tcatttataa aaagatgtaa 3300
tgatcctgta atgaatgaaa aactacaccg gctgagaatt ctcaaaagca ctttaaaggc 3360
cagagaaggg gaagtagcca ttatcgataa agtcctagac aatccagact tgacatctaa 3420
agaattccaa caatggaagc agatgtacct cgaccttttc ttggatatct gtcaaaatac 3480
cacctcaaat gacccactga gtatttcttc tgaagtagat gtaatcactt cctctctagc 3540
acacactcat tcatacattg aaacgcatgt ctaaatgtat tctgccttca gaccatctag 3600
tacctgctgg tactctgaac aagtatataa ggtagttttt atatcaatgt gtggaacact 3660
tgacaagcta tactttaatg ttaccaaact atatgaaaca aaccatatat ggtcacaata 3720
ccactatctt taatgagcat ttgtatattt tatatgcaac agtgctcagc ttatgtttac 3780
catgtgcaaa atcaactgtc tttaatgact taaaattaac ttttgcaaac aattctaaat 3840
acaggtggtc ttcaagtagt aaaaccacaa aaggcagttt tctatctatg gtcatctttt 3900
ctccctttaa gttaatttta tataaacaag acttcaaaag taaatcacat tttttcaggt 3960
```

```
gcagacatcc ttgtgggtgg gaaagaattt aaaccttttt tatatttatt aaaatgttct 4020
aagaattttc ttaaacattg cacaaagttt aatgctgtag ttttattttt gtgaaatgta 4080
gatgcgcata caagagctaa gcaaaataga agagcatcga cataagaaaa gttcaggtat 4140
ctaatattcg tcttaatagt ctattaactt gtgaaagcta agttaatgga aatattattc 4200
caaatctatg agaacacttg gtgtatcagg gcaaagcttt gtaagatgtt tttgtaacta 4260
agaccaaaat tgaagataga gctgctttat tttcttggtt taaatcttcc tttattttg 4320
tagtgatgag atgctgattg tgtacagaag aatttgagag gggatttta aaaactgact 4380
taacacaccc agaaaggcag ctaacagcta tatatatata aaatttcag cccaaactca 4440
tgttttaaa ctccaactct taaaagacaa caaggtataa actgaaatga atcaactttc 4500
cacttagttt ccaattttcc cctagtccac taattaaact taggtaatta tacttcaggt 4560
agggaagtac aatatgttta gtttcaggct gatgtgtgtt ataaaaaaca acactgaaaa 4620
ataaaaatgt acttcccttc taaggagcaa gcaggtgatg gtcattcaaa gagatgtcac 4680
attgaattat gagagaaaca atttagaggt ttttttcctg gcttcatgaa ttgttctata 4740
gagtggatga agtctaagga aaagtcctct tcatatattt ccatttataa gcgtcttgtt 4800
tttgaaagtg atcacagcat gaaaatgact gtgctgcttt ttagtgtctg gctgcataat 4860
gtacaagtca caatttgctg tttttttcag gaggagaaag ggaacctcct ttactattct 4920
atatcctaaa atctacttct aatcagcttt atactgttgc ctgtacagct cagtgaatgt 4980
actttcatct ttaagagttc agatatatgc cagtgaatat ttttgctgta gaggagaaag 5040
taaaaactcc acagcgggga tcttttcttt tgcttttgaa accaccattg aatcactatc 5100
gttttgcaga ctttgcacaa ctgtacagga gagtggcctt tctacagcac attttcagta 5160
atcctatatt tagtcaaaat ggatgagaaa tcatgtatta atgtttgtat ggaattttgg 5220
gtccagtgta atattttat catttaaaaa gaactctatt tgtaaaaaca tttatttact 5280
gcatggatat tgacgcacat taaatttgtg ggattttgta tatgtaaaaa aaaaaaaaaa 5340
aaaaaaaaac aaaaaacctc ttgtcctaaa atgaagtgtg cttgttaaca ggtgtttaga 5400
cttattgatg tttactagac caaatgtgta tgttcactta aaaatatatg tacctgatgg 5460
atgtgtcatg tttacagtgg ccaggttgtg gcctgtaaac agcaagcagt tgacgggaag 5520
actagctctg ttgctactaa gcagctttta cttttgtaaa gtcagctctg ttgttttaaa 5580
tggtaaaaat taaactaatg aatttgacaa gactcgtggc tagcctagca tgaaagagac 5640
cttttaacac tatataatat ctgtacattt tattgcattc gtttcaaatc taggagagag 5700
gcagcactgt aaactgaagt caaataaatt cagctcttaa tgaatcctt            5749
```

<210> 6
<211> 4350
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: cDNA of human
     Maguin-2

<400> 6
```
gtgctcgggg cttcactccc gcgcgtgagg cgagcgggca agttggctga gggcgtgcgg 60
cagaggctgc ttccctcggc gacgcgaccc ctcagcaact caagctatga actgaagctc 120
cctagggacg gagaccggag cggagcggcg gaggcagcag cagcagcagc agcagcagca 180
gcagcagcag ccgccgccgc cgccgcctta gcgggaactg agcagacccg gcgcggagcc 240
acgactcctg cacgtttacc tccctgtcgc cgttcctgcc ggcggttggc taaaagacgt 300
tacagccgcg agacccgaca cacaaaagcc gctttctccg cgccgcccgc ccagggaggc 360
tgcggccagc aagggacccc acctgagagc agctcgggct gctgagttcg ttttgtgtct 420
gagctctgcg ctctgcacgg aaccgacccc gtaccatgg ctctgataat ggaaccggtg 480
agcaaatggt ctccgagtca gtagtggac tggatgaaag gtcttgatga ctgtttgcag 540
cagtatatta agaactttga gagggagaag atcagtgggg accagctgct gcgcattaca 600
catcaggagc tagaagatct gggggtcagc cgcattggcc atcaggaact gatcttggaa 660
gcagttgacc ttctgtgtgc attgaattat ggcttggaaa cagaaaatct aaaaacccctt 720
```

```
tctcacaagt tgaatgcatc tgccaaaaat ctgcagaatt ttataacagg aaggagaagg 780
agtggccatt atgatgggag gaccagccga aaattgccaa acgactttct gacctcagtt 840
gtggatctga ttggagcagc caagagtctg cttgcctggt tggacaggtc accatttgct 900
gctgtgacag actattcagt tacaagaaat aatgtcatac aactctgcct ggagttaaca 960
acaattgtgc aacaggattg tactgtatat gaaacagaga ataaaattct tcacgtgtgt 1020
aaaactcttt ctggagtctg tgaccacatc atatccctgt cgtcagatcc tctggtttca 1080
cagtctgctc acctggaagt gattcagctg gcaaacatta aaccaagcga agggctgggt 1140
atgtatatta aatctacata tgatggcctc catgtaatta ctggaaccac agaaaattca 1200
cctgcagatc ggtgcaagaa aatccatgct ggcgatgaag tgattcaagt taatcatcag 1260
actgtggtgg ggtggcagtt gaaaaatttg gtgaatgcac tacgagagga cccgagtggt 1320
gttatcttaa ctttgaaaaa gcgacctcag agcatgctta cctcagcacc agctttactg 1380
aaaaatatga gatggaagcc ccttgctctg cagcctctta tacctagaag tcccacaagc 1440
agcgttgcca cgccttccag caccatcagt acacccacca aaagagacag ttctgccctc 1500
caggatctct acattccccc tcctcctgca gaaccatata ttcccaggga tgaaaaagga 1560
aaccttcctt gtgaagacct cagaggacat atggtgggca gccagtgca taagggatct 1620
gaatcaccaa attcatttct ggatcaggaa tatcgaaaga gatttaatat tgtcgaagaa 1680
gatactgtct tatattgcta tgaatatgaa aaaggaagat caagtagtca aggaagacga 1740
gaaagcaccc caacttatgg caagctacga cctatatcta tgccagtgga atataattgg 1800
gtgggggact atgaagatcc aaataagatg aagagagata gtagaagaga aaactctcta 1860
cttcggtata tgagcaatga aaagattgct caagaagaat acatgtttca gagaaacagc 1920
aaaaaggaca cagggaagaa gtcaaaaaag aagggtgata agagtaatag cccaactcac 1980
tattcattgc tacctagttt acaaatggat gcactgagac aagacatcat gggcactcct 2040
gtgccagaga ccacactata ccatacattt cagcagtcct cactgcagca caatcaaag 2100
aagaaaaaca aaggtcctat agcaggcaag agcaaagac gaatttcttg caaagatctt 2160
ggccgtggtg actgtgaggg ctggctttgg aaaaagaaag atgcgaagag ttactttca 2220
cagaaatgga aaaaatattg gtttgtccta aaggatgcat ccctttattg gtatattaat 2280
gaggaggatg aaaaagcaga aggattcatt agcctgcctg aatttaaaat tgatagagcc 2340
agtgaatgcc gcaaaaaata tgcattcaaa gcctgtcatc ctaaaatcaa aagcttttat 2400
tttgctgctg aacatcttga tgatatgaac aggtggctta acagaattaa tatgctgact 2460
gcaggatatg cagaaagaga gaggattaag caggaacaag attactggag tgagagtgac 2520
aaggaagaag cagatactcc atcaacacca aaacaagata gccctccacc cccatatgat 2580
acataccac gacctccctc gatgagttgc gccagtcctt atgtggaagc aaaacatagc 2640
cgactttcct ccacggagac ttctcagtct cagtcttctc atgaggagtt tcgccaggaa 2700
gtaactggga gcagtgcagt gtctcccatt cgcaagacag ccagtcagcg ccgctcctgg 2760
caggatttaa ttgagacgcc actgacaagt tcaggcttac actatcttca gactctgccc 2820
ctggaggatt ctgtcttctc tgactccgcg gccatctccc cagagcacag gcggcagtct 2880
accctgccaa ctcagaaatg ccacctgcag gatcactatg gccatacccc cttagctgag 2940
agtgagagga tgcaagtgct aaatggaaat ggggcaagc ctcgaagttt tactctgcct 3000
cgagatagcg ggttcaacca ttgctgtctg aatgctccag ttagtgcctg tgacccacag 3060
gatgacgtgc aaccccaga ggtggaggaa gaggaggag aggaggagga ggaaggggag 3120
gcagcagggg aaaacatagg agaaaaaagc taatacactg cgagagttgg tagaacctct 3180
ccatgccaaa tcggatccac ttctgttggc actcaaccca ttggactcac agattgataa 3240
gctaatgttt agagaattta gatcggagag agtcggtacg cgcagactc aacatcaacc 3300
tcttgcaagc aactaaaatg gcctcgtcct tgctgtttat aacagaaaac agacttgtaa 3360
aaagcttaga tcatcaagtg ttttggattg ggggcctccc aaagggatat aagaggggca 3420
ggccactctt aagaagaatg cgagctttct acattgggac tagcataaga tcaaagccaa 3480
tcaagatgga gcacagtaac agaaaactgc ggtttctgtg ggagaacaga aggggaaagg 3540
gtcttaactg ggaaagggct ctgtgtggta acacctcagt tgtgttctcc tgacaccagg 3600
aaaagagagg gatcagcttc aataactaga aaattctggc tgtttaatgg actctttggt 3660
ggcctcttta aggcaaagca gagaaagcaa attatgtatt aagtgtattt tgcattttta 3720
aaacttgacg tgctgtattg tactaaatta agtgtaatct attaaggcaa ggtatacaca 3780
atttgctttg aaacttacta tgtttattct attataaagt gtattcaggt gcaacacaga 3840
gactgctttc ggtgacatta atgaagaaaa tttctcatgc caggctttat tatagaatct 3900
tcagctaaaa tcctaacttt ctccttattt cttggcactt gtatacaagt ggtgttgcct 3960
```

```
cttagggcag gcatgagcta ttcttttctg taaaatattt tgaatctata ggctgtgggt 4020
ttcatttttg aaaagtattt tgtctggatg tctttcaaac tagcttcaga tattatttaa 4080
tactatgtaa ctgggtcccc tatggctcaa tcaatattgc ttatttttct tctgtagtgg 4140
atgtgaaatt tcctttagtt ggataagata cactgtaata attttaatgc taattaatga 4200
tatttcatac tgtgcaatga acagataatt taacactgta ttttgaaatg ttttttctt  4260
cctgtcaccg cagtgtgtgg tattgcataa tgtgaatacc tgtaaaaata taaattactt 4320
aaaaataaaa atatgaccaa ttggtatcag                                   4350
```

<210> 7
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: cDNA fragment
      of Maguin-1

<400> 7
ggagagaggc agcactgtaa actgaagtca aataaattca gctcttaatg   50

<210> 8
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
      One-base-anchor oligonucleotides

<400> 8
httttttttt tta   13

<210> 9
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
      One-base-anchor oligonucleotides

<400> 9
httttttttt ttg   13

<210> 10
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
```

<223> Description of Artificial Sequence:
      One-base-anchor oligonucleotides

<400> 10
httttttttt ttc                                                                          13


<210> 11
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer for
      Maguin-1

<400> 11
cagcaagcag ttgacggga                                                                    19


<210> 12
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer for
      Maguin-1

<400> 12
tgaatttgac aagactcgtg gc                                                                22


<210> 13
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer for
      Maguin-2

<400> 13
gggcctccca aagggatat                                                                    19


<210> 14
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer for
      Maguin-2

```
<400> 14
cccaatgtag aaagctcgca tt                                              22


<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for
      cyclophilin B

<400> 15
actgaagcac tacgggcctg                                                 20


<210> 16
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for
      cyclophilin B

<400> 16
agccgttggt gtctttgcc                                                  19


<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer for
      ribosomal protein S9

<400> 17
ggtcaaattt accctggcca                                                 20


<210> 18
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer for
      ribosomal protein S9

<400> 18
```

tctcatcaag cgtcagcagt tc   22

<210> 19
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for
       beta-actin

<400> 19
tggaacggtg aaggtgaca   19

<210> 20
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for
       beta-actin

<400> 20
ggcaagggac ttcctgtaa   19

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer for
       GAPDH

<400> 21
cgtcatgggt gtgaaccatg   20

<210> 22
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer for
       GAPDH

<400> 22
gctaagcagt tggtggtgca g   21

```
<210> 23
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer for
      transferrin receptor

<400> 23
gtcgctggtc agttcgtgat t                                    21


<210> 24
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer for
      transferrin receptor

<400> 24
agcagttggc tgttgtacct ctc                                  23
```

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/02857

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7   C07K14/47   C12N15/12   C12N5/10   C07K16/18   G01N33/53
C12Q1/68   A61K38/16   A61K48/00   A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7   C12N   C07K   G01N   C12Q   A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

GENSEQ, EMBL, EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! 16 January 2002 (2002-01-16) LANIGAN,T.M. AND GUAN, K.L.: "Homo sapiens connector enhancer of KSR2A mRNA, complete cds." Database accession no. AF418269 XP002210679 ─── -/--	11,13, 14,16, 20,26, 28,29

[X] Further documents are listed in the continuation of box C.   [ ] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
18 June 2003	30/06/2003

| Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL – 2280 HV Rijswijk
 Tel. (+31–70) 340–2040, Tx. 31 651 epo nl,
 Fax: (+31–70) 340–3016 | Authorized officer

 ALCONADA RODRIG.., A |

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International ●●●●ion No

PCT/EP 03/02857

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE GENSEQ 'Online! 8 November 2000 (2000-11-08) TAKAI,Y. ET AL.: "Rat MAGUIN 1 protein" Database accession no. AAY92942 XP002210736 -& DATABASE WPI Section Ch, Week 200033 Derwent Publications Ltd., London, GB; Class B04, AN 2000-387785 XP002210680 & WO 00 29572 A (KAGAKU GIJUTSU SHINKO JIGYODAN), 25 May 2000 (2000-05-25) abstract ---	11,13, 14,16, 20,26, 28,29
X	DATABASE GENSEQ 'Online! 8 November 2000 (2000-11-08) TAKAI, Y. ET AL.: "Rat MAGUIN 2 protein" Database accession no. AAY92943 XP002210737 -& DATABASE WPI Section Ch, Week 200033 Derwent Publications Ltd., London, GB; Class B04, AN 2000-387785 XP002210680 & WO 00 29572 A (KAGAKU GIJUTSU SHINKO JIGYODAN), 25 May 2000 (2000-05-25) abstract -----	11,13, 14,16, 20,26, 28,29

FURTHER INFORMATION CONTINUED FROM   PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.:   12-15 (in part) and 19, 21-25 (complete)

Present claim 12 relates to a method of treating or preventing a
neurodegenerative disease, said method comprising adminstering to said
subject an amount of an agent, wherein said agent is defined by reference
to a desirable characterisitc or property, namely, that said agent
directly or indirectly modulates the activity or level of the (i) gene
coding for human MAGUIN-1 and/or human MAGUIN-2; and/or (ii) a
transcription product of a gene coding for human MAGUIN-1 or human
MAGUIN-2 and/or (iii) a translation product of a gene coding for human
MAGUIN-1 and/or human MAGUIN-2 and/or a fragment, or derivative, or
variant of (i) to (iii). The claims cover the methods that involve the
adminastration of an agent having this characteristic or property,
whereas the application provides support within the meaning of Article 6
PCT and disclosure within the meaning of Article 5 PCT for only a very
limited number of such agents. In the present case, the claims so lack
support, and the application so lacks disclosure, that a meaningful
search of the claimed scope is impossible. Independent of the above
reasoning, the claims also lack clarity (Article 6 PCT). An attempt is
made to define the agent by reference to a result to be achieved. Again,
this lack of clarity in the present case is such as to render a
meaningful search over the whole of the claimed scope impossible.
Consequently, the search has been carried out for those parts of the
claims which appear to be clear, supported and disclosed, namely those
parts relating to the methods which make use of the agent, wherein the
agent comprises the human MAGUIN-1 or MAGUIN-2 polypeptide sequences or
the corresponding polynucleotide sequence in sense or antisense
orientation (see page 14 from the description).

The same objection applies to claim 13, which refers to the above
mentioned agent or modulator as such, to claim 14 which refers to
pharmaceutical compositions comprising said modulator and to claim 15,
which refers to the second medical use of said modulator.

Present claim 19 relates to a method for the identification of a compound
for inhibition of binding between a ligand and human MAGUIN-1 or
MAGUIN-2, wherein said method implies contacting MAGUIN-1 or MAGUIN-2
with a detectable ligand in the presence of the compound to be tested.
The claim cover all possible MAGUIN ligands, whereas the application does
not provides support within the meaning of Article 6 PCT or disclosure
within the meaning of Article 5 PCT for any of such MAGUIN ligandss. In
the present case, the claim so lacks support, and the application so
lacks disclosure, that a meaningful search of the claim is impossible.
Independent of the above reasoning, the claim also lack clarity (Article
6 PCT). An attempt is made to define the product by reference to a result
to be achieved. Again, this lack of clarity in the present case is such
as to render a meaningful search over the whole of the claimed scope
impossible. Consequently, the search has been not carried out for those
claims.

Claims 21-25 relate to methods of producing medicaments and medicaments

FURTHER INFORMATION CONTINUED FROM   PCT/ISA/ 210

obtained by said method, wherein said medicaments contain a compound
which is defined by reference to a desirable characterisitic or property,
namely, that the compund can be identified by the methods of claim 18-20.
The claims cover all compounds having this characteristic or property,
whereas the application provides support within the meaning of Article 6
PCT and disclosure within the meaning of Article 5 PCT for none of such
compounds. In the present case, the claims so lack support, and the
application so lacks disclosure, that a meaningful search over the whole
of the claimed scope is impossible. Independent of the above reasoning,
the claims also lack clarity (Article 6 PCT). An attempt is made to
define the compound by reference to a result to be achieved. Again, this
lack of clarity in the present case is such as to render a meaningful
search of the claim impossible. Consequently, the search has not been
carried out for those claims.

The applicant's attention is drawn to the fact that claims, or parts of
claims, relating to inventions in respect of which no international
search report has been established need not be the subject of an
international preliminary examination (Rule 66.1(e) PCT). The applicant
is advised that the EPO policy when acting as an International
Preliminary Examining Authority is normally not to carry out a
preliminary examination on matter which has not been searched. This is
the case irrespective of whether or not the claims are amended following
receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

| Box I | Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet) |

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:

   Although claims 12 and 17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [X] Claims Nos.:   12-15 (in part) and 19, 21-25 (complete)
   because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

   see FURTHER INFORMATION sheet PCT/ISA/210

3. [ ] Claims Nos.:
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

| Box II | Observations where unity of invention is lacking (Continuation of Item 2 of first sheet) |

This International Searching Authority found multiple inventions in this International application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☑ **BLACK BORDERS**

- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

- ☐ **FADED TEXT OR DRAWING**

- ☑ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

- ☐ **SKEWED/SLANTED IMAGES**

- ☑ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

- ☐ **GRAY SCALE DOCUMENTS**

- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

- ☑ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.